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A B S T R A C T
RNA Polymerase II (Pol II) transcripts comprise many different RNA classes that
undergo co-transcriptionally complex maturation processes including the addition
of a 5’ cap structure, removal of introns via splicing, 3’ end processing and the as-
sembly into transport competent ribonucleoprotein particles. How all these processes
are coordinated, regulated and quality controlled, is a central question in RNA biol-
ogy. One of the processes all Pol II transcripts have in common is the addition of a
cap structure to the 5’ end. This 5’ cap structure is immediately bound by the het-
erodimeric cap binding complex CBC comprising subunit CBP80 and the cap binding
subunit CBP20. The cap structure as well as CBC are crucial for the correct process-
ing of the nascent transcript. The subsequent maturation processes including the
involved processing machineries depend on the RNA class. However, some proteins
like NELF-E (negative elongation factor subunit E) and ARS2 (arsenite-resistance pro-
tein 2) seem to associate with the RNA-CBC complex regardless of the type of RNA,
whereas other CBC interacting proteins like the phosphorylated adaptor for RNA
export PHAX are important for distinct RNAs.
To better understand the individual CBC complexes, different biochemical, bio-
physical and structural methods were used to analyse the individual interactions
between CBC and ARS2, PHAX as well as NELF-E on molecular level. The studies
showed the incompatibility of ARS2 and NELF-E binding to CBC and revealed that
both proteins are sharing the same binding site on CBC and that their interacting
residues show high conservation and similarities. In addition, solving the structure
of human ARS2 allowed the identification of domains and residues involved in RNA
and protein-protein interactions. Further analysis also led to the identification of a
novel CBC-ARS2 complex, including the nuclear cap binding protein NCBP3, namely
CBC-ARS2-NCBP3. The results obtained support the hypothesis that ARS2 serves as
additional binding surface for proper sorting and processing of nascent transcripts.
Additionally, all results together enable to propose a model of RNA processing con-
taining mutually exclusive RNA-CBC complexes based on the RNA maturation stage
as well as the RNA class.
v
Z U S A M M E N FA S S U N G
Viele verschiedene RNA Klassen werden von der RNA Polymerase II (Pol II) syn-
thetisiert. All diese Pol II Transkripte durchlaufen co-transkriptional zahlreiche kom-
plexe Reifungsprozesse wie die Modifikation des 5’ Endes durch Anfügen einer Cap
Struktur, das Entfernen von Introns durch Spleißen, die 3’ Ende Modifizierung und
die Bildung von Transport-kompetenten Ribonukleoprotein-Partikeln. Wie all diese
Prozesse koordiniert, reguliert und kontrolliert werden ist eine zentrale Frage in-
nerhalb der RNA Biologie. Eine Weiterverarbeitung haben alle Pol II Transkripte
gemeinsam: die Addition der Cap Struktur am 5’ Ende. Diese 5’ Cap Struktur wird
sofort von dem Cap bindenden Komplex CBC gebunden, welcher aus CBP80 und
CBP20 besteht. Die Cap Struktur genauso wie CBC ist essentiell für die korrekte
Weiterverarbeitung des entstehenden Transkriptes. Die weiteren Reifungsprozesse
und die damit verbundenen Prozessierungskomplexe sind abhängig von der RNA
Klasse. Allerdings scheinen einige Proteine wie NELF-E (Untereinheit E von NELF
(negative elongation factor)) und ARS2 (arsenite-resistance protein 2) den RNA-CBC
Komplex unabhängig von der RNA Art zu binden, während andere Proteine wie der
snRNA Export Adapter PHAX spezifisch für individuelle RNA Klassen sind.
Um die individuellen CBC Komplexe besser zu verstehen, wurden die Interaktio-
nen zwischen CBC und ARS2, PHAX und NELF-E durch verschiedene biochemische,
biophysikalische und strukturbiologische Methoden auf molekularem Level unter-
sucht. Die Studien zeigten, dass die Interaktion von ARS2 und NELF-E mit CBC nicht
kompatibel ist und dass dies durch eine gemeinsame Bindungsstelle von NELF-E
und ARS2 an CBC verursacht wird. Zudem weisen die CBC-ARS2 und CBC-NELF-E
Interaktionen viele Gemeinsamkeiten auf. Die mittels Kristallographie determinierte
Struktur des humanen ARS2 diente der Identifikation von Domänen und Amino-
säureresten, die in RNA-Protein und Protein-Protein Interaktionen beteiligt sind.
Dies führte unter anderem zu der Entdeckung eines neuen CBC-ARS2 Komplexes,
dem CBC-ARS2-NCBP3 Komplex. Des Weiteren unterstützen all diese Ergebnisse ein
Model der RNA Weiterverarbeitung, in dem sich, abhängig von dem Reifegrad der
RNA und der RNA Klasse, gegenseitig ausschließende RNA-CBC Komplexe bilden.
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1
I N T R O D U C T I O N
1.1 gene expression
Genetic information is encoded in deoxyribonucleic acid (DNA) and the process
of transferring this information into functional molecules such as ribonucleic acids
(RNAs) and proteins is called gene expression. The initial step of gene expression
is the transcription of the genetic information from DNA to RNA. In humans most
of the genome is transcribed [42, 75], although protein-coding genes comprise less
than 3% of the human genome [36]. Co-transcriptionally nascent RNAs undergo
complex maturation processes including the addition of a 5’ cap structure, removal
of introns via splicing, 3’ end processing and assembly into transport competent
ribonucleoprotein (RNP) particles. To ensure the correct maturation and thus the
correct transfer of information, all these processes need to be coordinated, regulated
and quality controlled and how this is achieved for different kinds of RNAs is a
central question in RNA biology.
1.2 rna classes
RNA is a biological macromolecule essential for all known forms of life. For a long
time, only three RNA types involved in protein synthesis were known: messenger
RNA (mRNA) as the carrier of genetic information, transfer RNA (tRNA) linking
mRNA and protein biosynthesis, and ribosomal RNA (rRNA) as part of ribosomes.
In most eukaryotic cells, these RNA classes account for 98% of cellular RNA mass
[216]. However, RNA plays a much bigger role apart from being essential for protein
biosynthesis. For example in some viruses RNA instead of DNA is the carrier of
the genetic information and RNA can act as an enzyme, called ribozyme. RNAs
together with proteins form RNPs that are involved in different processes and can
have enzymatic activity (e.g. snRNAs are components of spliceosomes and rRNAs
of ribosomes). Additionally, RNAs are involved in the regulation of many cellular
processes like differentiation, cell division, growth, aging and death. All these RNA
functions are mediated by distinct RNA classes. As RNAs have a very complex role,
dysregulation or defects in certain RNAs have been associated with a number of
human diseases.
In metazoan cells, in addition to mRNAs, RNA transcripts include non-coding
RNAs such as tRNAs and rRNAs, long non-coding RNAs (lncRNAs), microRNAs
(miRNAs), small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNAs), PIWI-
interacting RNAs (piRNAs), telomerase RNAs and signal recognition particle (SRP)
RNAs. At certain cellular stages like embryogenesis, cell division and germ cell devel-
opment specific RNA levels can either be up or down regulated. Thus, the abundance
of individual RNAs changes depending on the cell cycle as well as the cell type.
1
2 introduction
In eukaryotes the different RNAs are synthesised by three different RNA poly-
merases, namely RNA polymerase I (Pol I), RNA polymerase II (Pol II) and RNA
polymerase III (Pol III). The main transcripts of the different polymerases are the
following: 18S, 5.8S and 28S rRNAs are synthesised by Pol I, mRNAs together with
snRNAs are synthesised by Pol II while 5S rRNAs and tRNAs are synthesised by
Po III.
1.3 rna polymerase ii transcripts
1.3.1 Role of RNA Polymerase II C-terminal Domain in Transcription Regulation and Co-
transcriptional Processing
Pol II transcripts comprise the precursors of mRNAs and many non-coding RNAs,
e.g. snRNAs, miRNAs and piRNAs. Transcription by Pol II is divided into initiation,
elongation and termination phases (Figure 1.1) and each stage is linked to RNA
processing and regulatory events [88].
Most eukaryotic RNA precursors undergo extensive co-transcriptional maturational
processing, including 5’ end capping, splicing, and 3’ end cleavage and polyadeny-
lation. Many nuclear factors involved in these co-transcriptional events are recruited
via the C-terminal repeat domain (CTD) of Pol II, which is a unique feature of this
polymerase. It is made up of 15 to 52 heptad repeats with the consensus sequence
Tyr1–Ser2–Pro3–Thr4–Ser5–Pro6–Ser7 [37] and is subject to hyperphosphorylation at
Tyr1, Ser2, Thr4, Ser5 and Ser7 [14, 28, 54, 81, 88, 191]. The phosphorylation state of
the CTD changes through the transcription cycle with different patterns of modifica-
tions recruiting enzymes and proteins in a transcription-stage specific manner.
At the transcription start site (tss) transcription initiation factors assemble and re-
cruit Pol II, which leads to the formation of the preinitiation complex (PIC) (Figure
1.1). Part of this complex is the cyclin-dependent kinase (CDK)7, the kinase of the
transcription factor TFIIH, which phosphorylates the CTD on Ser5 (Ser5P). Ser5P
leads to the recruitment of different transcription elongation factors and start of elon-
gation. In addition, the capping enzyme (CE) directly binds via its RNA guanylyl-
transferase to the Ser5P CTD, which stimulates the activity of the CE [52, 65]. Ser5P
is further known to enhance the recruitment of histone lysine methyltransferase Set2,
which transfers methyl groups on histone H3 K36 residues [106]. Recently, it was
also shown that TFIIH can phosphorylate the CTD on Ser7 (Ser7P) [2, 68, 101]. Ser7P
mainly stays in context with the recruitment of the multisubunit Integrator complex
for mammalian snRNA 3’ end processing [11, 48].
During elongation, the level of Ser5P decreases while the phosphorylation on Ser2
(Ser2P) increases until Pol II reaches the 3´ end of the transcription unit. Rtr1 [149]
and Ssu72 [107] as well as Fcp1 [26] were identified as Ser dephosphatases, with
Rtr1 dephosphorylating Ser5P and possibly playing a role in the early elongation
phase. Ssu72 was shown to dephosphorylate the remaining Ser5P at the cleavage
and polyadenylation sites [107, 215, 225, 232] and Fcp1 to remove the Ser2P when
Pol II reaches the 3´ end of genes [35]. Besides, CDK9, subunit of the positive tran-
scription elongation factor b (P-TEFb), was described to phosphorylate Ser2 as well
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as the DRB sensitivity-inducing factor (DSIF) [166]. DSIF consists of subunits Spt4
and Spt5, with Spt5 also containing a C-terminal region (CTR) with repeats that can
be phosphorylated at Thr4 [226]. The recruitment and kinase activity of P-TEFb are
important to promote elongation by releasing the promoter-proximal paused Pol II
(see Sec. 1.3.2).
Altogether, the dynamic and stage-specific phosphorylation/dephosphorylation of
the Pol II CTD is critical for proper RNA biogenesis.
1.3.2 Promoter Proximal Pausing of RNA Polymerase II
One major rate-limiting step within transcription and gene expression is the pro-
moter proximal pausing of Pol II (Figure 1.1). At more than 70% of metazoan genes
Pol II pauses after synthesising 20-40 nucleotides (nts) nascent RNA [125]. This pro-
cess is controlled by the phosphorylation pattern of the CTD of Pol II (see Sec. 1.3.1).
Paused Pol II shows an enrichment of Ser5P, whereas enrichment of Ser2P stimulates
elongation. DSIF and the negative elongation factor (NELF) are the key players for
Pol II pausing, although other factors contribute to the stability of paused Pol II [20,
32]. The mechanisms behind promoter proximal Pol II pausing remain elusive, with
new aspects being continually revealed.
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Figure 1.1 – Promoter proximal pausing of RNA Polymerase II
After forming of the preinitiation complex, the CTD of RNA polymerase II (Pol II) is phos-
phorylated at Ser5 by the transcription factor TFIIH. Ser5P leads to initiation of transcription
through the recruitment of elongation factors. After 20-40 nts Pol II pausing is induced by
binding of DSIF and NELF. The capping enzymes (CEs), which cap the nascent transcript at
its 5’ end, are recruited by Ser5P and DSIF. Phosphorylation of NELF, DSIF and the CTD at
Ser2 by P-TEFb induces the release of the paused Pol II and productive elongation. Phospho-
rylated NELF dissociates from the complex and phosphorylated DSIF acts as positive elon-
gation factor. At this stage also other positive elongation factors are recruited. The m7G cap
structure is bound by the cap binding complex CBC, which accompanies the RNA through
the following maturation and transport processes.
A critical factor essential and sufficient for the release of paused Pol II is P-TEFb
[169]. P-TEFb consists of cyclin T and CDK9, a kinase that phosphorylates the NELF-
E subunit of NELF [60] and the CTR repeats of DSIF at Thr4 [226]. Phosphory-
lated NELF dissociates from the stalled complex and phosphorylated DSIF acts as
elongation-stimulating factor [126, 207]. Subsequently, P-TEFb also phosphorylates
Ser2 of the Pol II CTD [166]. The recruitment of P-TEFb seems to be the rate-limiting
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step in the release of paused Pol II and is regulated through several protein factors
and cellular signals [21, 169, 233].
The function of promoter proximal Pol II pausing is unclear. Hypotheses include
that Pol II pausing enables rapid and/or synchronous transcription of specific genes
and that pausing serves as checkpoint for coupling elongation and RNA process-
ing for which the 5’ cap structure is important. The latter is supported by the fact
that 5’ capping occurs when the nascent RNA extends from 20-30 nts in length and
that Ser5P is bound by the CE stimulating its activity [52, 65]. Also DSIF enhances
the recruitment and activity of the CE (by CE binding to the CTR of Spt5) [7, 124,
131, 165, 214], while the binding of CE rescues transcriptional repression by NELF
[131]. Further evidence for a coupling of promoter proximal pausing, capping and
transcription elongation is provided by the discovery that the nuclear cap binding
complex (CBC), which binds the cap structure of the nascent transcript (see Sec. 1.4),
promotes the recruitment of P-TEFb, thus linking capping with transcription elonga-
tion [120].
1.3.3 5’ end Capping
The co-transcriptionally addition of a 7-methylguanosine (m7G) cap structure to the
5’ end of the nascent transcript is a common feature all Pol II transcripts share. At
a length of 20-30 nts a m7G is connected via a 5’-5’ triphosphate bridge to the first
nucleotide of the nascent transcript [150, 190]. The addition of m7G is catalysed by
three enzymatic activities (Figure 1.2A). First, the RNA 5’ triphosphatase removes
the terminal γ-phosphate of the transcript, generating a diphosphate 5’ end. Then
the RNA guanylyltransferase (GTase) catalyses the addition of guanosine monophos-
phate (GMP) to the 5’ diphosphate, followed by the addition of the methyl group
to the N-7 amine of the guanosine cap by the guanine-7-methyltransferase to form
the cap 0 structure. In higher eukaryotes, post-transcriptionally the first and second
nucleotide can be further methylated at the 2´-O position of the ribose generating the
cap 1 and cap 2 structures, respectively (Figure 1.2).
These unique caps of Pol II transcripts are recognised and bound by specific pro-
cessing factors. In the nucleus the nuclear cap binding complex CBC (see Sec. 1.4)
immediately binds the 5’ m7G cap structure, protecting the RNA from degradation
and accompanying the transcripts though various processing steps that are promoted
by the cap.
The specificity of the m7G cap to Pol II transcripts arises from the recruitment of
the CE by the CTD of Pol II. The mammalian GTase directly binds to the Ser5 and
Ser2 phosphorylated Pol II CTD [83]. Furthermore, Ser5P binding seems to stimulate
the formation of the enzyme-GMP intermediate and serves as allosteric activator of
the CE [65, 83].
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Figure 1.2 – The 5’ 7-methylguanosine cap
A: 5’ cap synthesis. The RNA 5’-triphosphatase (RTPase) hydrolyses the γ-phosphate from
the 5’ end of the nascent transcript. Then the guanylyltransferase (GTase) transfers a GMP
to the newly formed end and the guanine-7-methyltransferase (N7MTase) methylates the
guanosine on position 7. 2’-O-methylation at the first nucleotide by a 2´-O-ribose methyltrans-
ferase (2’OMTase) leads to the generation of the cap 1 structure. SAM: S-adenosylmethionine,
SAH: S-adenosylhomocysteine.
B: 5’ cap structure. The 7-methylguanosine (m7G) is linked via a 5’-5’ triphosphate bridge
to the RNA. Additional methylation of the first nucleotides results in the cap 1 and cap 2
structure. Scheme adapted from [167].
1.3.4 Splicing
Most precursor messenger RNA (pre-mRNA) transcripts and precursor of long in-
tergenic/intervening non-coding RNAs (lincRNAs) contain sequences (introns) that
are intervening the mature RNA sequences (exons). For proper RNA maturation the
removal of the introns is essential. The respective process is called RNA splicing and
comprises cleavage at conserved sequences and ligation of the exons by several steps.
In addition, alternative splicing enables the arrangement of selected exons and gives
rise to distinct RNAs from the same precursor RNA. RNA splicing is catalysed by the
spliceosome, which is composed of small nuclear ribonucleoproteins (snRNPs) and
many additional co-factors [96, 218]. For correct pre-mRNA splicing the cap struc-
ture as well as CBC are required. It was shown that the co-transcriptional assembly
of the spliceosome relies on the interaction of CBC with U4/U6.U5 tri-snRNP [162].
Also a model including the interaction between CBC and splicing factors has been
proposed [120].
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1.3.5 3’ end Formation
1.3.5.1 mRNA 3’ end Processing
The 3’ end of a pre-mRNA is not defined by its translational stop codon as Pol II
transcribes also the 3’ untranslated region (UTR) after the stop codon. For proper
maturation the nascent pre-mRNA transcript must be cleaved and polyadenylated
at its 3’ end. This 3’ end processing of pre-mRNAs plays an important role at many
stages. It enhances the stability of mRNAs [217, 220], promotes mRNA export from
the nucleus to the cytoplasm [199, 204] and translation of mRNAs into proteins [29,
185, 217, 220]. Furthermore, 3’ end processing is linked to transcription and splicing
[82, 171, 173, 234] and the poly(A) tail is necessary for transcriptional termination
[22, 171, 172].
The 3 ’end cleavage of pre-mRNAs is based on the recognition of cis-acting ele-
ments in the 3’ UTR of the pre-mRNA by a complex machinery. Following cleavage,
pre-mRNAs, except histone replication-dependent transcripts (see Sec. 1.3.5.2), ac-
quire a polyadenylated tail at the newly formed 3’ end. In mammals, the cleavage site
is defined by the following cis-elements. 10-30 bases upstream of the cleavage site lo-
cated is the hexamer AAUAAA polyadenylation signal (PAS), which is recognised by
the five subunit cleavage and polyadenylation specificity factor (CPSF) complex [30].
About 30 bases downstream of the cleavage site lies a U- or GU-rich element called
DSE (distal sequence element), that is recognised by the heterotrimeric cleavage stim-
ulatory factor (CstF). Often additionally a U-rich element, which is recognised by the
heterodimeric cleavage factor Im (CFIm) [19, 203] and enhances the efficiency of cleav-
age and polyadenylation, is present in one or more copies upstream of the cleavage
site [89]. Another auxiliary element can be located downstream of the cleavage site
and is generally G-rich [10, 30]. The cleavage site itself is not strictly conserved but
cleavage preferentially occurs after a CA dinucleotide [132].
The mammalian 3’ end processing machinery contains more than 14 proteins
comprising CPSF, CstF, CFIm and CFIIm subcomplexes as well as poly(A) poly-
merase (PAP), poly(A) binding protein (PABP), Symplekin and Pol II CTD. Some
of these factors are also involved in transcriptional initiation, transcriptional termina-
tion or splicing. The cleavage is catalysed by the enzyme CPSF73, a subunit of CPSF,
leading to a 3’ hydroxyl and 5’ phosphate end, respectively [45, 133, 181]. After cleav-
age PAP, which interacts with CPSF, adds 150-250 adenylate residues in a template
independent manner to the 3’ end. However, in mammals PAP is not only required
for polyadenylation, but also for cleavage. The new, short poly(A) tail is bound by
PABP [208] enhancing the affinity of PAP for the RNA [100]. After around 250 nts the
interaction between PAP and CPSF weakens, which halts polyadenylation and thus
determines the length of the poly(A) tail [109, 209].
The mammalian Pol II CTD is necessary for cleavage [142] and its phosphorylation
stimulates in vitro 3’ end processing [182]. The CTD interacts with CPSF via CPSF160
[41, 142] and CstF via CstF50 [142]. However, already during transcription CPSF
associates via CPSF30 with the body of Pol II and signals the polymerase to terminate
transcription after passing the TTATTT PAS sequence [153].
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Figure 1.3 – 3’end processing of mRNA, replication dependent histone mRNA and snRNA
Models displaying the main factors as well as structural and sequence elements of the RNA
involved in 3’ end processing of mRNA, replication dependent histone mRNA and snRNA.
For more details see Sec. 1.3.5.
1.3.5.2 Histone mRNA 3´ end Processing
During S phase, the genomic DNA gets replicated and histone proteins must be
produced in large amounts. As the different histone types must be synthesised in a
fixed ratio, their synthesis must be coordinated with the replication of DNA. There-
fore, their transcription and expression are strictly regulated in a cell cycle dependent
manner and differ from the processing of other pre-mRNAs. Replication dependent
histone pre-mRNAs lack introns and apart from 5’ capping (see Sec. 1.3.3), the 3’
end processing is their only maturation process, which includes a cleavage but no
polyadenylation.
In contrast to other pre-mRNAs the cleavage site of replication dependent histone
pre-mRNAs is defined by structural and sequence elements [44]. A conserved 16 nts
stem-loop lies in the 3’ UTR and a purine-rich sequence called histone downstream
element (HDE) is located 12-19 nts downstream of the cleavage site. The highly con-
served stem-loop, consisting of a six nts stem and four nts U-rich loop, lies 24-70 nts
downstream of the stop codon and five nts upstream of the cleavage site. The stem-
loop is bound by the stem-loop binding protein (SLBP) [134, 212] and the HDE in-
teracts with U7 snRNP by base pairing with the U7 snRNA (Figure 1.3). Then the
cleavage factor is recruited. It comprises proteins of the CPSF (CPSF73, CPSF100
and FIP1) and Symplekin, which are also part of the complex that processes 3’ end
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polyadenylated pre-mRNAs. CPSF73 seems to be the endonuclease cleaving both
histone pre-mRNAs [45] and polyadenylated pre-mRNAs [133, 181]. Additionally,
CBC [156], NELF [156], ZFP100 [43], FLICE-associated huge protein (FLASH) [194,
229], arsenite-resistance protein 2 (ARS2) [71, 183] and U2 snRNP [59] are involved
in replication dependent histone pre-mRNA 3’ end processing. However, the exact
mechanism leading to proper histone mRNA processing instead of polyadenlyation
and the function of the individual proteins remains poorly understood.
1.3.5.3 snRNA 3´ end Processing
The processing of precursor small nuclear RNA (pre-snRNA) is comparable to repli-
cation dependent histone pre-mRNA processing (see Sec. 1.3.5.2). Following 3’ end
endonucleolytic cleavage in the nucleus, the RNAs are not polyadenylated and con-
tain a terminal 3’ stem loop structure [67]. However, the endonucleolytic cleavage is
mediated by a machinery containing the multidomain Integrator complex and the 3’
end of pre-snRNAs undergoes additional trimming in the cytoplasm.
For U snRNA transcription an U snRNA specific promoter containing a distal
sequence element (DSE) and a proximal sequence element (PSE) are required [23].
These sequences recruit snRNA specific transcription factors (Oct1 and snRNA ac-
tivation protein complexs (SNAPCs)) in addition to the general transcription fac-
tors (GTFs) (TFIIA, TFIIB, TFIIE, TFIIF, TFIIH) [148]. Furthermore, snRNA genes
contain a conserved sequence called 3’ box 9-19 nts downstream of the mature end
of the U snRNA [79, 80, 230].
In the current model of pre-snRNA co-transcriptional 3’ end processing (Figure 1.3)
the cyclin-dependent kinase (CDK)7 of TFIIH phosphorylates the Pol II CTD on Ser5
and Ser7 [2, 68] upon transcription initiation of U snRNA genes. Ser7P recruits the
putative Ser5 phosphatase RNA polymerase II associated protein 2 (RPAP2), which
leads to the association of first Integrator subunits. During elongation Ser5P is de-
phosphorylated by RPAP2 and CDK9, the kinase of P-TEFb, phosphorylates Ser2,
allowing the remaining Integrator subunits to bind. After the 3’ end box is tran-
scribed Integrator cleaves the nascent pre-snRNA, which might be recognised via its
stem-loop. Integrator is a conserved multisubunit complex of which two domains,
Int9 and Int11, show homology with CPSF100 and CPSF73, respectively. This homol-
ogy leads to the assumption that Int11 is the endonuclease of the Integrator complex
[3].
Recent studies showed that Integrator is recruited not only to loci of snRNA genes
but also binds to the 3´ end of replication dependent histone pre-mRNAs and pro-
moter proximal sites at protein coding transcripts that Ser7P is not required for its
recruitment [193]. Furthermore, Integrator seems to be involved in Pol II transcrip-
tion initiation, pause release, elongation as well as termination at mRNA encoding
genes [63, 193, 196]. At mRNAs, snRNAs and replication dependent histone mRNAs,
Integrator co-localises with NELF and DSIF and its recruitment is DSIF-dependent
[193]. Thus, DSIF and NELF as well as Integrator appear to be involved in the proper
RNA maturation of different Pol II RNA classes [228]. However, to understand their
function within the distinct RNA processing, further investigations are required.
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1.3.6 Nuclear RNA Export
Regulation of gene expression also occurs at the level of RNA transport. For exam-
ple the separation of transcription and translation allows the proper processing and
quality control of new mRNAs. The mature RNAs are exported from the nucleus to
the cytoplasm through the nuclear pore complex (NPC). This requires the assembly
of transport factors to the transcripts to form export-competent RNPs. Part of these
RNPs are the mature RNA, CBC, export adaptor and export receptor proteins. The
adaptor proteins associate with RNA already during RNA transcription and process-
ing and serve as RNA mark to recruit the respective export receptor. Export receptors
mediate the RNPs transport through the NPC. There are two major heterodimeric ex-
port receptors Nxf1-Nxt1 and CRM1-Ran leading to distinct export pathways. Most
mRNAs are exported in Nxf1-Nxt1 dependent manner, whereas rRNAs, snRNAs are
exported via the CRM1-Ran pathway (Figure 1.4), which also exports nuclear export
signal (NES) containing proteins [57, 61, 159, 195].
1.3.6.1 mRNA Export
In metazoa the transcription-export (TREX) complex is recruited to the nascent mRNPs
by the splicing machinery, whereas in yeast the transcription machinery recruits the
TREX complex [33, 135, 198]. In humans the TREX complex contains ALY, UAP56,
Tex1 and the multisubunit THO complex. The THO complex and UAP56, an RNA
helicase essential for splicing, assemble first on mRNA. UAP56 then recruits the
adaptor protein ALY to mRNA, followed by UAP56 dissociation from the complex
in an ATP-dependent manner [47, 200]. This leads to the recruitment of Nxf1-Nxt1
[47, 77, 197–199]. Then the mRNP is rearranged and ALY dissociates from the tran-
script, allowing Nxf1 to bind the mRNA [77]. Subsequently, Nxf1-Nxt1 shuttles the
transcript through the NPC [98, 187, 189]. Notably, also other adaptor proteins have
been reported like UAP56 interacting factor (UIF) and Chtop [27, 78]. Also CBC was
described to link transport receptors and mRNA [33, 74, 157] and CBP80, the bigger
subunit of the CBC heterodimer, directly interacts with ALY [33]. Furthermore, some
mRNAs seem to be exported via the CRM1-Ran pathway [38, 103] (Sec. 1.3.6.2).
1.3.6.2 U snRNA Export in Metazoans
Typically, snRNAs are shorter than mRNAs ranging from 200-300 nts [136] and as-
sociate specifically with the snRNA export adaptor PHAX (phosphorylated adap-
tor for RNA export) [140, 158]. In contrast, longer transcripts are bound by the
heterogeneous nuclear ribonucleoprotein (hnRNP) C1/C2, which replaces PHAX
from mRNAs but not from U snRNAs [140]. Within the pre-export complex con-
taining CBC, PHAX and the transcript, PHAX binds to both CBC and snRNA. Sub-
sequently, PHAX is phosphorylated by the casein kinase 2 (CK2), leading to the re-
cruitment of the export receptor CRM1 together with the small GTPase Ran [158]. In-
terestingly, phosphorylated PHAX alone does not interact with chromosomal region
maintenance 1 (CRM1) [158]. In the cytoplasm GTP hydrolysis by Ran and dephos-
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phorylation of PHAX by protein phosphatase 2A (PP2A) leads to the disassembly of
the U snRNA export complex [105, 158].
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Figure 1.4 – Nuclear RNA export
Model illustrating the main factors involved in the nuclear export of mRNAs and snRNAs.
mRNAs are mainly exported via the Nxf1-Nxt1 pathway (see Sec. 1.3.6.1), while snRNAs
require the export adaptor PHAX and the export receptor CRM1-Ran (see Sec. 1.3.6.2).
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1.3.7 Nuclear Quality Control
Pol II transcripts undergo various maturation processes including 5’ capping, splic-
ing, 3’ end processing and packing into export-competent RNPs. Although these pro-
cesses are very efficient, errors can occur within each step leading to the production
of aberrant RNAs and/or the formation of aberrant RNPs. As these irregular RNAs/
RNPs can interfere with the normal RNA metabolism and protein production, the cell
needs to destruct the non-functional transcripts. Additionally, also the accumulation
of unwanted RNAs and transcriptional by-products can disrupt the RNA metabolism
and must be prevented. To ensure that only functional RNAs are further processed
and exported from the nucleus, different nuclear quality control pathways are linked
to the individual processing steps. The nuclear exosome plays a central role in the
degradation of dysfunctional RNA molecules and thus in the regulation of the RNA
metabolism [4, 34, 146, 147]. The eukaryotic exosome is a conserved ribonucleolytic
complex consisting of 10 or 11 subunits with 3’-5’ exo- and endo-nucleolytic activities
[147]. To achieve its full activity and to target specific and correct substrates co-factors
need to assemble to the RNAs [116, 154]. The main adapter complex required for the
degradation of RNAs is the TRAMP (Trf4/Air2/MTR4 polyadenylation) complex,
containing the MTR4 RNA helicase that unwinds the transcript [110, 202, 224]. How-
ever, for promoter upstream transcripts (PROMPTs), enhancer RNAs (eRNAs) and
pre-snRNAs, the nuclear exosome targeting (NEXT) complex consisting of RBM7,
ZCCHC8 and MTR4 links the RNAs via MTR4 to the exosome [128]. Additionally,
the poly(A) tail exosome targeting (PAXT) complex, containing ZFC3H1, PABPN1
and MTR4 promotes the exosomal degradation of longer and more mature RNAs
than the NEXT complex [144]. Interestingly, all complexes require MTR4 and the
interaction of ZCCHC8 and ZFC3H1 with MTR4 is mutually exclusive, leading to
the selection of the NEXT or PAXT pathway [144]. Moreover, both complexes, NEXT
and PAXT, interact with the CBC-ARS2 complex via ZC3H18 [6, 144]. Also additional
pathways including DICER and XRN2 are under discussion to target RNAs for degra-
dation [39] and further studies are needed to understand how the different co-factors
are recruited to target the distinct dysfunctional transcript classes for degradation.
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1.4 the nuclear cap binding complex - cbc
Immediately after 5’ capping the highly conserved cap binding complex CBC, con-
sisting of CBP80 (NCBP1 - 90 kDa) and CBP20 (NCBP2 - 20 kDa), specifically binds
to the m7G cap of the nascent Pol II transcript [94]. Depending on the capped RNA,
different nuclear RNA processing and transport machineries are recruited and CBC
seems to interact directly or indirectly with some of these components (e.g. ALY [33],
CTIF [102], hnRNP C [140], NELF [156]). Therefore, CBC is involved and plays an
important role in many RNA processing events including pre-mRNA splicing [94],
RNA 3´ end processing [56, 156], nonsense-mediated decay [86, 118], mRNA and
snRNA nuclear exports [33, 93] and miRNA processing [72, 113, 184]. Additionally,
it was shown that CBC is implicated in the pioneer round of translation [92]. How-
ever, the role of CBC in helping the distinct RNAs to select their appropriate nuclear
RNA maturation pathways is poorly understood.
The crystal structure of CBC in complex with m7GpppG (PDB: 1H2T [139]) shows
that CBP20 with its RNA recognition motif (RRM) binds the cap structure (Figure
1.5A, B), although the interaction of both CBP80 and CBP20 is necessary for cap
binding [93, 94, 99]. Furthermore, CBP20, especially the residues involved in cap
binding, is highly conserved (Figure 1.5C). Cap binding leads to stabilisation and
proper folding of around 50 residues of CBP20 surrounding the RRM domain [139].
Hence, apo-CBC [137] and CBC bound to the cap [138, 139] can be distinguished
by their overall conformation. CBP80 contains three linked domains, each of them
containing consecutive helical hairpins that resemble the MIF4G (middle domain of
eIF4G) domain (Figure 1.5A).
In addition to the nanomolar affinity and high specificity of CBC for the m7G cap
structure [222], CBP20 as well as CBP80 seem to directly interact with RNA [12, 24,
161]. However, the significance of these interactions remains elusive.
In the cell CBC shows a predominantly nuclear localisation, although it is exported
from the nucleus to the cytoplasm together with the capped RNA through the nuclear
pore (see Sec. 1.3.6). A bipartite nuclear localisation signal (NLS), important for the
correct localisation of CBC, lies in the N-terminus of CBP80 [95, 205] and CBP20
is presumed to be co-imported with CBP80 via the importin-α/importin-β pathway
[122]. Additionally, the release of the cap from CBC in the cytoplasm is promoted
by binding of CBC to the nuclear import machinery (importin-α and importin-β) [40,
70].
Although CBC has been shown to be important for the proper processing of many
RNAs, the depletion of CBC in S. cerevisiae or A. thaliana leads to a growth deficient
phenotype, but is not lethal [1, 58, 201]. Knock down of CBP80 in mammalian cells
results in a reduced cell proliferation [156] and depletion of CBP20 impacts the export
of mRNAs leading to accumulation of poly(A) RNAs in the nucleus [33, 64].
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Figure 1.5 – Structural overview of the nuclear cap binding complex CBC
A: Crystal structure of CBC bound to m7GpppG (PDB: 1H2T [138]). CBP80 is made up of
three helical domains (purple shades) and CBP20 (pink) is binding m7GpppG (cyan).
B: Close up view of the cap binding site within CBP20.
C: Surface conservation of human CBC displayed on the m7GpppG-CBC crystal structure
(PDB: 1H2T [138]).
1.5 the nuclear cap binding protein 3 - ncbp3
Recently, another putative cap binding protein the nuclear cap binding protein 3
(NCBP3), also known as ELG protein, has been described [64]. Initially NCBP3 was
identified as component of messenger ribonucleoprotein (mRNP) particles involved
in splicing [145]. NCBP3 is a protein of 73 kDa with a predicted canonical RNA
recognition motif (RRM) in its N-terminal region (residues 126-187). A N-terminal
construct of NCBP3 containing the RRM domain (NCBP31-282) bound m7GTP in the
micromolar range (KD~15 µM) [64]. Additionally, mutations in the conserved WLDD
motif of the RRM domain, which is supposed to be located in the RNA binding
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grove, resulted in loss of this interaction. It has been postulated that NCBP3 directly
interacts with CBP80 to form an alternative cap binding complex [64]. In addition,
proteins of the TREX complex, the exon junction complex (EJC) as well as mRNAs
seem to associate with NCBP3. Therefore, NCBP3 is possibly involved in the export
of mRNAs [64]. However, its precise function and the underlying mechanism remain
unclear.
1.6 the phosphorylated adaptor for rna export - phax
PHAX [158] is a conserved, metazoan specific protein of 44 kDa. It contains two NLS,
a NES and an RNA binding domain (RBD) [188]. Two major phosphorylation sites
were identified to be important for the formation of the nuclear export complex com-
prising CBC, PHAX, CRM1 and RanGTP [105]. Although phosphorylation of PHAX
is required for interaction with CRM1 and RanGTP, this trimeric complex alone is
unstable and requires further stabilization by U snRNA and CBC [158]. PHAX is
phosphorylated in the nucleus by CK2 and dephosphorylated in the cytoplasm by
PP2A [105]. This compartmentalised phosphorylation/dephosphorylation system is
important for the U snRNA export (see Sec. 1.3.6.2). Recently, it was also shown
that ARS2 binds to the CBC-PHAX complex and to snRNAs stimulating their 3’
end processing [73]. Furthermore, PHAX is involved in the intranuclear transport
of snoRNAs together with CBC and CRM1 [15, 16, 111]. Thus, depletion of PHAX
leads to incorrect nuclear localisation of U snRNAs and snoRNAs and hinders the
nuclear export of U snRNAs [119, 213].
Until now, structural information is only available for the RBD of PHAX (Figure
1.6). Nuclear magnetic resonance (NMR) studies showed that the human PHAX RBD
only acquires a ternary structure upon binding to single stranded (ss) RNA [151].
Furthermore, PHAX shows a weak affinity to ssDNA (150 µM) and binds ss RNA
sequence unspecific in the micromolar range (4.2-6.5 µM) [151]. The structure of
PHAX RBD bound to AUCG reveals an entirely α-helical fold (PDB: 2XC7 [151])
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Figure 1.6 – Solution structure of PHAX RNA binding domain bound to ssRNA
A: NMR structure of PHAX RBD in complex with the ssRNA AUCG (PDB: 2XC7 [151]).
B: Close up view of the RNA binding site showing the interaction of PHAX with the RNA
sugar-phosphate backbone.
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(Figure 1.6A). The interaction of the RNA and PHAX is mainly mediated by the sugar-
phosphate backbone, explaining the non-sequence-specific binding (Figure 1.6B).
1.7 the arsenite-resistance protein 2 - ars2
ARS2, also known as serrate RNA effector molecule homolog SRRT, is an 107 kDa
conserved metazoan protein [5, 69, 170, 219] initially identified as protein involved
in arsenite resistance [180]. Later studies demonstrated that ARS2 is essential for
cell proliferation and development in Drosophila, zebrafish and mouse [5, 69, 72, 219].
ARS2 shows a predominantly nuclear localisation [219] and its NLS is supposed to be
part of the N-terminal 147 amino acids [114, 160]. ARS2 was shown to be part of sev-
eral distinct RNA complexes involved in miRNA biogenesis [72, 160], snRNA export
[73], exosomal degradation [6, 144] and RNA 3’ end processing [71, 73, 104]. ARS2
binds directly to CBC as well as to CBC-PHAX [73]. Furthermore, ARS2 also seems to
interact with proteins involved in different RNA processing pathways such as FLASH
[104], ZC3H18 [6] and DROSHA [72], thereby linking CBC bound transcripts to the
distinct processing machineries. Knockdown of ARS2 in mammalian cells leads to
defects in 3´ end processing of certain transcripts such as histone mRNAs and sn-
RNAs and in reduced degradation of short-lived transcripts like PROMPTs [6, 71,
73]. The precise biological function of ARS2 is largely unknown, especially on molec-
ular level, since only the crystal structure of the A. thaliana ARS2 homolog SERRATE
is available (PDB: 3AX1 [129]), which adopts an unusual protein structure (Figure
1.7). Remarkably, the metazoan ARS2 contains an additional highly conserved RRM
domain, which is absent in plants [160]. Five isoforms of human ARS2 are described.
Arabidopsis SERRATE (3AX1)
C-terminal 
zinc nger 
domain
N-terminal
domain
Mid domain
N
C
Figure 1.7 – Crystal structure of ARS2 plant homolog SERRATE
The A. thaliana SERRATE crystal structure (PDB:3AX1 [129]) is rainbow coloured with the
N-terminus in blue and the C-terminus in red.
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They are produced by alternative splicing and show either a deletion of a single
residue (isoform 3 - E388), the replacement of five residues by a serine (isoform 2
- 776-780 to S), the combination of both (isoform 4) or the deletion of the single
residue 387 combined with the deletion of a residue 196-231 (isoform 5). However,
the existence of isoform 5 as protein has not been confirmed experimentally.
Recent studies analysed ARS2 by mutagenesis to map possible RNA and protein-
protein interaction sites, suppose that ARS2 is either associated with DROSHA and
primary microRNA (pri-miRNA) or FLASH and replication dependent histone mRNA
[160]. Furthermore, it has been reported that the interaction between FLASH and
ARS2 is required for S phase progression [104], demonstrating a direct link between
the two proteins and their relevance within the cell cycle. The ARS2-FLASH interac-
tion is mediated by only 13 out of 1982 amino acids of FLASH, called FLASH-ARS2-
binding (FARB) region [104]. Until now the actual binding site of FLASH and other
proteins as well as RNA on ARS2 has not been identified.
1.8 the negative elongation factor - nelf
Another protein complex shown to be involved in 3’ end processing of replication
dependent histone mRNA is NELF, which only exists in metazoa [155]. NELF con-
sists of the four subunits NELF-A, NELF-B, NELF-C (or splice variant NELF-D) and
NELF-E [155, 227]. The NELF complex was originally identified to mediate Pol II
pausing together with DSIF [177, 227] (see Sec. 1.3.2). Recently, it has been shown
that NELF-A and NELF-C form the core of the NELF complex. NELF-A contains a
Pol II binding site, whereas all other NELF subunits associate with RNA [206]. The
RRM domain of NELF-E binds to a specific RNA motif, called NELF-E binding el-
ement (NBE), which is enriched in promoter proximal regions in Drosophila [174].
Thus, the binding of NELF-E to NBE is thought to regulate the promoter proximal
pausing of Pol II in a transcript specific manner [163].
Interestingly, NELF-E directly binds to CBC and it was shown that NELF-E’s C-
terminal residues (NELF-E360-380) are important for this interaction [156]. Depletion
of either CBP80 or NELF-E lead to the accumulation of aberrant poly-adenylated
histone mRNAs in HeLa cells, indicating a common role in correct 3’ end process-
ing of replication-dependent histone mRNA [156]. Within the last years the role of
NELF in proper 3´ end processing has been extended to snRNAs. It was shown that
NELF and DSIF (via respectively NELF-A and Spt5) interact with the multiprotein
Integrator complex, which is responsible for 3´ end processing of pre-snRNAs [196,
228] (see Sec. 1.3.5.3).
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1.9 aim of the work
The nuclear cap binding complex CBC plays a major role in the maturation of many
different classes of Pol II transcripts. It directly binds the nascent transcripts and
serves as binding surface for processing factors. These interactions seem to be crucial
for the correct processing and export of Pol II transcripts. However, the molecular
mechanisms that give rise to the individual complexes remain unknown. Thus, the
goal of this doctoral thesis was to elucidate the role of CBC in sorting different fam-
ilies of Pol II transcripts to the appropriate nuclear processing pathway. Therefore,
different CBC complexes including CBC-PHAX, CBC-ARS2 and CBC-NELF-E were
investigated. For a better understanding of the arrangement of the complexes dif-
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Figure 1.8 – Model of RNA Polymerase II transcript pathways with focus on CBC-ARS2
All Pol II transcripts are bound by CBC via their m7G cap before entering different processing
and transport pathways. Depending on the RNA ARS2 or even ARS2 plus additional proteins
are recruited to the complex. However, the molecular basis of the recruitment and formation
of the individual processing complexes remains elusive. Additionally, another putative cap
binding complex consisting of NCBP3 and CBP80 with unknown function has been described
recently [64].
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ferent biophysical, structural and biochemical methods were used to analyse the
protein-protein interaction.
Apart from CBC, also ARS2 associates with different RNAs (e.g. miRNAs, his-
tone mRNAs, snRNsA and mRNAs) and interacts with proteins involved in distinct
RNA processing pathways (e.g. FLASH [104], DROSHA [72] and ZC3H18 [6]). To
get insight into the role of ARS2 and its interactions atomic resolution structural in-
formation is required. Currently, there is only a crystal structure of the homologous
protein SERRATE from A. thaliana available, which exhibits a unique ‘walking man’
(body, leading and lagging leg) topology [129]. However, metazoan ARS2 differs
from SERRATE in having a number of insertions including a putative RRM domain
of unknown function ([160]). Thus, another goal was to obtain structural information
of ARS2 and to investigate its interaction with RNA and different RNA processing
machineries (e.g. PAXT, NEXT, DROSHA and FLASH).
Additionally, the recent description of NCBP3 and CBP80 as alternative nuclear cap
binding complex was analysed to understand and to learn more about its function
within RNA processing.
2
M AT E R I A L S A N D M E T H O D S
2.1 materials
2.1.1 Antibodies
• DIS Alexa Fluor 488 anti-BrdU antibody (BioLegend) - Mouse IgG1, κ
• Alexa Fluor 647 anti-GFP antibody (BioLegend) - Rat IgG2a, κ
2.1.2 Bacteria
• E. coli Rosetta 2 (DE3) (Novagen): F-ompT hsdSB(rB- mB-) gal dcm (DE3)
pRARE2 (CamR)
• E. coli DH10 Bac (Invitrogen): F-mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15
ΔlacX74 recA1 endA1 araD139 Δ(ara, leu)7697 galU galK λ-rpsL nupG/p-
MON14272/pMON7124
• E. coli TOP10 (Invitrogen): F-mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15
ΔlacX74 recA1 araD139 Δ(ara, leu)7697 galU galK rpsL (StrR) endA1 nupG
2.1.3 Chemicals
Chemicals were purchased from the following companies: Euromedex, Fluka, Sigma-
Aldrich, CARLO ERBA Reagents, Merck, MP Biomedicals, Roche, Roth.
2.1.4 Cell Lines
• Homo sapiens embryonic kidney (HEK 293T/17) cells (ATCC)
• Spodoptera frugiperda (Sf21) insect cells (Gibco)
• Trichoplusia ni (High Five) insect cells (Gibco)
2.1.5 Composition of Solutions
All buffers and solutions were prepared with ultrapure water (Millipore systems)
and filtered through a 0.22 μm membrane filter. Buffers for chromatography at an
ÄKTA System were additionally degassed before use. The composition of all media
and buffers used in this work are listed in Table A.1 and Table A.2 in Appendix A.1.
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2.1.6 Cross-linker
• disuccinimidyl suberate DSS -H12/D12 (Creative Molecules Inc.)
2.1.7 Enzymes
Enzymes used in this thesis are listed in Table 2.1.
Table 2.1 – Enzymes
enzyme manufacturer
Calf Intestinal Phosphatase (CIP) NEB
DNA Ligation Kit, Mighty Mix Takara
Phusion High Fidelity DNA Polymerase NEB
Polymerase GoTaq Green Master Mix Promega
PrimeSTAR Max DNA Polymerase Takara
Restriction Endonucleases NEB
RNase A, DNase and protease free Thermo Fisher Scientific
Sequencing Grade Modified Trypsin Promega
T7 Polymerase EMBL Heidelberg, Germany
His-tagged TEV protease EMBL Heidelberg, Germany
Lysyl Endopeptidase (Lys-C), Mass
Spectrometry Grade
Wako
2.1.8 Instruments
Instruments used in this study are listed in Table A.3 in Appendix A.2.
2.1.9 Kits
Kits used in this study are listed in Appendix A.3 Table A.4.
2.1.10 Oligonucleotides
DNA-oligonucleotides were ordered from Thermo Fisher Scientific (Waltham, United
States). RNA-oligonucleotides and FAM-labeled RNA-oligonucleotides were obtained
from iba (Göttingen, Germany).
2.1.11 Peptides
Peptides and FAM-labeled peptides were bought from GenScript (Piscataway, United
States).
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2.1.12 Plasmids
General plasmids used as basis within this study are listed in Table 2.2.
Table A.5 in Appendix A.4 contains all plasmids constructed for protein expression
used within this work.
Table 2.2 – Plasmids
plasmid resis-
tance
manufac-
turer
description
pcDNA3.1 Amp Invitrogen one multiple cloning site, for mammalian
cell line expression
pETM11 Kan EMBL N-terminal His tag followed by TEV
cleavage site, for bacterial expression
pETM30 Amp EMBL N-terminal His tag followed by GST tag
and TEV cleavage site, for bacterial
expression
pETM41 Amp EMBL N-terminal His tag followed by MBP tag
and TEV cleavage site, for bacterial
expression
pETM11
SUMO
Amp EMBL N-terminal His tag followed by SUMO
tag and TEV cleavage site, for bacterial
expression
pETDuet Amp Novagen two multiple cloning sites (one with
N-terminal His tag followed by TEV
cleavage site), for bacterial expression
pET-15b Amp Takara two multiple cloning sites (one with
N-terminal His tag followed by TEV
cleavage site), for bacterial expression
pFastBac Amp Life Tech-
nologies
one multiple cloning site, for baculovirus
expression
pFastBac
HTb
Amp Life Tech-
nologies
N-terminal His tag followed by TEV
cleavage site, for baculovirus expression
pFastBac
Dual
Amp Life Tech-
nologies
two multiple cloning sites (one with
N-terminal His tag followed by TEV
cleavage site), for baculovirus expression
2.1.13 Saccharomyces cerevisiae Strains
The yeast strains used within this study are listed in Table 2.3.
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Table 2.3 – Yeast strain genotypes
strain genotype reference
CG1945 MATa, ura3-52, his3-200, ade2-101, lys2-801,
trp1-901, leu2-3, 112, gal4-542, gal80-538, cyhr2,
LYS2::GAL1UAS-GAL1TATA-HIS3, URA3::GAL4
17-mers (x3)-CyC1TATA-lacZ
[55]
Y187 MATα, ura3-52, his3-200, ade2-101, trp1-901,
leu2-3, 112, gal4Δ, met–, gal80Δ,
URA3::GAL1UAS-GAL1TATA-lacZ
[76]
2.1.14 Transfection Reagents
• X-tremeGENE HP DNA Transfection Reagent (Roche Life Science)
• polyethylenimine (PEI), branched MW 25 kDa (Sigma-Aldrich)
2.2 molecular biology methods
2.2.1 Antibiotics
After transformation of a resistance encoding plasmid the following antibiotics were
used at the specified concentrations:
• ampicillin (100 mg/ml)
• chloramphenicol (30 mg/ml)
• gentamycin (7 mg/ml)
• kanamycin (50 mg/ml)
• streptomycin (50 mg/ml)
• tetracycline (10 mg/ml)
2.2.2 Polymerase Chain Reaction
DNA fragments for cloning were amplified with Phusion High-Fidelity DNA Poly-
merase or PrimeStar Max (Takara) according to the standard procedures [186]. For
colony polymerase chain reaction (PCR) GoTaq polymerase (Promega) was used.
2.2.3 Agarose Gel Electrophoresis
DNA fragments were separated depending on their size in 1-2% (w/v) agarose EDTA
gels supplemented with 1:20 000 SYBR Safe DNA Gel Stain (Invitrogen). DNA was
visualised using a UV lamp.
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2.2.4 DNA Restriction
All restriction digestions were performed with Type II endonucleases (NEB) accord-
ing manufacturer’s protocols.
2.2.5 DNA Purification
After PCR and restriction digestions DNA fragments were purified using either the
QIAquick PCR Purification Kit (Qiagen), the QIAquick Gel Extraction Kit (Qiagen)
or the NucleoSpin Gel and PCR Clean-up Kit (Macherey-Nagel) according to manu-
facturer’s protocol.
2.2.6 DNA Ligation
Purified insert and plasmid were ligated using the DNA Ligation Kit, Mighty Mix
(Takara). Plasmid and insert were mixed in an 1:3 molar ratio and incubated for 1 h
at 16ºC.
2.2.7 In-Fusion Cloning
To insert one or multiple DNA fragments at once into a plasmid the In-Fusion HD
Cloning Kit (Clontech) was used. Plasmid and insert containing a 15-20 bp overlap at
their ends were mixed in an 1:1.1 molar ratio and incubated with the In-Fusion HD
Enzyme Premix for 15 min at 55ºC prior transformation into E. coli (see Sec. 2.2.12).
2.2.8 Plasmid Preparation
Plasmids were isolated and purified using the QIAprep Spin Miniprep Kit (Qiagen)
or NucleoSpin Plasmid Kit (Macherey-Nagel) according to manufacturer’s instruc-
tions.
2.2.9 DNA and RNA Concentration Determination
To estimate the concentrations of single stranded (ss) DNA and ssRNA oligonu-
cleotides the absorbance at 260 nm was measured with a NanoDrop spectropho-
tometer (Thermo Fisher Scientific).
2.2.10 Site-directed Mutagenesis
Mutations were introduced using site directed mutagenesis [84, 176]. Two overlap-
ping primers containing the mutation of interest were used for PCR (see Sec. 2.2.2).
After DpnI digestion the DNA was transformed into E. coli (see Sec. 2.2.12).
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2.2.11 Preparation of Chemically Competent E. coli
Chemically competent E. coli were prepared using a standard rubidium chloride
method. LB media supplemented with the respective antibiotics was inoculated with
1% (v/v) of an overnight culture and grown at 37ºC until the OD600 nm reached 0.6.
Bacteria were pelleted (6500 g, 10 min, 4ºC), resuspended gently in solution CC1 and
incubated for 1 h on ice. After another round of centrifugation (6500 g, 10 min, 4ºC)
the bacteria were resuspended in buffer CC2 and incubated 15 min on ice. Then the
bacteria were aliquoted and flash frozen in liquid nitrogen before stored at -80ºC.
2.2.12 Transformation of Chemically Competent E. coli
DNA was transformed into E. coli via heat shock. Briefly, chemically competent bac-
teria were thawed on ice and incubated with the DNA of interest. After 10-20 min
they were incubated for 1 min at 42°C following 1-5 min incubation on ice. 1 ml of
LB medium was added and the bacteria were incubated for 30-60 min at 37°C before
plating on the appropriate selective media and incubation at 37°C overnight.
2.2.13 Transformation of Saccharomyces cerevisiae
Appropriate yeast colonies were resuspended in 500 µl 0.1 M lithium acetate and
centrifuged (2500 g, 2 min, RT). After resuspending the pellet in 100 µl 0.1 M lithium
acetate, 10 µl 10 mg/ml herring sperm DNA, 1-2 µg plasmid DNA and 700 µl 0.1 M
lithium acetate, 40% (w/v) PEG in Tris-EDTA Buffer were added, mixed and incu-
bated 30 min at 30°C. Then 88 µl DMSO were added and the cells thermo shocked
for 7 min at 42°C. The cells were pelleted (2500 g, 2 min, RT) and washed once with
water before plated on the corresponding plates.
2.2.14 Yeast Two-Hybrid Assay
For the yeast bridged two-hybrid assay pACT2 and p422 (ADE2 multicopy) plasmids
were transformed into Y187 and pAS2 plasmids were introduced into CG1945 hap-
loid Saccharomyces cerevisiae. Strains were crossed for 4 h at 30°C and diploids were
plated on triple- and quadruple-selective media (-Ade –Leu -Trp or -Ade -Leu -Trp
-His). After 3 days at 30°C cell growths was assessed visually.
2.2.15 Bacmid Production
1-2 μg of plasmid DNA encoding the gene of interest were transformed into E. coli
DH10 Bac by heat shock as described in Sec. 2.2.12. To enable DNA recombination the
culture was incubated 4-6 h at 37°C. Afterwards different dilution were streaked out
on kanamycin/tetracycline/gentamycin /IPTG/Bluo-Gal plates. To exclude any con-
tamination, the next day white colonies were picked and restreaked. For the bacmid
preparation two 2 ml overnight cultures of two individual white clones were pelleted
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(2200 g, 5 min, RT). For the following steps buffers from the QIAprep Spin Miniprep
Kit (Qiagen) were used. The pellet was resuspended in 300 μl Buffer P1 and trans-
ferred to an 1.5 ml tube before adding 300 μl of Buffer P2. The tube was gently
inverted and incubated for 2 min at room temperature. Afterwards 300 μl of Buffer
N3 were added and the tube was inverted ten times. The suspension was centrifuged
(18000 g, 10 min, RT) and the supernatant was transferred to a new tube followed by
centrifugation (18000 g, 5 min, RT). In a new tube 700 μl of 100% isopropanol were
added to the supernatant and gently mixed. The DNA was pelleted (18000 g, 10 min,
RT) and washed twice with 70% (v/v) ethanol (18000 g, 5 min, RT).
2.2.16 Protein Constructs
An overview of all in this thesis used constructs encoding for the protein of interest
can be found in Table A.5 in Appendix A.4.
2.3 cell biology methods
2.3.1 Insect Cell Culture
Sf21 and High Five insect cells were cultured shaking at 27°C at a density of
0.5·106 cells/ml in their individual medium.
2.3.2 Baculovirus Production
After isolation of the bacmid (see Sec. 2.2.15) the ethanol was removed and the
bacmid was first resuspended in 20 μl water before further dilution with 200 μl SF21
medium. 10 μl of X-tremeGENE transfection reagent (Roche Life Science) were added
to 100 μl of SF21 medium and then added together to the DNA containing tube. Af-
ter incubation for 10 min 0.5-1·106 Sf21 cells/well were transfected with 150 μl of the
mixture in a 6-well plate. After 72 h the supernatant (V0) was removed and stored at
4ºC. To obtain the V1 25 ml of Sf21 at 0.5·106 cells/ml were infected with 3 ml of V0.
Cells were diluted with medium to maintain the density below 1·106 cells/ml. 72 h
after proliferation arrest the V1 was harvested by pelleting the cells (10000 g, 10 min,
RT) and stored at 4ºC.
2.3.3 Mammalian Cell Culture
HEK 293T/17 cells were grown in high glucose Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS). Cells were main-
tained at 37°C and 5% (v/v) CO2 and split every 2-3 days. To split the cells the
medium was removed and cells were washed twice with PBS before incubation with
0.01% (w/v) trypsin-EDTA for 3 min. Then cells were resuspended and diluted in
whole medium before seeded in new flasks.
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2.3.4 Transfection of Mammalian Cell Lines
Mammalian cells were transfected using PEI in a DNA:PEI ratio of 1:2 (Table 2.4).
One day before transfection cells were split to the desired density.
Table 2.4 – Transfected DNA mixtures
dish dna pei
6-well plate 1 μg 2 μl
T25 flask 2.5 μg 5 μl
T75 flask 7 μg 14 μl
2.3.5 Cell Cycle Analysis
For bromodeoxyuridine (BrdU) cell cycle experiments, 0.5·105 HEK 293T/17 cells
were seeded on T25 flasks and the next day transfected with the desired plasmids.
24 h post transfection, cells were transferred onto a T75 flask to allow growth. The
next day, cells were given a 30 min BrdU pulse and fixed with 60% (v/v) ethanol
overnight. Cells were incubated with 2 M hydrochloric acid for 20 min at 37ºC. Af-
ter centrifugation (4 min, 400 g, RT) cells were resuspended in 0.1 M sodium borate.
After washing the cells twice with PBS (4 min, 400 g, RT), cells were counted and
labeled with mouse Alexa Fluor 488 conjugated anti-BrdU antibody (BioLegend)
and rat Alexa Fluor 647 conjugated anti-GFP antibody (BioLegend) in Labeling
Buffer for 1 h at room temperature. Cells were washed three times (4 min, 400 g,
RT) and resuspended in Labeling Buffer supplemented with 3 µM 4’,6-diamidino-2-
phenylindole (DAPI). A total of 104 GFP-positive events per sample were collected
on a BD LSRFortessa flow cytometer at the Flow Cytometry Core Facility EMBL
Heidelberg.
2.3.6 Immunofluorescence
For immunofluorescence 3·105 cells/well were seeded onto a glass coverslip in a
6-well plate. The next day cells were transfected with 1 µg of DNA. 48 h after trans-
fection cells were washed twice with PBS and incubated with 4% (w/v) PFA in PBS
for 15 min at room temperature in the dark followed by a PBS wash and 15 min in-
cubation with 0.1% (v/v) Triton X-100 in PBS. Then the coverslips were washed two
more times with PBS, mounted using Fluoroshield Mounting Medium with DAPI
(abcam) onto microscope slides and sealed using nail polish. Slides were kept in the
dark at 4°C until analysed by confocal microscopy (Leica TCS SP5).
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2.4 expression and purification of proteins
2.4.1 Bacterial Protein Expression
For bacterial protein expression the constructs of interest (Appendix A.4 Table A.5)
were transformed into E. coli Rossetta 2 and generally expressed overnight at 18°C
after induction with 0.4 mM IPTG at an OD600 nm of 0.6-0.9. CBP20, GST and PHAX
full length were expressed at 30°C for 6 h. The cells were harvested by centrifugation
(800 g, 10 min, 10°C), flash frozen in liquid nitrogen and stored at -20°C before
protein purification.
2.4.2 Protein Expression in Insect Cells
For protein expression High Five insect cells were cultivated in Express Five Serum-
free Medium (Invitrogen) supplemented with 18 mM L-glutamine and 100 µg/ml
penicillin and streptomycin. Cells were transfected at 0.5·10 6 cells/ml with 0.1-0.5%
(v/v) virus V1 to stop cell division after 24 h. After additional 48 h the cells were
harvested by centrifugation (800 g, 10 min, 10°C), flash frozen in liquid nitrogen and
stored at -20°C before protein purification.
2.4.3 Seleno-methionine Labeling in Bacteria
M9 medium supplemented with 1 mM magnesium sulfate, 0.1 mM calcium chloride,
20% (w/v) glucose, 2 mg/ml thiamine and appropriate antibiotics was inoculated
with 0.1% (v/v) LB preculture and grown at 37ºC overnight. 50 ml of this preculture
were used to inoculate each final liter of supplemented M9 medium. At an OD 600 nm
of 0.7-0.9 the temperature was lowered to 18ºC. The dissolved amino acids (100 mg
Lys, 100 mg Phe, 100 mg Thr, 50 mg Ile, 50 mg Leu, 50 mg Val and 50 mg seleno-Met
per liter) were added and after additional 30 min the protein expression was induced
using 0.3 mM IPTG. The bacteria were harvested by centrifugation (6500 g, 15 min,
10°C) and stored at -20°C.
2.4.4 Cell Lysis
Bacteria and insect cells were lysed using a sonicator. The pellets were resuspended
in Lysis Buffer and sonicated on ice for 3.5 min (10 sec on/25 sec off) at an intensity
of 75%. Afterwards cell debris and aggregations were separated by centrifugation
(60000 g, 1 h, 10°C).
2.4.5 Ni Affinity Chromatography
After lysis and centrifugation, the cleared supernatant was loaded on Ni-Sepharose
(GE Healthcare) equilibrated with appropriate buffer in a BioRad gravity flow col-
umn. For the purification of CBC, first cleared His-tagged CBP20 lysate was loaded
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on the Ni-Sepharose. After washing with Lysis Buffer and the cleared CBP80 super-
natant was applied to the column. After washing with at least 10 column volumes of
Lysis Buffer supplemented with 20 mM imidazole, the His-tagged protein was eluted
with 300 mM imidazole in Lysis Buffer. Wash and elution fractions were analysed by
SDS-PAGE (see Sec. 2.5.2) and protein containing fractions pooled and further puri-
fied.
2.4.6 Tag Removal
To cleave the affinity tags from the construct of interest all fusion proteins carried
the specific recognition site for TEV protease. After elution from the affinity chroma-
tography fractions were pooled and overnight dialysed against 50-400 mM sodium
chloride, 10 mM β-mercaptoethanol, 5% (v/v) glycerol, 20 mM HEPES pH 7.8 in the
presence of 1 mg TEV protease (EMBL Heidelberg) per 50 mg recombinant protein.
Afterwards the protein solution was applied again to the Ni affinity chromatography
and the flow through kept for further purification.
2.4.7 Ion Exchange Chromatography
Before loading the sample on the column the salt concentration was adjusted by dial-
ysis or diluting the sample to allow the sample to bind to the resin. After washing
away all unbound components the protein was eluted using a sodium chloride gra-
dient on an ÄKTA Protein Purification System (ÄKTA Prime, Basic, or Purifier, GE
Healthcare).
2.4.8 Size Exclusion Chromatography
Size exclusion chromatography (SEC) was used in the final step of purification, for
buffer exchange, for checking the protein quality, for interaction studies and for re-
constitution of protein-complexes.
Depending on the size of the protein or protein-complex a Superdex 200 PC3.2/30,
Superdex 75 10/300, Superdex 200 10/300 or a Superose 6 10/300 was used on an
ÄKTA System. Up to 1 ml of sample was injected on the column equilibrated in
the buffer of choice. Flow rates were typically 0.4 ml/min for 10/300 columns on
an ÄKTA Protein Purification System and 0.05 ml/min for PC3.2/30 columns on an
ÄKTA Micro system.
2.4.9 Concentration of Protein Solutions
Protein solutions were concentrated using Amicon Ultra Centrifugal Filters (Merck
Millipore) with a cut off below half of the molecular weight of the protein. In case
of protein precipitation during concentration the sodium chloride concentration was
increased up to 500 mM.
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2.4.10 Protein Storage
For long-term storage or shipment purified protein was divided into small aliquots
and flash-frozen in liquid nitrogen. Aliquots were stored at -80 °C and shipped on
dry ice.
2.5 biochemical and biophysical methods
2.5.1 Protein Concentration Determination
Protein concentrations were determined using the calorimetric Bio-Rad Protein Assay,
an assay based on the absorbance shift of Coomassie brillant blue G-250 [17].
2.5.2 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
The presence and purity of proteins were analysed by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE). Depending on the size of the proteins
between 6-18% (w/v) SDS-polyacrylamide gels were cast. Samples were mixed with
SDS Sample Buffer and electrophoresis was conducted with 1x SDS Running Buffer
(200-300 V for 30-60 min). To estimate the size of protein bands a molecular weight
standard was used. Gels were stained with Coomassie (InstantBlue, Expedeon) for
5-10 min followed by washing and destaining with water. To detect low concentra-
tions of protein on a SDS-PAGE gel as from a single crystal the Silver Stain Plus Kit
(Bio-Rad) was used following manufacturer’s instructions.
2.5.3 Identification of Proteins from SDS-PAGE Gels by Mass Spectrometry
After electrophoresis (see Sec. 2.5.2) SDS-PAGE gels were fixed with 45% (v/v) me-
thanol and 10% (v/v) acetic acid for 15-60 min. After rinsing the gel twice for 5 min
with water the gel was stained with Coomassie blue solution for 1-3 hours. The gel
was washed twice with water before destained overnight with 45% (v/v) methanol
and 10% (v/v) acetic acid. After washing with water, the gel was stored in 1% (v/v)
acetic acid. The bands were excised from the gel, trypsin digested and identified by
mass spectrometry (EMBL Proteomics Core Facility Heidelberg).
2.5.4 Limited Proteolysis
To identify stable protein subcomplexes and protein-protein complexes the individ-
ual proteins or complexes were treated with different proteases. Therefore, the pro-
teins were incubated with trypsin (1:1000 (w/w)), chymotrypsin (1:500 (w/w)), elas-
tase (1:500 (w/w)) or papain (1:1000 (w/w)) in 50 mM HEPES pH 7.7, 150 mM
sodium chloride for up to 2.5 h at room temperature or over night at 4ºC before
analysis by SDS-PAGE or gel filtration followed by SDS-PAGE (see Sec. 2.5.2).
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2.5.5 Isothermal Titration Calorimetry
To determine thermodynamic parameters of protein-protein interactions the isother-
mal titration calorimetry (ITC) was used. In the ITC experiment one protein solution
in the syringe is titrated into the cell containing the other protein. In case of molecular
interaction heat is either released or absorbed. Measurements of this difference allow
the determination of the standard Gibbs free energy change ΔG, the equilibrium
binding constant Ka and the dissociation constant KD, the enthalpy change ΔH, the
entropy change ΔS and the stoichiometry n of the interaction. Correlation between
the parameters is given by: ΔG = −RTlnKa = RTlnKD = ∆H − TΔS (with R as
universal gas constant and T as temperature in degrees Kelvin).
ITC measurements were performed at 25°C with a MicroCal200 calorimeter (Mal-
vern). Prior to measurements, proteins were dialysed overnight in the same buffer
to exclude buffer differences. The titration was performed by stepwise addition of
the 5-20 times higher concentrated sample in the syringe to the protein in the sam-
ple cell at a stirring speed of 800 rpm. As control the solution in the syringe was
titrated into buffer to subtract possible effects due to dilution during titration. Data
analysis was carried out with the MicroCal ITC Origin software suite (Malvern). The
integrated heat values were fitted to the “single binding site” model and iterated
until the chi squared value reached the minimum. KD values and standard devia-
tions listed within this study represent the average from at least two independent
experiments.
2.5.6 Fluorescence Polarisation Assay
Fluorescence polarisation binding assays were performed with N-terminal FAM-
labeled ARS2845-871 (ARS2845-871(FAM)) and NELF-E354-380 (NELF-E354-380(FAM)) pep-
tides. 40 nM peptides were titrated with increasing concentrations of proteins in
Buffer A. For the competition assay CBC-ARS2 and CBC-NELF-E complexes were
preformed in the presence of 25 µM m7GTP using 40 nM ARS2827-871(FAM) peptide
and 60 nM CBC and 40 nM NELF-E354-380(FAM) peptide with 1 µM CBC. These
preformed complexes were titrated with NELF-E244-380, ARS2827-871 and PHAX103-327,
respectively. For the displacement assay between PHAX and NELF-E, PHAX103-327
was titrated to a premixture of 40 nM ARS2827-871(FAM) peptide, 60 nM CBC and
270 nM NELF-E244-380 in the presence of 25 µM m7GTP.
For RNA-binding studies FAM-labeled RNA was used at a concentration of
37.5 nM and titrated with increasing amounts of protein in RNA Binding Buffer.
Fluorescence polarisation was measured at 25 °C with a microplate reader (BMG
LABTECH) using an excitation wavelength of 495 nm and an emission wavelength
of 515 nm. For analysis the polarisation value for the peptide alone was subtracted
from the measurements and the KD values derived by curve fitting using GraphPad
Prism version 5.00 and 7.00 for Windows (GraphPad Software, La Jolla, California,
United States).
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2.5.7 Protein Cross-Linking Combined with Mass Spectrometry
Purified protein complexes were cross-linked at 0.5 mg/ml with 2 mM DSS (Cre-
ative Molecules Inc.) at 35ºC at 600 rpm for 30 min. To quench the reaction 0.1 vol-
ume quenching solution (250 mM ammonium bicarbonate, 10 M urea) were added
and incubated additional 10 min at 35ºC and 600 rpm. Then additional 0.8 volume
quenching solutions were added and the sample twice sonicated for 5 s. After ad-
dition of DTT to a final concentration of 10 mM and incubation for 30 min at 30ºC
and 600 rpm, iodoacetamide was added to a final concentration of 15 mM and incu-
bated 30 min at room temperature in the dark. Proteins were digested by addition
of Lys-C (Wako) (1:100, 4 h at 37 °C) and following dilution of urea to 1.5 M with
trypsin (Promega) (1:50, over night at 37°C). 2% (v/v) trifluoroacetic acid (TFA) was
added and incubated for 30 min at 37°C. After centrifugation (10 min, 12 000 g, RT)
samples were loaded on Macro SpinColumns (Harvard Apparatus) (4 min, 1000 g,
RT). After four washes with 500 µl 5% (v/v) acetonitril (ACN), 0.1% (v/v) formic
acid (FA) (2 min, 1000 g, RT) the peptides were eluted three times with 250 µl in
50% (v/v) ACN, 0.1% (v/v) FA (4 min, 1000 g, RT) and lyophilised in a Speed-Vac.
Samples were reconstituted in 20 µl water/ACN/TFA (70:30:0.1) and subjected to
SEC (Superdex Peptide PC3.2/30). Fractions of interest were lyophilised and sent
to the Proteomics Core Facility (EMBL Heidelberg) for mass spectrometric analysis.
For the identification of peptides the xQuest/xProphet software was used [117, 211].
Cross-linked peptides were filtered with a delta score <0.95 and a false discovery rate
<0.05.
2.5.8 m7GTP-Sepharose Pull Down
To pull down specifically cap-binding proteins m7GTP-Sepharose (GE Healthcare)
affinity chromatography was used. The purified proteins were incubated with pre-
quilibrated resin rotating at 10°C for at least 30 min. For the competition assay or to
test interaction with other proteins the resin bound cap binding complex was incu-
bated with additional protein before washing with buffer and eluting using 2x SDS
Sample Buffer. The presence of proteins of interest in the flow though, wash and
elution was analysed by SDS-PAGE (see Sec. 2.5.2).
2.5.9 GST Pull Down
Purified GST-tagged proteins or GST-tagged proteins from precleared lysate were
immobilised using Glutathione Sepharose (GE Healthcare) affinity resin before incu-
bation with possible interacting partners in Buffer A. After extensive washing with
Buffer A (400 g, 2 min, 10°C) the complexes were eluted using 10 mM reduced Glu-
tathione or 2x SDS Sample Buffer. Presence of proteins of interest in the elution was
analysed by SDS-PAGE (see Sec. 2.5.2).
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2.5.10 EGFP Affinity Purification Followed by Mass Spectrometry
Frozen cell pellets were thawed on ice, resuspended in HEK 293 Lysis Buffer supple-
mented with protease inhibitor tablets and 1 µg/ml RNAse H and 30 min incubated
on ice. After centrifugation (16000 g, 20 min, 4°C) the supernatant was precleared
for 1 h at 4ºC with 100 µl preequilibrated Sepharose A beads (GE Healthcare) before
incubation with 25 µl GFP-Trap (ChromoTek) beads at 4ºC for 2 h. After washing
the beads three times with 500 µl HEK 293 Lysis Buffer (400 g, 2 min, 10°C) the
protein was eluted using 50 µl 0.1 M glycine pH 2.3 followed by a second elution
with 30 µl. The eluted protein was neutralised with 0.1 M Tris-HCl pH 8.5 and flash
frozen in liquid nitrogen. Within the Proteomics Core Facility (EMBL Heidelberg) the
samples were digested and labeled with tandem mass tags (TMTs) before analysed
by mass spectrometry. Also further analysis of the obtained data was performed by
the Proteomics Core Facility.
2.6 protein crystallization and data collection
2.6.1 Protein Crystallization
Initial screening experiments were performed by the high-throughput crystallisation
(HTX) platform at EMBL Grenoble using the six pre-made screens (Classic Suite,
JCSG+, PACT premier, PEGs-I, Salt Grid, Wizard I&II). Conditions leading to crystals
were manually reproduced and further optimised in terms of precipitant, salt and
protein concentrations as well as screened for possible additives. Crystals were flash-
frozen in well solution supplemented with 20% (v/v) glycerol prior X-ray diffraction
analysis.
The CBC-ARS2827-871 complex was prepared by mixing CBC with an excess of
ARS2827-871 in the presence of 1 mM m7GTP and subjecting the mixture to gel filtra-
tion (120 mM sodium chloride, 5 mM β-mercaptoethanol, 20 mM HEPES pH 7.8). The
complex was concentrated to 8 mg/ml using Amicon ultra centrifugal filters (Milli-
pore). The best crystals were obtained in mother liquor containing 0.1 M sodium ac-
etate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20°C. For the NELF-
E complex m7GTP or m7GpppG together with NELF-E360-380 or CBC-NELF-E354-380
was added to CBC before setting up the drops. The best crystals of m7GTP-CBC-
NELF-E360-380 were obtained by mixing 6 mg/ml CBC, 500 µM m7GTP and 500 µM
peptide in 120 mM sodium chloride, 1 mM TCEP, 20 mM HEPES pH 7.8. Crystals
grew at 20°C in mother liquor containing 0.2 M lithium citrate and 20% (w/v) PEG
3350.
For ARS2 the best diffracting crystals were obtained at 4°C in mother liquor con-
taining 0.2 M potassium citrate tribasic monohydrate, 20% (w/v) PEG 3350 (for ARS2
147-270 + 408-763 and ARS2 147-270 + 408-763∆567-599 GSGSGS); 1.2 M sodium dihydrogen phos-
phate, 0.8 M dipotassium hydrogen phosphate, 0.1 M CAPS pH 10.5, 0.2 M lithium
sulfate (for ARS2 171-270 + 408-763); 0.1 M Bis-Tris propane pH 6.5, 0.2 M lithium sulfate,
22% (w/v) PEG 3350 (for ARS2 147-270 + 408-763∆539-554 GSA) and 0.2 M lithium sulfate,
20% (w/v) PEG 3550 (for ARS2147-270+408-763 + FLASH921-946).
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2.6.2 Data Collection
X-ray diffraction data of single crystals were collected under cryo-conditions at the
European Synchrotron Radiation Facility (ESRF) beamlines (Grenoble, France), name-
ly, ID30A-1 (MASSIF-1), ID23-1 and ID29. On ID30A-1 datasets were recorded at
a fixed energy of 12.835 keV (0.966 Å) with a Pilatus3 2M detector (Dectris). The
tunable beamline ID23-1 was used with an energy of 14.200 keV (0.873Å) and is
equipped with a PILATUS 6M-F detector (Dectris). On the tunable beamline ID29
datasets of seleno-methionine crystals were collected at 12.6578 keV (0.9795 Å) and all
other datasets were collected at 12.600 keV (0.984 Å) with a PILATUS 6M-F detector
(Dectris).
At ID23-1 and ID29 initial indexing and determination of the optimal data collec-
tion strategy were automatically calculated from four initial diffraction images using
EDNA [90], MOSFLM [121], RADDOSE [164] and BEST [168] which are implemented
in MXCube user interface [62].
2.7 bioinformatics and computational methods
2.7.1 Sequence Analysis and Alignments
Multiple protein sequence alignments were generated with Clustal Omega [123, 143,
192] and visualised using ESPript [179]. Additionally, the CLC Sequence Viewer 6.9
(CLC Genomics Workbench 9.5.3) was used to align amino acid and DNA sequences.
2.7.2 Secondary Structure and Protein Disorder Prediction
Secondary structure and protein disorder prediction were performed with PrDOS
[91] and JPred [46].
2.7.3 Data Analysis
ITC data were analysed with the MicroCal ITC-ORIGIN Analysis Software suite
(Malvern) (see Sec. 2.5.5). Graphical presentations and fluorescence anisotropy curve
fitting were performed with GraphPad Prism version 5.00 and 7.00 for Windows
(GraphPad Software, La Jolla, California, United States). For the analysis and visual-
isation of the obtained flow cytometry data FlowJo V10 was used (TreeStar Software,
Ashland, United States). After gating for single cells, cells with high EGFP staining
were analysed for their BrdU incorporation in respect to their DNA amount. For the
DNA/cell cycle analysis the univariate model was used to quantify the cells in the
distinct cell phases. To compare the mutants with the wild type of all three experi-
ments the One-way ANOVA followed by Dunnett’s multiple comparisons test was
performed using GraphPad Prism.
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2.7.4 Structure Analysis and Presentation
Structure figures were drawn and root-mean-square deviation (RMSD) values
were calculated with PyMOL (PyMOL Molecular Graphics System, Version 1.8
Schrödinger, LLC). Conservation studies were performed using the ConSurf Server
[8, 9, 25, 112]. The PISA server [108] was used to calculate macromolecular interfaces,
LIGPLOT [210] to visualise ligand-protein interactions and BobScript [50, 51] to draw
omit difference electron density maps.
2.7.5 Structure Determination
2.7.5.1 Molecular Replacement
X-ray diffraction data were indexed, integrated and scaled with XDS [97] and ana-
lysed using the CCP4i suite [221]. For CBC complexes the phase problem was solved
by molecular replacement with PHASER [141] and using the known structure of CBC
bound to m7GpppG (PDB:1H2T [139]). After obtaining the ARS2 structure additional
ARS2 data sets were solved by using the obtained structure as model for molecular
replacement.
2.7.5.2 Atomic Model Building, Refinement and Validation
Refinement was performed with REFMAC5 [152] and BUSTER [18] with local non-
crystallographic symmetry restraints. COOT [49] was used for model building and
structure analysis. For structure validation MolProbity [31] and the PDB validation
tools [175] were used.
2.7.5.3 Phasing and Initial Model Building for ARS2
For phasing of the ARS2171-270 +408-763 data a subset of four datasets was identified
from a larger pool that maximised the anomalous signal while retaining acceptable
merging R-values. The selection was performed with the help of Max Nanao using
a genetic algorithm [231]. These datasets were merged in XSCALE and submitted
to the CRANK2 pipeline in combination with the native dataset for substructure
determination and phasing by single isomorphous replacement (SIR). The resulting
map was used for automatic model building followed by iterative rounds of manual
building and refinement (Sec. 2.7.5.2). The well-defined seleno-methionine positions
were used as sequence markers.
3
R E S U LT S
3.1 biochemical characterisation of cbc complexes
To gain insight into the CBC-ARS2, CBC-PHAX, CBC-PHAX-ARS2 and CBC-NELF-E
complexes, the different proteins were expressed and purified independently. Based
on protein disorder predictions and described domains (Figure 3.1) different pro-
tein constructs were cloned in expression plasmids and the respective proteins were
expressed in insect cells or bacteria. An overview of the constructs, plasmids and
expression systems used in this study as well as the purification can be found in
Section 2.1.12, Section 2.4 and Appendix A.4 Table A.5.
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Figure 3.1 – Protein domain organisation and protein disorder prediction
Depiction of human (h) ARS2, PHAX, NELF-E and NCBP3 protein illustrating their reported
domains and their disorder prediction of each protein. Region below threshold (red line) are
considered to be ordered. FP: false positive rate of prediction.
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3.1.1 Protein Expression and Purification
For bacterial protein expression pETM11 plasmids containing a T7 promoter, which
originates from bacteriophage T7, showed a higher expression of the desired proteins
than the pProEx HTb plasmid containing the synthetic trc promoter (data not shown).
CBP20 showed only a weak bacterial expression from the pRSET A plasmid (data not
shown). A higher yield was reached when the protein was expressed as GST-tagged
protein from pETM30 (data not shown).
After plasmid optimisation CBP20, NCBP3, PHAX and NELF-E could be expressed
as full length proteins, whereas soluble protein could only be obtained for a truncated
construct of ARS2 (residues 147-871 or ARS2147-871) lacking the predicted unstruc-
tured N-terminal region (Figure 3.1). Based on previous protein-engineering CBP80
was expressed as CBP80ΔNLS lacking the first 19 amino acids including the NLS or
as CBP80ΔNLSΔCC lacking additionally the coiled coil region (amino acids 653–701
replaced by a glycine) [138, 139]. CBP80ΔNLS was used for interaction studies and
is in the following referred to as CBP80 and in complex with CBP20 as CBC. For
crystallisation trials CBP80ΔNLSΔCC was additionally used.
These protein constructs served as basis for initial in vitro interaction studies be-
fore the interacting regions were narrowed down using shorter constructs. Figure
3.2 shows an example of the purified proteins. While most of the proteins were quite
stable after purification, ARS2 and NCBP3 showed slight degradation (Figure 3.2).
In general the proteins were expressed as His-tagged protein and purified using Ni
affinity chromatography followed by TEV cleavage and a second Ni affinity chro-
matography to separate the cleaved tag from the protein. To remove any DNA or
RNA contamination ion exchange chromatography was used. As final step and to
check the quality of the protein the sample was subjected to SEC.
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Figure 3.2 – Purified proteins
Coomassie-stained SDS-PAGE of purified proteins. ARS2 and NCBP3 showed slight degra-
dation bands, whereas all other proteins are more stable and show only a single band.
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3.1.2 Biochemical Characterisation of the CBC-ARS2 Complex
A direct interaction between ARS2147-871 and CBC or the individual subunits CBP80
or CBP20 could not be observed by SEC and GST pull down (Figure 3.3A, B, data for
subunits not shown). However, as previously described by Hallais et al. [73], the pro-
teins co-eluted when CBC was immobilised on m7GTP-Sepharose before incubation
with ARS2 (data not shown). To test if the interaction is dependent on the cap ana-
logue the SEC and GST pull down were repeated in the presence of m7GTP, which
resulted in the co-elution of CBC and ARS2 (Figure 3.3A, B). The result that a stable
CBC-ARS2 complex was only formed in the presence of m7GTP indicates a m7GTP-
dependent complex formation. This result was confirmed by ITC showing a twelve
times higher affinity of ARS2 towards CBC in the presence of m7GTP (KD~1 µM com-
pared to KD~12 µM without m7GTP) (Figure 3.3C). For ITC experiments C-terminal
ARS2 constructs (ARS2763-871 and ARS2827-871) were used as longer versions tend to
precipitate at the required concentrations.
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Figure 3.3 – Interaction of CBC-ARS2 is cap-dependent
A: SEC of CBC and ARS2 with and without m7GTP. CBC and ARS2147-871 were mixed with
or without m7GTP and subjected to gel filtration. Their elution profiles were overlaid and
single fractions analysed by SDS-PAGE followed by Coomassie staining.
B: GST-CBP20/CBP80-ARS2 pull down in the absence and presence of m7GTP. CBC contain-
ing GST-tagged CBP20 was immobilised on Glutathione resin and incubated with ARS2147-871
in the presence and absence of m7GTP. Input (in), last wash (W) and elution (E) fractions were
analysed by Coomassie-stained SDS-PAGE.
C: Determination of the affinity of ARS2827-871 for CBC in the presence and absence of m7GTP.
CBC or m7GTP-CBC in the sample cell was titrated by ARS2827-871. In each panel, the upper
graph shows the raw data and the bottom graph shows the ligand concentration dependence
of the heat released upon binding after normalisation. KD values and standard deviation
represent the average from at least two independent experiments.
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Since the ITC data suggested different binding ratios (n=0.4-2) the complex was
analysed by SEC-multi angle light scattering (MALS), which revealed an 1:1 stoi-
chiometry in the presence of m7GTP (see Appendix B.1 Figure B.1A). Thus, the ob-
served ratio within the ITC experiment is likely due to inaccurate determination of
the sample concentrations.
Using different ARS2 constructs the interacting region of ARS2 with CBC was
narrowed down to the highly conserved C-terminal region of ARS2, compromising
the last 27 amino acids (Figure 3.4A). A synthesised peptide containing ARS2845-871
bound with the same affinity (KD~1 µM) to m7GTP-CBC as the longer constructs
ARS2763-871 and ARS2827-871, while a construct missing the last 27 amino acids
(ARS2763-845) did not interact with CBC (Figure 3.4B). Thus, the highly conserved
C-terminus of ARS2 (ARS2845-871) is necessary and sufficient to bind to CBC (Fig-
ure 3.4). An overview of the analysed CBC-ARS2 interaction is given in Appendix
B.1 Table B.1.
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Figure 3.4 – The C-terminus of ARS2 mediates the interaction with CBC
A: Multiple sequence alignment of the C-terminus of ARS2. Conserved residues are high-
lighted in red and residues with a conservation above 70% are indicated below.
B: ITC of C-terminal ARS2 constructs with CBC in the presence of m7GTP. m7GTP-CBC in
the sample cell was titrated by ARS2763-845 or ARS2845-871. The data were plotted as described
in the caption to Figure 3.3C.
3.1.3 Biochemical Characterisation of the CBC-PHAX Complex
The CBC-PHAX complex, which has been reconstituted previously [158], was imme-
diately obtained after mixing the two proteins and subjecting them to SEC (Figure
3.5A). However, no complex between CBP20 nor CBP80 alone and PHAX could be
observed (data not shown). To determine the dissociation constant ITC experiments
were performed, showing a KD of 300 nM for CBC-PHAX in the absence and a KD
of 125 nM in the presence of the cap analogue m7GTP (Figure 3.5C). Thus, the in-
teraction of CBC and PHAX shows a slight, but not significant stabilisation of the
CBC-PHAX complex upon cap-binding unlike observed previously for CBC-ARS2
(see Sec. 3.1.2). Using different constructs for SEC and ITC the binding site of PHAX
on CBC could be narrowed down to the residues 103-294 (Figure 3.5B), containing
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most of the RRM domain of PHAX (residues 227-308). By ITC a KD of 350 nM was
measured for binding of PHAX103-327 to CBC in the absence of m7GTP, comparable
to full length PHAX, whereas PHAX103-308 and PHAX103-294 showed slightly reduced
affinities with KDs of 600 and 850 nM, respectively (Figure 3.5C). The analysed CBC-
PHAX interactions are summarised in Figure 3.5B.
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Figure 3.5 – PHAX binding to CBC
A: Reconstitution of the CBC-PHAX complex. CBC was incubated with molar excess of
PHAX before subjected to SEC. Single fractions were analysed by SDS-PGAE followed by
Coomassie-staining.
B: Overview of PHAX-CBC binding studies. Different PHAX constructs were tested for CBC
binding using SEC and ITC. In case of co-elution from the SEC the KD was determined using
ITC.
C: ITC data and curve fit to determine the affinity of PHAX for CBC in the presence and
absence of m7GTP. CBC or m7GTP-CBC in the sample cell was titrated by PHAX. The data
were plotted as described in the caption to Figure 3.3C.
3.1.4 Biochemical Characterisation of the CBC-NELF-E Complex
The interaction of CBC with the N-terminal part of NELF-E244-380 has been described
previously [156] and therefore this construct, which could be expressed in E. coli,
was used along with the full length protein expressed in insect cells for interaction
studies. When analysing the binding affinities for CBC and NELF-E244-380 by ITC a
cap-dependent 8-fold increase of the dissociation constant was detected (KD~0.4 µM
to KD~0.05 µM) (Figure 3.6D). Consistent with this and similar to ARS2 (see Sec.
3.1.2), a stable CBC-NELF-E complex was only formed in the presence of the cap
analogue m7GTP (Figure 3.6A). Already in the absence of m7GTP CBC and NELF-E
40 results
showed slight co-elution (Figure 3.6A middle), indicating a weak interaction of the
two proteins, which could be stabilised by the addition of m7GTP (Figure 3.6A right).
Additionally, as observed before by Narita et al. [156], the deletion of the last 20
amino acids (NELF-E244-360) abolished CBC binding completely, since no interaction
between NELF-E244-360 and m7GTP-CBC could be detected by either SEC or ITC (Fig-
ure 3.6B, Appendix B.3 Table B.3). To test whether the highly conserved C-terminal
21 amino acids (Figure 3.6C) are sufficient for CBC binding, the synthetic peptide
NELF-E360-380 was used for ITC binding studies. With a KD of 3.3 µM NELF-E360-380
showed a much weaker affinity for m7GTP-CBC than NELF-E244-380 (KD~0.05 µM)
(Figure 3.6D). Extending the peptide to 27 amino acids NELF-E354-380 resulted in the
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Figure 3.6 – NELF-E C-terminus binds CBC in a cap-dependent manner
A: Interaction of NELF-E and CBC in absence and presence of m7GTP. CBC and NELF-E
were mixed with or without m7GTP and subjected to gel filtration. Their elution profiles
were overlaid and single fractions analysed by Coomassie-stained SDS-PAGE.
B: SEC of CBC and NELF-E244-360. CBC was mixed with molar excess of NELF-E244-360and
m7GTP and subjected to SEC. Protein containing fractions were analysed by Coomassie
stained SDS-PAGE.
C: Sequence alignment of the C-terminus of NELF-E. Conserved residues are highlighted in
red and residues with a conservation above 70% are indicated below.
D: Affinity determination for NELF-E-CBC binding in the presence and absence of m7GTP.
CBC or m7GTP-CBC in the sample cell was titrated by different NELF-E constructs. The data
were plotted as described in the caption to Figure 3.3C.
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same weak affinity (KD~3.8 µM) (see Appendix B.3 Table B.3). This suggests that the
C-terminus of NELF-E plays an important part in the interaction with CBC, though
the interaction is also stabilised by further protein-protein interactions. Notably, these
interactions are not sufficient to obtain the CBC-NELF-E complex in the absence of
C-terminal 20 amino acids of NELF-E (NELF-E244-360). A summary of the studied
CBC-NELF-E interactions is given in Appendix B.3 Table B.3.
3.1.5 Compatibility of PHAX, ARS2 and NELF-E Binding to CBC
After identifying the minimum CBC binding regions of ARS2, PHAX and NELF-E
the next question was, if and which proteins can bind CBC at the same time in vitro.
Earlier it has been shown that ARS2 binding is compatible with PHAX binding [73].
A stable complex containing CBC, PHAX and ARS2147-871 could be reconstituted
by incubating the proteins together with m7GTP and subjecting them to SEC (Fig-
ure 3.7A). However, no complex containing CBC-NELF-E and PHAX nor ARS2 was
observed using SEC (see Appendix B.4 Figure B.7). To further analyse if the interac-
tions of NELF-E and ARS2 with CBC are compatible, preformed CBC-NELF-E com-
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Figure 3.7 – Competition between NELF-E and ARS2/PHAX for CBC binding
A: Reconstitution of the m7GTP-CBC-ARS2-PHAX complex. ARS2147-871 was incubated with
molar excess of m7GTP-CBC and PHAX before subjected to SEC. The protein containing
fraction were analysed by Coomassie-stained SDS-PAGE.
B: Set up of m7GTP-Sepharose displacement pull down. CBC-NELF-E or CBC-PHAX were
immobilised on m7GTP-Sepharose and incubated with different amounts of ARS2147-871 or
NELF-E, respectively. Flow through and elutions were analysed by Coomassie-stained SDS-
PAGE (C).
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plex was immobilised on m7GTP-Sepharose and incubated with different amounts
of ARS2147-871 (Figure 3.7B left). The protein bound to the resin and the flow through
for each sample were then analysed by SDS-PAGE. The results showed that with
increasing amounts of ARS2147-871 more NELF-E was in the flow through and less
NELF-E remained bound to CBC, whereas, more ARS2 co-eluted with CBC (Figure
3.7C left). Thus, ARS2 was competing with NELF-E for CBC binding. Performing
the same assay with preformed CBC-PHAX and adding NELF-E to the immobilised
complex (Figure 3.7B right) resulted in the displacement of PHAX from CBC (Figure
3.7C right), showing that also PHAX and NELF-E are competing for CBC binding.
Titrating ARS2147-871 to a preformed CBC-PHAX within the same experimental set
up resulted in a stable complex containing CBC, ARS2 and PHAX (data not shown).
The same competition was observed in a fluorescence polarisation assay us-
ing N-terminal FAM-labeled ARS2845-871 (ARS2845-871(FAM)) or FAM-labeled NELF-
E354-380 (NELF-E354-380(FAM)) (Figure 3.8). As expected, addition of m7GTP-CBC to
either of these labeled peptides led to an increase in fluorescence polarisation, indi-
cating binding (Figure 3.8A, D). Further addition of NELF-E244-380 or NELF-E360-380
to the preformed m7GTP-CBC-ARS2845-871(FAM) complex led to dissociation of CBC
from ARS2845-871(FAM) shown by a decreasing polarisation (Figure 3.8B, data not
shown for NELF-E360-380). The same result was also obtained for the addition of
ARS2827-871 or ARS2845-871 to the preformed m7GTP-CBC-NELF-E354-380(FAM) com-
plex (Figure 3.8E, data not shown for ARS2845-871). Thus, ARS2 and NELF-E were
competing for CBC binding. However, titrating PHAX103-327, that shows a better be-
haviour than the full length protein at high protein concentration, to m7GTP-CBC-
ARS2845-871(FAM) or m7GTP-CBC-NELF-E354-380(FAM) led to no change in polarisa-
tion (Figure 3.8F, G). Interestingly, the addition of PHAX103-327 to a mixture of CBC,
FAM-ARS2827-871 and NELF-E244-380 showed an increase in polarisation, indicating
that PHAX can replace NELF-E244-380 from CBC and allows ARS2845-871(FAM) to
bind again CBC (Figure 3.8C). This demonstrates that binding of NELF-E354-380 but
not NELF-E244-380 to CBC is compatible with PHAX103-327 binding, suggesting that
NELF-E locates at the same position around CBC as PHAX. Notably, for both pro-
teins these competing domains include the RRM domains, which are the predicted
most structures parts of PHAX and NELF-E (see Figure 3.1). However, for ARS2 and
NELF-E the C-terminal peptides were sufficient to compete with each other, respec-
tively. To exclude that the changes in polarisation were due to interactions of NELF-E
or PHAX with ARS2845-871(FAM) and ARS2 or PHAX with NELF-E354-380(FAM), the
same experiments were performed in the absence of CBC. All these control experi-
ments showed no significant change in polarisation (see Appendix B.4 Figure B.8),
indicating that the observed changes in polarisation are caused by interactions of the
labeled peptide with CBC.
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Figure 3.8 – Fluorescence polarisation assay
Fluorescence polarisation data showing the titration of
A: m7GTP-CBC to ARS2845-871(FAM).
B: NELF-E244-380 to m7GTP-CBC-ARS2845-871(FAM).
C: PHAX103-327 to m7GTP-CBC-ARS2845-871 (FAM)/NELF-E244-380.
D: m7GTP-CBC to NELF-E354-380(FAM).
E: ARS2827-871 to m7GTP-CBC-NELF-E354-380(FAM).
F: PHAX103-327 to m7GTP-CBC- ARS2845-871(FAM).
G: PHAX103-327 to m7GTP-CBC-NELF-E354-380(FAM).
Displayed are the median and error bars (SD) of three independent experiments.
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3.2 structural characterisation of cbc complexes
3.2.1 Structure of m7GTP-CBC-ARS2
3.2.1.1 Structure Determination of m7GTP-CBC-ARS2
To investigate the structural basis for the CBC-ARS2 interaction, crystallisation trials
of CBCΔNLS and CBCΔNLSΔCC with different CBC binding ARS2 constructs (see
Appendix B.1 Table B.1) were performed in the presence of m7GTP or m7GpppG.
Only the complex containing m7GTP-CBCΔNLS-ARS2827-871 purified by SEC re-
sulted in three different crystal forms after 24-72 h at 20°C (not shown). Two of
these crystals could be manually reproduced and the conditions were further opti-
mised to obtain bigger monocrystalline crystals. Most of the crystals showed only
weak diffraction or no extra density for the peptide. The best crystal showing unam-
biguous density for the ARS2 peptide diffracted to 2.8 Å resolution. Initial phases
were obtained by molecular replacement using the known m7GpppG-CBC complex
structure (PDB:1H2T [139]) as search model. The crystal belonged to space group P1
with cell dimensions of α=γ=90°, β=90.3° and a=70.52, b=122.99 and c=270.98. There
are eight complexes in the asymmetric unit with variable occupancy for the ARS2
peptide. Data collection and refinement statistics are summarised in Table 3.1 and
Table 3.2. The omit difference density map of the ARS2 peptide is shown in Figure
3.9C.
Table 3.1 – Data collection statistics for m7GTP-CBCΔNLS-ARS2827-871
crystal m7GTP-CBCΔNLS-ARS2827-871
Beamline ID23-1
Wavelength (Å) 0.97917
Space group P1
Cell dimensions (Å) a=70.52 b=112.99 c=270.98
Cell angles (°) α=γ=90 β=90.30
Resolution range of data (last shell) (Å) 50.0-2.80 (2.80-2.80)
Completeness (last shell) (%) 97.5 (96.3)
R-sym (last shell) (%) 9.7 (69.7)
I/σvI (last shell) 6.63 (1.20)
CC(1/2) (last shell) 0.995 (0.585)
Redundancy (last shell) 2.08 (2.00)
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Table 3.2 – Refinement statistics for m7GTP-CBCΔNLS-ARS2827-871
crystal m7GTP-CBCΔNLS-ARS2827-871
Reflections used in refinement work (free) 190778 (10059)
R-work (last shell) 0.230 (0.382)
R-free (last shell) 0.266 (0.364)
Number of non-hydrogen atoms 58818
Protein 57540 (8x CBC)
Ligand (m7GTP) 264 (8x m7GTP)
Peptide 938 (chains C, F, I, L, O, R, U, X)
Geometry and B-factors
RMSD (bonds) 0.008
RMSD (angles) 1.194
Ramachandran favored (%) 97.9
Ramachandran outliers (%) 0.03
Clash score 0.86
MolProbity score 0.88
Average B-factor 73.3
Protein 72.8 (8x CBC)
Ligand (m7GTP) 66.3 (8x m7GTP)
Peptide 106.1 (chains C, F, I, L, O, R, U, X)
3.2.1.2 Structure Analysis of m7GTP-CBC-ARS2
The overall structure of CBC and the binding of CBP20 to the cap analogue in the
ARS2 bound complex is similar to the cap bound CBC [139]. Only locally ARS2 per-
turbs the interaction of CBP20 with CBP80 (Figure 3.9A). The ARS2 peptide, which
is visible from residues 850-861 and 868-871, forms an extended chain, which wraps
around the CBP80-CBP20 interface, interacting with both subunits (Figure 3.9A).
There are two main binding regions of the ARS2 peptide: one involving residues
852-861 (proximal site) and the other one involving the extreme C-terminal residues
868-871 (distal site). For the highly conserved residues 862-867, which are linking
the interacting region, no electron density is present. The main interacting regions
are residues 460-463, 557-570, 607-616 and 647-651 of CBP80 and residues 48-55 and
71-80 of CBP20. These CBP20 residues belong to the RNP domain, namely the β1-α2
loop and the β2-β3 loop. The total buried surface area upon ARS2 peptide binding to
CBC is 2257 Å2 (PISA server [108]) shared 52% and 48% respectively between CBP80
and CBP20.
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Figure 3.9 – Crystal structure of m7GTP-CBCΔNLS-ARS2827-871
A: Overview of the m7GTP-CBCΔNLS-ARS2827-871 crystal structure. The C-terminus of ARS2
(yellow) lies in the interface of CBP80 (purple) and CBP20 (pink), which binds m7GTP (cyan).
B: Close-up view of the key interacting residues. Black dashed lines indicate polar contacts.
C: Omit difference density map of the ARS2 peptide contoured at 2σv. The main interacting
residues are labeled and the highly conserved residues within the C-terminus of ARS2 are
highlighted in red within the sequence.
D: Superposition of CBC structures (1H2V apo (gray) and 1H2T (rose) and 1H2U (light blue)
[139] bound to m7GpppG (cyan)) with m7GTP-CBC-ARS2827-871 via CBP80 shows successive
relative displacements of the CBP20 subunit.
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In the proximal binding site including ARS2 residues 852-861 Asp852, Arg854 and
Tyr859 are the main interacting residues (Figure 3.9B, left). Asp852 stacks on Tyr50
of CBP20 and electrostatically stabilises Arg854, which stacks via its guanidinium
group on Tyr461 of CBP80 and forms a salt bridge with Asp107 from CBP20. In the
crystal structure without the ARS2 peptide, the hydroxyl groups from CBP80 Tyr461
and CBP20 Tyr50 interact at the intersubunit interface [139]. However, this conforma-
tion is sterically incompatible with the presence of ARS2 Asp852 and Arg854. Thus,
in the presence of the ARS2 peptide CBP20 Tyr50 adopts an alternative conforma-
tion allowing to interact with ARS2 Asp852. Additionally, Ile856 makes hydrophobic
contacts with CBP20 Tyr50 and Thr79. Further along the peptide chain ARS2 Tyr859
is inserted between CBP20 and CBP80 (Figure 3.9B, middle) making contacts with
CBP20 Met71 and Leu73 and CBP80 Ser558 and His561. Furthermore, its hydroxyl
group points towards the main-chain amino group of CBP20 Glu53, whose side-chain
makes CBC intersubunit interactions. Superposition of CBP80 of the m7GpppG-CBC
complexes (RMSD: 0.35 Å for 1H2T and 0.38 Å for 1H2U [139]) on the m7GTP-CBC-
ARS2 complex shows that the CBP20 β2-β3 loop (residues 71-81) and C-terminal ex-
tension of the RRM domain (residues 126-150) are slightly shifted (Figure 3.9D). This
results in the closure of the groove in which the ARS2 peptide binds, with a maxi-
mum displacement of 2.0 Å. Moreover, it allows the main-chain of CBP20 residues
78-80 to run anti-parallel to the ARS2 residues 857-859. There are hydrogen bonds
between the carbonyl oxygen of Lys78 with the amino group of Tyr859 and the car-
bonyl group of Val857 with the amino group of Ala80 . Additional contacts are made
between Arg860 and CBP20 Leu73 (Appendix B.1 Figure B.2).
In the distal site the terminal ARS2 residue Phe871 is buried in a hydrophobic
pocket at the base of the long, solvent exposed coiled-coil of CBP80, formed by
CBP80 Ile609, Cys616, Met648 and His651. The side-chain of His651 partially stacks
on Phe871 and also interacts electrostatically with the C-terminal carboxylate of ARS2
(Figure 3.9B, right). Moreover, CBP20 residue Tyr89 mediates hydrogen bonds with
ARS2 Asp869 and stacks on CBP80 Arg610, whose carbonyl-oxygen hydrogen inter-
acts with the amino groups of ARS2 Phe870 and Phe871.
All of the cited interacting residues are highly conserved in metazoan ARS2 (Fig-
ure 3.4A) or CBC suggesting conservation of this interaction and underscoring its
biological importance. An overview of all interactions can be found in Appendix
B.1 Figure B.2A.
In light of the structural organisation of the CBC-ARS2 complex, the increased
affinity of ARS2 to cap bound CBC can be explained by comparing the crystal struc-
ture of apo-CBC (PDB:1H2V [139]) (Figure 3.9D). Upon binding of the cap analogue
m7GTP CBP20 acquires a more structured N- and C-terminal region, which also re-
sults in an initial closure of the groove between CBP20 and CBP80, in which the
ARS2 peptide binds (Figure 3.9D). This probably leads to a stabilisation of the inter-
action between CBC and the ARS2 peptide, which is important for the CBC-ARS2
interaction in vitro.
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3.2.2 Validation of the Observed CBC-ARS2 Interaction Site
To validate the observed binding site, point mutations were introduced into ARS2
as well as in the corresponding interacting residues of CBP80 and CBP20 using site
directed mutagenesis. These mutants were then used for subsequent binding studies.
For ARS2 the in E. coli expressed and well behaved ARS2827-871 construct was mu-
tated and used for ITC experiments in the presence of the cap analogue m7GTP (Fig-
ure 3.10A). The mutation of F871D led to a slight decrease in affinity (KD~1.8 µM)
compared to the wild type construct (KD~1 µM, see Figure 3.3C). However, the dou-
ble mutation of R854A and Y859A weakened the interaction considerably, so that no
KD could be obtained from the binding data. Introducing all three point mutations to-
gether completely abolished the interaction with CBC. This data show that R854 and
Y859 are essential for the interaction between CBC and ARS2, whereas F871 plays a
minor role.
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Figure 3.10 – Abolishing the interaction by mutating ARS2 and CBC
A: Analysis of ARS2 mutants for CBC binding. Mutations were introduced into the
main interacting residues of ARS2 and their effects on CBC binding were tested by ITC.
ARS2827-871was titrated to CBC in the presence of m7GTP. All mutations led to a lower KD
compared to wild type ARS2 827-871 (KD~1 µM, see Sec. 3.1.2). The data were plotted as
described in the caption to Figure 3.3C.
B: Analysis of CBC mutants for ARS2 binding. Mutations were introduced into the main
interacting residues of CBP80 and CBP20. The CBC complexes were reconstituted and immo-
bilised on m7GTP-Sepharose. After incubation with ARS2827-871 the wash (W) and elution (E)
fractions were analysed via SDS-PAGE followed by Coomassie staining. The right gel shows
additionally the flow through (FT).
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For CBC mutations in CBP80 Y461A R610E H651A as well as CBP20 Y50A Y89A
D107R were introduced and initially tested for ARS2 binding via pull down using
m7GTP-Sepharose. As CBP80 was expressed in insect cells all mutations were intro-
duced at once, whereas for CBP20 expressed in E. coli mutations were introduced
one after the other resulting in CBP20 Y50A, CBP20 Y50A Y89A and CBP20 Y50A
Y89A D107R mutants. The immobilised CBP20/CBP80 complexes were incubated
with ARS2827-871 and the elutions analysed by SDS-PAGE. The obtained results (Fig-
ure 3.10B) showed that mutations in all three residues in CBP20 or CBP80, respec-
tively, are not sufficient to abolish ARS2 binding. Also the combination of CBP80
Y461A R610E H651A with CBP20 Y50A or CBP20 Y50A Y89A still showed slight
affinity for ARS2. Only the combination of mutations in all three residues in CBP20
and CBP80 led to no detectable co-elution of ARS2 . However, compared with the
other CBC elutions less of the complex carrying the six mutations eluted from the
resin, indicating reduced affinity for the cap analogue m7GTP.
Next ITC experiments were performed to determine the affinity of the mutated
CBC (Table 3.3). To exclude side effects caused by the introduced mutations, the
binding of m7GTP and PHAX were also tested to ensure that the overall conforma-
tion of CBC did not change upon mutation and only the interaction with ARS2 is
abolished. The triple mutant CBP20 Y50A Y89A D107R resulted in a reduced m7GTP
affinity (KD~70 µM compared to wild type KD~0.1 µM) and was therefore excluded
from further experiments. CBC consisting of CBP80 Y461A R610E H651A and CBP20
Y50A or CBP20 Y50A Y89A were binding m7GTP and PHAX with the same affinity
Table 3.3 – Interaction studies of CBC mutants
Using ITC the interactions of different CBC constructs were tested and compared to the wild
type.
interaction kd
m7GTP + CBC 0.112 ± 0.045 µM
m7GTP + CBC (CBP80 Y461A R610E H651A + CBP20
Y50A Y89A D107R)
70 ± 14 µM
m7GTP + CBC (CBP80 Y461A R610E H651A + CBP20
Y50A Y89A)
0.148 ± 0.025 µM
m7GTP + CBCmut (CBP80 Y461A R610E H651A + CBP20
Y50A)
0.095 ± 0.024 µM
CBC (CBP80 Y461A R610E H651A + CBP20 Y50A Y89A) +
PHAX
0.6 ± 0.23 µM
CBCmut (CBP80 Y461A R610E H651A + CBP20 Y50A) +
PHAX
0.5 ± 0.14 µM
m7GTP-CBC (CBP80 Y461A R610E H651A + CBP20 Y50A
Y89A) + ARS2 827-871
10.9 ± 0.5 µM
m7GTP-CBCmut (CBP80 Y461A R610E H651A + CBP20
Y50A) + ARS2 827-871
11.6 ± 1.1 µM
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as CBC wild type and were therefore used for further ARS2 binding studies. In ITC
experiments both CBC mutants showed an eleven to twelve times weaker affinity
(KD~11-12 µM) to ARS2827-871 in the presence of m7GTP (Table 3.3), confirming that
the mutated residues are involved in ARS2 binding. As no additional change in affin-
ity was observed for CBC containing the additional mutation Y89A in CBP20 com-
pared to CBP20 Y50A, CBC carrying mutations in CBP20 Y50A and CBP80 Y461A
R610E H651A was used for further experiments and is referred to as CBCmut.
To test the mutations in full length CBC and ARS2 the bridged yeast two-hybrid
system was used. Here Alix (ALG-2-interacting protein X), a cytoplasmic protein
involved in apoptosis, served as negative control. CBP80 was fused to the GAL4
DNA-binding domain (pAS2) and expressed together with CBP20 (p422) in Y187
strains, while ARS2 and Alix on pACTII fused to the GAL4 transcription activating
domain were transformed into CG1945 strain. After crossing the strains and plating
them on selection media, only colonies for CBC containing both wild type subunits
and ARS2 wild type could grow on the quadruple-selective media (Table 3.4). Also
a few colonies of ARS2 wild type crossed with CBP80 wild type CBP20 Y50A were
obtained, showing that the mutation in CBP20 alone is not sufficient to abolish com-
pletely the interaction with ARS2. For the mutated ARS2 construct no colonies were
obtained. This showed that mutation of all three ARS2 residues or mutations in both
CBC subunits (CBP80 Y461A R610E H651A + CBP20 Y50A) were sufficient to abol-
ish the interaction in the bridged yeast two-hybrid system (Table 3.4). Overall these
results confirmed the ITC and pull down data and demonstrated additionally that
the low affinity of the CBC mutant for ARS2 detected in the pull down and ITC ex-
periments is not strong enough to form a stable CBC-ARS2 complex within the yeast
two-hybrid system.
Table 3.4 – Bridge yeast two-hybrid assay using CBC and ARS2 mutants
CBP80 fused to the GAL4 DNA binding domain in pAS2 and CBP20 in p422 were trans-
formed into Y187. ARS2 and the control Alix were transformed as GAL4 transcription ac-
tivating domain fused proteins (pACTII) in CG1945. After mating of haploid strains, the
diploid strains were selected on –Ala-Leu-Thr media and analysed for their interaction via
their growth on –Ala-Leu-Thr-His media.
– indicates no colony, +/- few colonies and + many colonies.
pAS2 / pACT II
ARS2
wt
ARS2
R854A Y859A
F871A
Alix
(control)
CBP80 wt - - -
CBP80 Y461A R610E H651A - - -
CBP80 wt + CBP20 wt + - -
CBP80 wt + CBP20 Y50A + / - - -
CBP80 Y461A R610E H651A +
CBP20 Y50A
- - -
CBP20 Y50A - - -
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3.2.3 Structural Characterisation of the CBC-PHAX Complex
To better understand the interaction of CBC and PHAX, crystallisation trials contain-
ing CBC, different PHAX constructs and/or m7GTP or RNA were set up, but no
diffracting crystal could be obtained. Nevertheless, to map the PHAX binding site on
CBC cross-linking mass spectrometry was performed using the two amine-reactive,
homo-bifunctional reagent disuccinimidyl suberate (DSS). The cross-linked peptides
were subjected to mass spectrometric analysis and stringently identified using the
xQuest/xProphet software by the EMBL Proteomics Core Facility [117]. All identi-
fied intra-protein cross-links are listed in Appendix B.2 Table B.2. Although only
a few cross-links could be identified, four different CBC-PHAX inter-protein cross-
links were obtained: three between CBP20 and PHAX and one between CBP80 and
PHAX (Figure 3.11A, B). The identified cross-linked lysines from PHAX K163, K173,
K216 and K256 lie all within residues 103-294, which were identified to be essential
for CBC binding (see Sec. 3.1.3). The cross-linked lysines of CBC are located close to
CBP20 K34
CBP20 K120CBP80 K327
CBP80 CC
A
PHAX 207-LGNRPEMNYKGR-218 – CBP20 113-TDWDAGFKEGR-123 
PHAX 252-IIGNKK-257 – CBP20 113-TDWDAGFKEGR-123
PHAX 170-DLDKELDEYMHGGKK-184 – CBP20 27-GDNEEQEKLLK-37 
PHAX 162-KESQEHTK-169 – CBP80 324-SHWKER-329 
C
hPHAX 
RBD
1 394227 308
NLS NES NLS
30°
N C
N C
N C
CBP80
CBP20
PHAX
B
Figure 3.11 – Mapping of the CBC-PHAX interaction site
CBC-PHAX was cross-linked using the lysine-specific bifunctional cross-linker DSS, frag-
mented by proteolysis and cross-linked peptides were identified by mass spectrometry.
A: Overview of intra- (red) and inter-protein (blue) cross-links of CBC-PHAX.
B: Cross-links identified between CBP80 (purple) or CBP20 (pink) and PHAX (green). Loca-
tion of the cross-linked lysines of PHAX are indicated as arrows on the depiction of PHAX.
Identified cross-linked lysines of PHAX and CBP80 or CBP20 within the cross-linked peptide
sequence are underlined and in bold.
C: Location of cross-linked CBC residues. Cross-linked lysine residues of CBC are highlighted
in green within the CBC crystal structure (PDB:1H2V [139]) with CBP80 in purple and CBP20
in pink.
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each other on the surface (Figure 3.11C). CBP20 K34 and K120 belong to the more un-
structured region of CBP20 before and after its RNP domain. CBP80 K327 is part of
the loop connecting helix α15 and α16 next to the CBP20 interface. All these residues
are facing into the grove between CBP20 and the coiled coil of CBP80 next to the
ARS2 binding site (see Figure 3.9). In line with the cap-independent binding of PHAX
to CBC (see Sec. 3.1.3), this area does not undergo big conformational change upon
cap-binding [139]. Furthermore, the data provide evidence that residues of CBP20
and CBP80 are interacting with PHAX and are stabilising the CBC-PHAX complex,
which explains the non-existence of a CBP80-PHAX or CBP20-PHAX complex.
3.2.4 Structural Characterisation of the CBC-NELF-E Complex
3.2.4.1 Structure Determination of m7GTP-CBC-NELF-E
To visualise the binding site of NELF-E on CBC, crystallisation trials of CBCΔNLS
and CBCΔNLSΔCC with different NELF-E constructs (see Appendix B.3 Table B.3)
were performed in the presence of m7GTP or m7GpppG. Crystals were obtained
only for complexes with NELF-E360-380 and NELF-E354-380 in the presence of m7GTP
or m7GpppG. The crystals showed varying symmetries but in general no or only very
weak density for the NELF-E peptide. The best result was obtained with CBC-NELF-
E360-380 and m7GTP giving a P21 monoclinic crystal that diffracted to 2.8 Å resolution
(Table 3.5). Molecular replacement was performed using the known m7GpppG-CBC
complex structure (PDB:1H2T, [139]) as search model. There are four m7GTP bound
CBC complexes in the asymmetric unit with clear electron density for the NELF-
E360-380 peptide in one of them and weaker in the other copies. The omit difference
density map is shown in Appendix B.3 Figure B.4 and an overview about the data
collection and refinement statistics is given in Table 3.5.
3.2.4.2 Structure Analysis of m7GTP-CBC-NELF-E
Within m7GTP-CBC-NELF-E CBC shows the same overall structure as reported for
CBC bound to the cap analogue [139]. Surprisingly, The NELF-E peptide binds ex-
actly to the same site at the CBP20 and CBP80 interface of m7GTP-CBC (Figure 3.12)
and in an extremely similar manner to that of ARS2 (Figure 3.9). Also the slight
displacement of interacting regions of CBP20 is identical to the one described for
ARS2 (see Figure 3.12). With 2501 Å2 (PISA server [108]) the total buried surface area
upon NELF-E360-380 binding to CBC is slightly higher than for ARS2 (2257 Å2). Fur-
thermore, as ARS2 the NELF-E peptide shows two binding sites including residues
360-372 (proximal site) and residues 378-380 (distal site). The residues 375-377 con-
necting these two regions show no electron density (Appendix B.3 Figure B.4A) and
thus are poorly ordered within the CBC-ARS2 complex.
There are analogous interactions of NELF-E Arg362 with CBP80 Tyr461 and CBP20
Gln55 and Asp107 (Figure 3.12B left) as previously seen for Arg854 of ARS2. Addi-
tionally, NELF-E Tyr367, that is partially stacked on Ile365, is buried in the same
pocket as ARS2 Tyr859 and also the hydroxyl group of Tyr367 is interacting with the
side chain of CBP20 Glu53 (Figure 3.12B middle). Within this binding site there is an
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Figure 3.12 – Crystal structure of m7GTP-CBCΔNLS-NELF-E360-380
A: Overview of the m7GTP-CBCΔNLS-NELF-E360-380 crystal structure. The C-terminus of
NELF-E (green) lies in the interface of CBP80 (purple) and CBP20 (pink), which binds m7GTP
(cyan).
B: Close-up view of the key interacting residues. Black dashed lines indicate polar contacts.
additional Tyr372, which is buried in the interface, stacking on the other side with
CBP20 Ile70 and hydrogen bonding to the main-chain amino group of CBP20 Met71
(Figure 3.12B middle). Additional putative electrostatic contacts are made between
Asp369 and CBP20 Lys78 and Asp370 and CBP80 Lys568. As Phe871 of ARS2 the C-
terminal Phe380 of NELF-E is buried in the hydrophobic pocket of CBP80, stacking
on CBP80 His651 (Figure 3.12B right). Superposition of m7GTP-CBC-NELF-E with
m7GpppG-CBC (PDB:1H2T RMSD: 0.33 Å and 1H2U RMSD: 0.36 Å [139]) and apo-
CBC (PDB:1H2V [139] RMSD: 0.58 Å) via CBP80 shows again that some residues of
CBP20 are slightly shifted in the direction of the peptide, with a maximum displace-
ment of 1.6 Å compared to 2.0 Å for the ARS2 peptide (see Appendix B.3 Figure
B.4B and Figure 3.9D). Overall the interaction of NELF-E with m7GTP-CBC appears
slightly more robust than that of ARS2, consistent with the twenty-fold difference in
affinity. An overview of all interactions between CBC and NELF-E can be found in
Appendix B.3 Figure B.5.
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Table 3.5 – Data collection and refinement statistics for m7GTP-CBCΔNLS-NELF-E360-380
crystal m7GTP-CBCΔNLS-NELF-E360-380
Diffraction data
Beamline ID30A1
Wavelength 0.966
Space group P21
Cell dimensions (Å) a=113.8 b=147.2 c=153.9
Cell angles (°) α=γ=90 β=91.48
Resolution range of data (last shell) (Å) 50.0-2.80 (2.87-2.80)
Completeness (last shell) (%) 98.4 (91.6)
R-sym (last shell) (%) 10.8 (129.2)
I/σvI (last shell) 9.2 (0.91)
CC(1/2) (last shell) 0.995 (0.363)
Redundancy (last shell) 2.71 (2.70)
Refinement
Reflections used in refinement work (free) 117089 (6345)
R-work (last shell) 0.202 (0.389)
R-free (last shell) 0.229 (0.394)
Number of non-hydrogen atoms 29303
Protein 28763 (4x CBC)
Ligand (m7GTP) 132 (4x m7GTP)
Peptide 408 (chains E, K, Z)
Geometry and B-factors
RMSD (bonds) 0.009
RMSD (angles) 1.312
Ramachandran favored (%) 97.0
Ramachandran outliers (%) 0.2
Clash score 1.0103
MolProbity score 1.17
Average B-factor 74.4
Protein 74.2 (4x CBC)
Ligand (m7GTP) 70.7 (4x m7GTP)
Peptide 111.5 (chains E, K, Z)
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3.2.5 Comparision of ARS2 and NELE-E Binding to CBC
Comparing the structure of CBC-ARS2 with CBC-NELF-E (see Sec. 3.2.1.2 and Sec.
3.2.4.2) and aligning the C-terminal residues of both proteins, highlights a remarkable
sequence homology that was not recognised before this structural analysis (Figure
3.13A). Seven residues out of 21 are identical. Among them the main residues of
both peptides involved in the interaction with CBC, namely R854 and Y859 for ARS2
and R362 and Y367 for NELF-E. Furthermore, this two residue motif (RxxxxY) is
absolutely conserved in both proteins. This shows that NELF-E and ARS2 bind with
their C-terminus in the same CBC binding pocket and are in fact competing for CBC
binding.
In line with the high similarity of the CBC-ARS2 and CBC-NELF-E binding CBC-
mut, comprising CBP80 Y461A R610E H651A and CBP20 Y50A, designed to abolish
the interaction with ARS2 (see Sec. 3.2.2) showed no interaction with NELF-E244-380
in the presence of m7GTP (Figure 3.13B).
hARS2 852 DPRAIVEYRD -LDAPDDVDFF
hNELF-E 360 DKRTQIVYSDDVYKENLVDGF
* * * * * * *
extraTyr
conserved Arg
conserved Tyr
conserved 
C-terminal Phe
A
Kd: n.d.
CBCmut-m7GTP 
+ NELF-E 244-380
B
Arg854
Tyr854
Phe380
Arg362
Phe380
Tyr372
Tyr367
Figure 3.13 – Comparison of ARS2 and NELF-E binding on CBC
A: Comparison of the conformation of NELF-E (green) and ARS2 (yellow) C-terminal pep-
tides after superposition of CBP80 of both CBC complexes (RMSD: 0.24 Å). Alignment of the
C-terminus of NELF-E and ARS2 highlighting the conserved residues in red and the identical
residues with a red star.
B: Validation of the binding site of NELF-E on CBC. In an ITC experiment the CBCmut (see
Sec. 3.2.2) in the sample cell was titrated by NELF-E244-380 in the presence of m7GTP. No
binding was observed, whereas the wild type bound with an affinity of 50 nM (see Appendix
B.3 Table B.3). The data were plotted as described in the caption to Figure 3.3C.
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3.3 structural studies of human ars2
3.3.1 Structure Determination of ARS2
To better understand the structural basics of ARS2s RNA and protein binding as
well as its overall structural organisation, crystallisation trials of different ARS2 con-
structs alone or in the presence of RNA or the FARB peptide were performed. First
crystals were obtained of ARS2147-763 diffracting to around 20 Å. Limited proteolysis
of ARS2147-763 with trypsin followed by SEC led to crystals diffracting up to 7 Å (Fig-
ure 3.14B, C). Mass spectrometric analysis of the two double bands revealed that the
protein has two separate structured regions (residues 147-274 and 393-763), which
form a stable complex after cleavage. Between the double bands no difference could
be detected, suggesting that the trypsin cleavage sites are very close to each other
and the differences could not be captured within the peptide mass fingerprinting.
The observation of two individual structured regions separated by a low complexity
sequence rich in glutamates and lysines goes in line with protein disorder predictions
(see Figure 3.1).
For further structural studies of ARS2 constructs containing residues 147-270 and
408-763, which lack additional glutamates compared to 147-274 and 393-763, were
used. Soluble protein of these regions could only be produced when co-expressing
both parts. Ultimately, crystals of ARS2147-270+408-763 diffracting to 3.7 Å were obtained.
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Figure 3.14 – Identification of a stable core of ARS2
A: Examples of obtained ARS2 crystals ranging from 20-200 µm.
B: Limited proteolysis revealed a stable ARS2 subcomplex. After proteolysis of ARS2147-763
with trypsin the sample was subjected to SEC. Elution profile as well as analysis of the indi-
vidual fractions by Coomassie-stained SDS-PAGE are displayed.
C: Silver-stained SDS-PAGE of a crystal obtained from crystallisation of the trypsinised com-
plex (B).
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Notably, first crystals diffracting up to 4 Å were obtained in the presence of the FARB
peptide. Repetition and optimisation of the conditions also led to crystals diffracting
to the same resolution without FARB. Using seleno-methionine-derivatised protein
the structure could be solved, revealing two molecules in the asymmetric unit. Fea-
tures resembling SERRATE could be visualised but the resolution was too low to per-
mit model building. Two new crystal forms, one of which diffracted to 3.2 Å, were
obtained by an additional N-terminal truncation (ARS2171-270+408-763). The structure
was solved by seleno-methionine phasing and showed one molecule in the asym-
metric unit. The resultant experimental map allowed to build an almost complete
model of the truncated ARS2171-270+408-763 and ultimately of the non-truncated con-
struct ARS2147-270+408-763 using the 3.7 Å resolution crystal data. However, also in
the presence of FARB for non of the crystals extra peptide density could be ob-
served. Based on the obtained ARS2 structure additional constructs for crystallisation
were designed lacking the unstructured residues 538-554 and residues 567-599. Us-
ing ARS2171-270+408-763Δ567-599 a structure including residues 538-554 could be solved.
A composite model including both loop 538-554 (from ARS2147-270+408-763Δ567-599) and
loop 567-599 (from ARS2147-270+408-763) was artificially constructed and used for dis-
play purposes. All tested constructs leading to reasonable diffraction are listed in
Table 3.6 and examples of crystals obtained for ARS2 are shown in Figure 3.14A.
A more detailed table containing all data collection and refinement statistics can be
found in the Appendix B.5 Table B.4, Table B.5 and Table B.6.
Table 3.6 – Overview of collected data from ARS2 constructs
construct space
group
cell dimensions resolution
ARS2 147-763 - - 20 Å
147-763 trypsinated P64 a=b=117.7 Å, c=147.9 Å
α=β=90° γ=120°
7.0 Å
147-270 + 408-763
(+ FARB)
P3121 a=b=136.64 Å, c=158.79 Å
α=β=90° γ=120°
3.7 Å
171-270 + 408-763
(+ FARB)
P6522 a=b=90.29 Å, c=265.72 Å
α=β=90° γ=120°
3.2 Å
171-270 + 408-763
(+ FARB)
P65 a=b=105.21 Å, c=267.04 Å
α=β=90° γ=120°
3.5 Å
147-270 + 408-763
Δ539-555
P3121 a=b=139.58 Å, c=156.16 Å
α=β=90° γ=120°
3.5 Å
147-270 + 408-763
Δ567-599
C2221 a=85.51 Å, b=148.27 Å,
c=235.66 Å, α=β=γ=90°
3.4 Å
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3.3.2 Structure Analysis of ARS2
The human ARS2 structure adopts an unusual protein structure (Figure 3.15A). Only
the homologous protein SERRATE from A. thaliana [129] shows overall the same
arrangement as human ARS2 (Figure 3.15C). The core of the molecule is made up of
five roughly parallel α-helices. The two extending domains, the C- and N-terminal
arm, are formed by two orthogonally oriented α-helices containing the N- and C-
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Figure 3.15 – Crystal structure of human ARS2
A: Composite ARS2 model showing loop 538-554 and ’EEEE’ helix from loop 567-599. The
structure is rainbow coloured from blue (N-terminus) to red (C-terminus). Loop regions are
indicated by dashed lines.
B: Schematic diagram showing the ordered regions that are separated by presumed intrinsi-
cally disordered regions.
C: Comparison of human ARS2 and SERRATE crystal structure. Structures are coloured as
described in (A).
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Figure 3.16 – Multiple alignment of ARS2 protein sequences and structures
Bioinformatical alignment of the protein structure of human ARS2 and SERRATE (PDB: 3AX1
[129]) as well as their protein sequences and the ARS2 protein sequence from mouse and
xenopus. The human ARS2 domain organisation, the loop 538-554, the loop 567-599 contain-
ing the ’EEEE’ helix, residues involves in zinc binding in A. thaliana and mutated lysines in
this domain as well as mutations introduced in the RRM domain of hARS2 are highlighted.
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terminus of the crystallised construct. The metazoan specific RRM or RNP domain
is packed on the helical core and shows the typical βαββαβ fold. The presence of
disordered loops 538-554 and 567-599 as well as the disordered N- and C-terminus
and the residues 270-408 implicate their possible roles in interactions with other
proteins and/or RNA. The main difference to the SERRATE structure is that the core
is reinforced by additional helices and the inserted metazoan specific RRM domain
(Figure 3.15C). Furthermore, the C-terminal arm of human ARS2 is rotated around
90° compared to SERRATE and is not stabilised by a bound zinc ion, although the
folding is similar. An alignment of the sequences as well as the secondary structures
of human ARS2 and SERRATE is displayed in Figure 3.16.
The RRM domain sits as distinct domain on top of the helical core, making only
few hydrophobic and polar contacts to the rest of the molecule. Four regions of the
core of ARS2 (187-200, 251-269, 631-641 and 759-762) are holding the RRM domain
in place. The helical surface is solvent exposed, while the β-sheets are oriented to-
wards the helical core, forming a grove between these two domains (Figure 3.15A).
Interestingly, this region shows a positively charged surface (Figure 3.18A), consist-
ing mainly of the β-sheets of the RRM domain. Residue Phe423, Arg425, Arg463 and
Trp465 from the second and third β-sheet are pointing towards the solvent, indicating
a putative interaction surface (Figure 3.17A).
Comparing human ARS2 RRM domain with other RRM domains it was found
that the RRM of RBM7 (PDB: 5LXY [53]), which binds ZCCHC8 within the nuclear
exosome targeting (NEXT) complex, shows the highest structural similarity. Superpo-
sition of the two structures shows that the hydrophobic patch of RMB7 comprising
residues Leu29, Leu70, Ile73 and Leu75 involved in ZCCHC8 binding is also present
in ARS2 (Leu439, Leu481, Ile484 and Leu486) (Figure 3.17B). Thus, the RRM domain
of ARS2 could indeed be involved in RNA and/or protein binding.
A BARS2 RRM ARS2 RRM RBM7 RRM ZCCHC8
Phe423
Arg425
Arg 463
Trp465
Ile
Leu
Leu
Leu
Figure 3.17 – Structure of ARS2’s RRM domain
A: Zoom-in view of the RRM domain showing residues putative involved in protein or RNA
interaction as sticks.
B: Superposition of ARS2 RRM domain with the RRM domain of RBM7 bound to a ZCCHC8
peptide (PDB: 5LXY RMSD: 1.38 Å [53]). Identical residues forming the hydrophobic pocket
(yellow box) are shown as sticks.
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However, within most crystal forms the basic RRM domain surface is the bind-
ing site of a negatively charged helix (‘EEEE’ helix) formed by residues 572-EEEE-
575 from a neighbouring molecule (Figure 3.18B). This ‘EEEE’ helix occurs in the
highly conserved and metazoan specific solvent exposed loop 567-599 (Figure 3.16,
Figure 3.18). Remarkably, irrespective of the space group and crystal form, this inter-
molecular crystal contact is present. Thus, to accommodate the same crystal contact
within different packing environments, some angular flexibility of the loop is re-
quired.
Additionally to the loop 567-599, which shows with the ‘EEEE’ helix a struc-
tural component and could partially be built, the loop 539-554 was in most crys-
tal forms disordered probably due to flexibility, except within a crystal form of
C-terminal 
arm N-terminal arm
C-terminal arm
acidic ‘EEEE’helix
RRM domain 
β-sheet surface
A
C
B
Figure 3.18 – Electrostatic surface potential of ARS2 and ARS2 crystal packing
A: Electrostatic surface potential (red –ve, blue +ve) for human ARS2147-270+408-763 in two ori-
entations.
B: Crystal contact between the ‘EEEE’ helix and the basic RRM β-sheet surface of a neigh-
bouring molecule within an ARS2171-270+408-763 crystal.
C: Close-up view of the crystal contact made by acidic ‘EEEE’ helix binding onto the basic
RRM β-sheet surface (B).
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ARS2147-270+408-763Δ567-599, in which the loop is well-structured, likely due to crystal
packing constraints. Notably, this loop contains Thr543, which is reported to be a
major phosphorylation site of human ARS2 [85].
Another positively charged surface, apart from the RRM domain, is located at the
outer surface of the C-terminal arm (Figure 3.18A), which in A. thaliana contains a
zinc finger. Although the C-terminal arm shows a rotation of around 90° its over-
all structure apart from the missing zinc ion is very similar. Three out of the four
residues involved in zinc binding in SERRATE are present in ARS2 (Cys714, His730
and His735), whereas the Cys505 in SERRATE is replaced by Ser717 (Figure 3.19).
Furthermore, the C-terminal arm of ARS2 contains many lysines, especially at the
tip of the arm (Lys709, Lys711, Lys719, Lys720, Lys722 and Lys734) (Figure 3.18).
Ser717
human ARS2
SERRATE
Cys505
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cabbage
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Figure 3.19 – Comparison of the C-terminal domain of ARS2 and SERRATE
A: Overlay of the C-terminal arm of ARS2 (orange) on the zinc finger of A. thaliana SERRATE
(gray) (PDB: 3AX1 [129]) showing the residues involved in zinc binding for SERRATE as well
as all lysines as sticks.
B: Multiple sequence alignment of amino acids of the N-terminal arm of ARS2. Conserved
residues are highlighted in red, the residues involved in zinc binding within SERRATE are
indicated with arrows and the residue Cys505 of SERRATE and Ser717 of human ARS2 are
labeled.
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3.4 interaction and functional studies of ars2
Initially, different ARS2 constructs designed based on protein disorder prediction
and limited proteolysis were purified and tested for their affinity towards CBC (see
Sec. 3.1.2), RNA and FLASH. After obtaining the crystal structure of ARS2 (see Sec.
3.3.2) additional specific mutants were constructed and their binding properties ana-
lysed. An overview of the different constructs and mutants used to identify the inter-
acting regions of ARS2 with RNA and FLASH is given in Table 3.7.
Table 3.7 – ARS2 constructs
construct comment
147-871 N-terminal truncation of predicted
disordered residues
147-763 N- and C-terminal truncation of
predicted disordered residues
147-270 + 408-763 predicted ordered residues forming a
stable complex
147-270 + 494-763 as above, plus additional deletion of
the RRM domain
147-871 K719A K722A K734A mutations in the C-terminal basic
patch
147-871 ∆692-743 GSG deletion of the C-terminal arm,
replaced by GSG
147-871 ∆271-408 GSGSGSGS N-terminal truncation and deletion of
predicted disordered residues in the
mid domain, replaced by GSGSGSGS
147-871 R426G R470G R498A R502A mutations within the RRM domain
147-871 R424A R426G R463A R465A mutations of the basic patch within
the RRM domain
147-871 ∆539-554 GSA deletion of loop 539-554, replaced by
GSA
147-871 ∆539-554 AAA deletion of loop 539-554, replaced by
AAA
147-871 ∆539-554 15A mutation of loop 539-554 to alanine
147-871 ∆567-599 GSGSGS deletion of loop 567-599, replaced by
GSGSGS
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3.4.1 ARS2 RNA Binding
To study the RNA binding of ARS2 fluorescence polarisation experiments were per-
formed using FAM-labeled RNA. ARS2147-871 showed affinity for single stranded (ss)
RNA (KD~2-5 µM) and partially double stranded (pds) RNA (KD~3-5 µM), whereas
only a very weak affinity (KD~25-37 µM) for double stranded (ds) RNA could be
determined (Figure 3.20). Although different RNA sequences were used within the
fluorescence polarisation assay, no sequence specificity could be observed (data not
shown). ARS2147-763 showed the same binding behaviour, whereas ARS2147-270+408-763
seemed to bind some pdsRNA with much lower affinity (KD~3-5 µM or 30-50 µM
depending on the pdsRNA, data not shown) than ssRNA (KD~2-5 µM). However,
so far no obvious explanation for the differences could be made and further studies
need to be performed to better understand ARS2 RNA binding.
To determine the RNA binding site on ARS2 different constructs as well as
ARS2147-871 point mutants based on the crystal structure were used and their affini-
ties for ssRNA were analysed. For ARS2 lacking the RRM domain (ARS2147-270+494-763)
only a very weak RNA binding was observed (KD~46 µM) (Figure 3.20B). Also point
mutations in the basic patch in the RRM domain (ARS2 F424A R426A R463A Y465A)
and in the basic batch just next to it (R426G R470G R498A R502A) led to a ten times
weaker RNA affinity as the wild type (Figure 3.20B), indicating that this region is
important for RNA binding by ARS2.
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Figure 3.20 – ARS2 RNA binding
A: Single stranded (ss), partially double stranded (pds) and double stranded (ds) RNA were
tested for ARS2 binding via fluorescence polarisation. FAM-labeled RNA was titrated with
increasing amounts of ARS2 and the change in fluorescence polarisation measured. Mean
values and standard deviations represent the average from three independent experiments.
B: Different ARS2 constructs and mutants were used within the fluorescence polarisation
assay to map the RNA binding site. Set up as described in A using only ssRNA.
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3.4.2 ARS2 – FLASH Interaction
In the transcription of histone pre-mRNAs FLICE-associated huge protein (FLASH,
1962 residues) plays an important scaffolding role for processing factors. It was
shown that a central 13 amino acid peptide of FLASH (931-943 DELEEGEIRSDSE),
called FLASH-ARS2-binding (FARB) region, is sufficient for the interaction with
ARS2 [104]. Furthermore, this interaction has been reported to be important for S
phase progression [104]. To better understand the basis of the ARS2-FLASH interac-
tion the structural, biochemical and functional studies were carried out.
3.4.2.1 ARS2 – FLASH Structural Characterisation
Crystallisation trials of different ARS2 constructs with the 13 amino acids long
FARB peptide or with a 26 amino acids long peptide including the FARB sequence
(FLASH921-946) yielded various crystals in many different conditions. The struc-
tures were solved by molecular replacement using the obtained ARS2 structure as
search model. However, only for crystals of ARS2147-270+408-763 plus FLASH921-946 that
diffracted up to 6 Å additional density possibly belonging to the peptide could
be found. This additional density lies between the end of the C-terminal arm of
ARS2719-734 and ARS2408 (data not shown) and could be a part of the FARB peptide.
As FARB is a very acidic peptide it is possible that it interacts with the basic patch of
the C-terminal arm of ARS2 (see Figure 3.18A).
3.4.2.2 ARS2 – FLASH Biochemical Characterisation
By ITC the minimal ARS2 construct ARS2147-270+494-763, missing the RRM, bound to
FARB with almost the same affinity (KD~0.5 µM) as ARS2147-270+408-763 (KD~0.6 µM)
(Figure 3.21, Table 3.8). ITC experiments with ARS2147-871 were performed at higher
salt conditions (250 mM NaCl), which enabled the use of ARS2147-871 and re-
sulted in a KD of around 5 µM for the FARB and FLASH921-946 peptide (Table
3.8). To map the FLASH binding site of ARS2 different ARS2 constructs were
designed based on the solved crystal structure (see Table 3.7). In order to per-
form pull down experiments between FARB and ARS2, FLASH903-943 containing
FARB (FLASH931-943 – SDLNKENQKPIYKSDKCTEADTCKNSPLDELEEGEIRSDSE)
was cloned into the GST-vector pETM30 and expressed in E. coli. After immobilizing
GST-FLASH903-943 on the Glutathione Sepharose and incubating with the different
ARS2147-871 constructs the elutions were analysed, showing that ARS2Δ692-743 GSG and
ARS2K719A K722A K734A did not interact with GST-FLASH903-943 (Figure 3.21B). ITC ex-
periments of these two constructs confirmed that both mutations abolished the in-
teraction with the FARB peptide (Table 3.8). Thus, the deletion of ARS2’s C-terminal
arm as well as the mutagenesis of its basic patch resulted in the loss of FARB bind-
ing. To exclude unspecific binding of the acidic FARB peptide to the basic patch of
ARS2 a scrambled ARS2 peptide (EGEIESELSEDDR), containing the same residues
randomly aligned and therefore showing the same acidity as the original FARB pep-
tide, was used as control resulting in no measurable interaction with ARS2147-871 by
ITC (Figure 3.21A).
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Furthermore, ARS2634-871, ARS2634-763 and ARS2677-758 were able to bind FARB with
10 µM affinity, whereas ARS2634-763K719A K722A K734A showed no binding (Table 3.8).
Also here, the scrambled FARB peptide showed no binding to ARS2677-758 by ITC
and supports a specific interaction between the peptide and the lysines located in
the C-terminal arm of ARS2. However, analyses of the short constructs alone by 1D
NMR gave no evidence for the existence of structured regions within this construct
(data not shown).
The result that lysines located in the C-terminal arm of ARS2 are mediating the
interaction with FLASH goes in line with the observed additional density close to
ARS2719-734 (see Sec. 3.4.2.1).
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Figure 3.21 – Interaction of ARS2 with FLASH
A: Determination of KD between ARS2 and FLASH constructs. ITC experiments with ARS2
in the sample cell and FLASH in the syringe were used to measure the affinity of different
constructs. The data were plotted as described in the caption to Figure 3.3C.
B: Mapping the interaction region of FLASH on ARS2. GST or GST-FLASH903-943, which in-
cludes the FARB peptide, was immobilised on Glutathione resin and incubated with different
ARS2147-871 constructs. The flow through (FT), last wash (W) and elution (E) fractions were
analysed via Coomassie-stained SDS-PAGE.
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Table 3.8 – ARS2 - FLASH interactions
Using ITC the interactions of different ARS2 constructs to FLASH were tested.
interaction kd
ARS2 147-871 + FARB (250 mM NaCl) 5.1 ± 1.1 µM
ARS2 147-871 + FLASH 921-946 (250 mM NaCl) 5.5 ± 0.7 µM
ARS2 147-871 + scrambled FARB (250 mM NaCl) n.d.
ARS2 147-763 + FARB (250 mM NaCl) 2.1 ± 0.4 µM
ARS2 (147-270 + 408-763) + FARB 0.6 ± 0.1 µM
ARS2 (171-270 + 408-763) + FARB (250 mM NaCl) 3.6 ± 0.3 µM
ARS2 (147-270 + 494-763) + FARB 0.5 ± 0.14 µM
ARS2 634-871 + FARB 11.1 ± 4.8 µM
ARS2 634-763 + FARB 10.8 ± 2.2 µM
ARS2 677-758 + FARB 12.3 ± 2.7 µM
ARS2 677-758 + scrambled FARB n.d.
ARS2 147-871 K719A K722A K734A + FARB (250 mM NaCl) n.d.
ARS2 147-871 Δ692-743 GSG + FARB (250 mM NaCl) n.d.
ARS2 634-763 K719A K722A K734A + FARB n.d.
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3.4.3 ARS2 Cell Based Assays
To gain a better insight into the functions of the different ARS2 domains and loops
constructs based on the crystal structure (see Table 3.7) were expressed as EGFP-
tagged fusion protein in HEK 293T/17 cells. Therefore, EGFP followed by a GSGGGS
linker and the ARS2 gene were cloned into pcDNA3.1. The EGFP tag enabled to
visualise directly the transfection efficiency and localisation of the proteins. All con-
structs except the N-terminal truncation ARS2147-871 and the deletion of loop 538-554
localised in the nucleus as the wild type (Figure 3.22). ARS2147-871 showed only cy-
toplasmic localisation, which is in agreement with the described NLS within these
N-terminal residues [114, 160]. The deletions of loop 538-554 (EGFP-ARS2Δ538-554 GSA
and EGFP-ARS2Δ538-554 AAA) but not the mutagenesis of all residues to alanine (EGFP-
ARS2Δ538-554 15A) led to a localisation of EGFP-ARS2 in distinct subnuclear compart-
ments, which are likely to be the nucleoli. Since overexpression of mCherry-Nop58 or
coilin, two predominantly nucleoli localised proteins, showed no specific localisation
in the nucleus within the performed experiments (data not shown), no conclusions
about the subnuclear compartment could be made. Interestingly, ARS2 wild type
however seemed not to localise within this nuclear regions.
10 µm 10 µm10 µm
EGFP-ARS2 147-871
10 µm
EGFP
EGFP-ARS2 
Δ538-554GSA
EGFP-ARS2 
Δ538-554AAA
10 µm
EGFP-ARS2 wt
Figure 3.22 – Localisation of EGFP-ARS2 in HEK293T/17 cells
30 h post transfection cells were fixed, permeablised and stained with DAPI before imaging
by confocal microscopy. Pictures taken for the DAPI (blue) and EGFP (green) channel were
overlaid and the contrast increased for printing purpose.
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3.4.3.1 Cell Cycle Analysis
Recently, it was reported by O’Sullivan et al. that overexpression of ARS2 leads to
early S phase cell cycle arrest [160]. In the study they also predicted the structure of
murine ARS2 and analysed the effect of different mutations based on the prediction.
Having solved the human ARS2 structure allowed the identification of the exact
residues involved in RNA (see Sec. 3.4.1) and FLASH binding (see Sec. 3.4.2). To
broaden the studies the effect of the different mutants on the cell cycle was analysed.
Therefore, 48 h post transfection of the EGFP-tagged ARS2 constructs the cells were
pulsed with BrdU and analysed for their BrdU incorporation and DNA content in
respect to their EGFP signal. Looking at the distribution of the cells among the cell
cycle a slight not significant increase of cells in the S phase was detected for EGFP-
ARS2 positive cells compared to cells transfected with the empty plasmid or EGFP
(data not shown). The cells showed a normal cell phase distribution (Figure 3.23 left).
Analysis of the different ARS2 constructs showed that the substitution of residues
538-554 by GSA or AAA led to an accumulation of cells in late S Phase or G2/M
phase (Figure 3.23 right, Figure 3.24B). Consequently, fewer cells were in G0/G1 or S
phase. Interestingly, the mutation of all these residues to alanine (Δ538-554 15A) did
not show this behavior (Figure 3.24B-D). This is in accordance with the differences
observed for the cellular localisation of these constructs (see Sec. 3.4.3) and needs
further investigation to exclude possible misfolding and/or mislocalisation of the
mutants with the truncated loop 538-554.
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Figure 3.23 – Effect of ARS2 overexpression on the cell cycle
Cell cycle analysis after overexpression of ARS2 and ARS2Δ538-554 GSA. HEK 293T/17 cells
were transfected with EGFP-ARS2 constructs and analysed after 48 h by flow cytometry for
their EGFP and DNA content. Displayed is the DNA content of EGFP positive cells trans-
fected with EGFP-ARS2 (left) and EGFP-ARS2Δ538-554 GSA (right). The data were fitted with
the univariate model to quantify the G0/G1 (blue), S (yellow) and G2/M (green) phase pop-
ulations.
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The mutant ARS2R426A R470A R498A R502A, with mutations within the basic patch
around the RRM domain that reduced RNA binding (see Sec. 3.4.1), showed a signifi-
cant enrichment in cells within the S phase compared to the wild type (Figure 3.24C).
As less cells were in the G0/G1 phase, this could indicate a possible involvement of
these residues in S phase progression and needs additional analysis.
Although O’Sullivan et al. described an early S phase arrest of C2C12 cells when
overexpressing ARS2, within the performed experiments using HEK 293T/17 only a
very small effect of ARS2 overexpression could be observed. This might explain that
only the deletion of loop Δ538-554 and mutations within the basic patch around the
RRM led to significant difference from the wild type. Until now the function of loop
Δ538-554 is unknown. Residues R42,6 R470, R498 and R502A were shown to mediate
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Figure 3.24 – Effect of overexpression of different ARS2 constructs on the cell cycle
A: Schematic overview of the cell cycle.
B-D: Quantification of EGFP positive cells in each phase of the cell cycle: (B) G0/G1 phase,
(C) S phase and (D) G2/M phase. Values derived from curve fitting described in caption of
Figure 3.23. P-value **** < 0.0001.
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RNA binding, which could impact S phase progression. However, the mutant with
mutations in the RRM domain, that also has reduced RNA affinity, did not show the
same cell phase distribution. The C-terminal domain mutants (ARS2Δ692-743 GSG and
ARS2K719A K722A K734A) involved in FLASH binding (see Sec. 3.4.2.2) showed no effect
on S phase progression. Thus, no conclusion of the impact of residues involved in
RNA- or FLASH-binding on the cell cycle could be made.
3.4.3.2 Identification of ARS2 Interaction Partners
To identify regions of ARS2 involved in protein-protein interactions EGFP-tagged
ARS2 constructs and their interacting factors were isolated via affinity purification
(AP) using GFP-Trap (see Appendix B Figure B.10). EGFP-ARS2Δ538-554 GSA, which
localised in a subnuclear compartment (see Sec. 3.4.3), remained in the insoluble
fraction and was not captured by GFP-Trap (see Appendix B Figure B.10). Therefore,
this sample together with EGFP and an empty vector was used as control. Tandem
mass tag (TMT) labeling and mass spectrometric analysis of the eluted fractions was
performed by the EMBL Proteomics Core Facility. The results (Figure 3.25) showed
an enrichment of CBP80, CBP20 and PHAX for ARS2 wild type as described by pre-
vious studies [73]. Furthermore, many proteins involved in RNA processing could be
identified such as splicing factors (THRAP3, TRA2B, SNRNP70 and RBMX), helicases
(DDX5, DDX3X, DHX30 and DDX17), 3’ end processing factors (CPSF2 and CPSF3)
and proteins involved in RNA packaging (different hnRNP complex components).
Besides PHAX also hnRNP C as well as ALY and components of the TREX complex
(THOC1 and THOC2), which are all associated with the transport of RNAs, were en-
riched for ARS2. Also different importins mediating protein import into the nucleus
were identified (importin-α1, importin-α3, importin-α4, importin-α7, importin-11 and
importin-β1). In high amounts NCBP3, WDR82 and the zinc finger proteins ZC3H4,
ZCCHC8 and ZFC3H1 were determined as ARS2 associated proteins. Notably, also
Gebhardt et al. reported the association of the nuclear cap binding protein NCBP3
with ARS2 [64]. WDR82 is a CTD binding protein involved in histone H3K4 methy-
lation [115, 223]. Until now the function of ZC3H4 is unknown, whereas ZCCHC8 is
part of the NEXT and ZFC3H1 belongs to the PAXT complex. Interestingly, the inter-
action of these two complexes is mutually exclusive and mediated via MTR4 [144],
which within this study was also identified as ARS2 associated protein.
Comparing the different ARS2 constructs many differences between ARS2 wild
type and ARS2Δ692-743 GSG and ARS2K719A K722A K734A were observed (Figure 3.25C, D).
Both constructs, ARS2Δ692-743GSG which is missing the basic C-terminal arm as well as
ARS2K719A K722A K734A containing mutations in the basic patch of the C-terminal arm,
showed for example no enrichment in NCBP3, ZC3H4, ZFC3H1, PHAX and MTR4
compared to ARS2 wild type. These results indicate that the C-terminal arm of ARS2
mediates different protein-protein interactions and is important for the assembly of
correct RNA processing complexes.
All as significantly enriched classified proteins for EGFP-ARS2 compared to EGFP
and the two C-terminal domain mutants, EGFP-ARS2K719A K722A K734A and EGFP-
ARS2Δ692-743GSG, are listed in Appendix B.6 Table B.7.
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Figure 3.25 – Proteomic analysis of proteins associated with ARS2
Volcano plot comparing the enrichment of proteins identified for
A: EGFP-ARS2 wild type with EGFP.
B: EGFP with empty plasmid.
C: EGFP-ARS2 wild type with EGFP-ARS2K719A K722A K734A.
D: EGFP-ARS2 wild type with EGFP-ARS2Δ692-743 GSG.
The as true classified hits are listed in Appendix B.6 Table B.7.
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3.5 ncbp3 binding studies
As NCBP3 was identified as binding partner of ARS2 by EGFP-ARS2 pull down (see
Sec. 3.4.3.2) and was reported to bind the cap analogue m7GTP as well as CBP80,
forming an alternative nuclear cap binding complex [64], NCBP3 and its interactions
were analysed in more detail. Two constructs were used for these initial studies:
NCBP3 full length (residues 1-620) and NCBP31-282, which was previously identified
as the cap-binding region [64]. The N-terminal construct NCBP31-282 expressed in
E. coli showed high degradation, whereas the full length protein expressed in insect
cells seemed to be more stable.
For the cap binding an affinity of 5.2 µM was determined for NCBP31-282 and
of 4.9 µM for NCBP3 full length (Figure 3.26A). This result is comparable to the
described KD of 16 µM determined by microscale thermophoresis experiments for
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Figure 3.26 – NCBP3 binding studies
A: Determination of NCBP3’s cap binding. ITC was performed with NCBP3 in the sample
cell and sequential titration of m7GTP. The data were plotted as described in the caption to
Figure 3.3C.
B: Interaction of NCBP3 with CBP80 and ARS2. NCBP3 was immobilised on m7GTP-
Sepharose and incubated with CBP80 and/or ARS2. Last wash (W) and elution (E) were
analysed by Coomassie-stained SDS-PAGE.
C: SEC elution profiles of (left) the formation of the NCBP3-CBP80-ARS2 complex at low
concentrations and (right) the formation of the NCBP3-CBP80-ARS2 complex at high protein
concentrations and reinjection of the peak fractions.
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NCBP31-282 and salt conditions of 225 mM [64] instead of 120 mM NaCl and shows
that the C-terminal residues 283-620 are not involved in cap binding.
To test the interaction of different proteins with NCBP3, NCBP3 was immobilised
on m7GTP-Sepharose and incubated with ARS2, CBP80, NELF-E or PHAX. The elu-
tion from the resin shows that CBP80 as well as ARS2147-871 were retained on NCBP3
bound to the resin (Figure 3.26B), whereas no interaction of PHAX or NELF-E with
NCBP3 could be detected (data not shown).
The interaction of NCBP3 with CBP80 was only observed for the full length
NCBP3 and not for the N-terminal construct containing the cap binding domain (data
not shown). However, the N-terminal construct NCBP31-282 was sufficient to bind
ARS2147-871. Furthermore, NCBP31-680 and NCBP31-282 co-eluted with GST-tagged-
ARS2147-871 in a GST pull down experiment in the absence of the cap analogue (Figure
3.27A), indicating that the interaction between NCBP3 and ARS2 is cap-independent
and mediated via the N-terminal 282 amino acids of NCBP3.
Additionally, co-elution of all three proteins NCBP3, CBP80 and ARS2 was ob-
served (Figure 3.26C left). This trimeric complex as well as the NCBP3-CBP80 and
NCBP3-ARS2 complex could be reconstituted in the absence of m7GTP by SEC as
indicated by a shift in elution volume (Figure 3.26C). However, all these NCBP3 com-
plexes did not seem to be very stable and disassembled when subjected to SEC at
low concentrations (Figure 3.26C right).
ITC experiments were used to determine the dissociation constants and revealed
a micromolar affinity of NCBP31-282 towards ARS2147-871 under increased salt con-
ditions (250 mM NaCl), which allowed to reach high enough concentrations of the
proteins to perform the ITC experiment. However, the interaction was too weak to
enable KD calculation (Figure 3.27B). Due to the experimental requirement of high
protein concentration at low salt concentrations no ITC experiments for the interac-
tion of CBP80 and NCBP3 could be performed.
The observation from the EGFP-ARS2 pull down experiment that EGFP-
ARS2Δ692-743 GSG and EGFP-ARS2K719A K722A K734A show less enrichment of NCBP3
than ARS2 wild type (see Sec. 3.4.3.2), led to the hypothesis that the C-terminal arm
of ARS2 might mediate the interaction. To test this and to identify the NCBP3 binding
region on ARS2 different ARS2147-871 constructs were tested for their NCBP3 binding
in vitro via m7GTP pull down. As shown in Figure 3.27C ARS2147-871 K719A K722A K734A
and ARS2147-871 Δ692-743 GSG did not bind to the m7GTP-Sepharose immobilised
NCBP3. This result was also confirmed by ITC, in which no binding of the two
constructs to NCBP31-282 could be measured (Figure 3.27B right, data not shown for
ARS2147-871 Δ692-743 GSG). Furthermore, GST-ARS2634-871 was sufficient to pull down
NCBP3 in a GST pull down experiment, whereas GST-ARS2634-871 K719A K722A K734A
did not interact with NCBP3 (Figure 3.27A). These results together with the mass
spectrometric analysis of the different ARS2 constructs indicate that the basic patch
on the C-terminal arm of ARS2 mediates the interaction with NCBP3.
Interestingly, the same mutations also abolished the interaction with FARB (see Sec.
3.4.2.2), resulting in the question if FLASH and NCBP3 might compete for ARS2 bind-
ing. To investigate this the GST-FLASH903-943-ARS2147-871 complex was immobilised
on a Glutathione Sepharose resin and titrated with different amounts of NCBP3 (Fig-
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ure 3.27D). Analysis of the flow through and elution of each sample showed that with
increasing amounts of NCBP3 less ARS2147-871 was retained on the resin with GST-
FLASH903-943 and more ARS2147-871 was in the flow through together with NCBP3.
Thus, NCBP3 is out competing FLASH from ARS2, illustrating that only FLASH or
NCBP3 can be bound to ARS2 at a time.
Assuming that NCBP3 binds in the same fashion to ARS2 as FLASH, sequence
analysis identified two acidic motifs similar to that of FARB (DELEEGEIRSDSE)
within the first 282 residues of NCBP3 (41-EVEEGELEI-49, 213-DEAEEGEVEDENS-
225). However, mutations of these residues to alanine in NCBP31-282 did not abolish
the binding of ARS2 in a m7GTP-Sepharose pull down experiment (data not shown).
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Figure 3.27 – NCBP3-ARS2 binding studies
A: Narrowing down the ARS2-NCBP3 interacting regions. Different GST-tagged ARS2 con-
structs were immobilised on Glutathione resin and incubated with NCBP3 full length or
NCBP31-282. Elutions were analysed by Coomassie-stained SDS-PAGE. Red stars indicate the
ARS2 bound NCBP3 constructs and green stars the unspecific binding also observed for GST
alone.
B: ITC of NCBP31-282 with ARS2147-871constructs. ARS2147-871in the sample cell was titrated
with NCBP31-282. The data were plotted as described in the caption to Figure 3.3C. Due to
the weak interaction a precise KD could not be determined.
C: Mapping the interaction site of NCBP3 on ARS2. NCBP3 was immobilised on m7GTP-
Sepharose and incubated with different ARS2147-871constructs. The elutions (E) were ana-
lysed by Coomassie-stained SDS-PAGE.
D: Competition between NCBP3 and FLASH for ARS2 binding. The GST-FLASH903-943-
ARS2147-871 complex was preformed on Glutathione Sepharose and incubated with differ-
ent amounts of NCBP31-282. The flow through and the elution fractions were analysed by
SDS-PAGE followed by Coomassie staining.
76 results
Observing the overlap of the NCBP3 and FLASH binding sites on ARS2 togther
with the weak stability of the different NCBP3 complexes and the 50 times weaker
affinity for the cap analog of NCBP3 compared to CBC (NCBP3 KD~5 µM; CBC
KD~0.1 µM) the question if NCBP3 might be part of a CBC-ARS2 complex arose.
Remarkably, Gebhardt et al. identified not only CBP80 and ARS2 within their pull
down experiment but also CBP20 as NCBP3 associated protein [64]. Therefore, the
compatibility of CBP20 and NCBP3 binding to CBP80 was first tested by pull down
and SEC in the absence of m7GTP. NCBP3 co-eluted in both experiments with CBC
(Figure 3.28B, pull down data not shown), but not with CBP20 alone (data not
shown). The SEC showed that a stable stoichiometric complex containing NCBP3,
CBP80 and CBP20 could be formed (Figure 3.28B) unlike the NCBP3-CBP80 com-
plex, which seemed to disassembly partially while SEC. Addition of ARS2147-871 to
this ternary complex led to a further shift in the elution volume and co-elution of
all four proteins (Figure 3.28A, C). In general the CBC-NCBP3 and CBC-NCBP3-
ARS2 complex seemed to form a more stable complex on the SEC compared to the
NCBP3-CBP80, NCBP3-ARS2 and NCBP3-ARS2-CBP80 complex. The stabilisation of
the NCBP3 complexes might be mediated by CBP20, when bound to CBP80, and/or
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Figure 3.28 – Reconstitution of the CBC-NCBP3 and CBC-ARS2-NCBP3 complex
A: To test the interaction of CBC with NCBP3 different proteins and pro-
tein mixtures (ARS2147-871, CBC+NCBP3, m7GTP-CBC+NCBP3+ARS2147-871 and m7GTP-
CBC+NCBP3+ARS2147-871+PHAX) were injected to SEC and their elution profiles overlaid.
B-D: Analysis of the protein containing fractions of SECs (A) by Coomassie-stained SDS-
PAGE.
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a conformational change of CBP80 upon CBP20 binding. Furthermore, within CBC-
NCBP3-ARS2, ARS2 is presumably interacting with CBP80 and NCBP3, thus linking
the two proteins and enhancing the stability of the complex.
To broaden the studies also the compatibility of CBC-NCBP3 and PHAX was ana-
lysed. Initial experiments show that no CBC-NCBP3-PHAX or CBC-ARS2-NCBP3-
PHAX complex can be formed (Figure 3.28D, data for CBC-NCBP3-PHAX not
shown), suggesting that the binding of NCBP3 and PHAX to CBC is incompatible.

4
D I S C U S S I O N
4.1 ars2 - a protein binding surface facilitating rna sorting and
processing
4.1.1 Human ARS2 Differs from its Plant Homolog SERRATE
The structure of human ARS2 combined with a systematic analysis of its RNA and
protein binding provides valuable information for a better understanding of its func-
tion. The human ARS2 compared to its homolog SERRATE from A. thaliana [129]
contains additional helices in its mid domain as well as an inserted RRM domain.
Although ARS2 shows high conservation and three out of the four residues involved
in zinc binding in SERRATE are present, the C-terminal arm of human ARS2 is not
stabilised by a zinc ion and shows a rotation of around 90° compared to SERRATE.
The loss of zinc binding can be explained by an amino acid exchange from cysteine
in plants (Cys505 in SERRATE) to serine in animals (human ARS2 Ser717) (see Fig-
ure 3.19). Sequence comparison of the C-terminal domain of SERRATE and ARS2
shows an enrichment of lysines for metazoan ARS2. The observation that three of
these lysines (Lys719, Lys721 and Lys734) are important for the binding of ARS2 to
NCBP3 as well as to FLASH and that the C-terminal arm is not required for RNA
binding indicates a different binding mechanism as well as a different function of
this domain in plants and animals.
4.1.2 The Core of Human ARS2 is Build Up by Two Fragments
The fact that the individual fragments of ARS2 (ARS2147-270 and ARS2408-763) could
only be expressed together and were resistant to limited proteolysis, already sug-
gested a tight interaction of these two parts within the protein. Indeed, the structure
obtained within this study shows that residues of the α-helices within the C-terminal
and N-terminal arm of ARS2 are interacting and that this interaction is probably
necessary for the correct folding of ARS2. However, the RRM domain, that is only
present in metazoan ARS2, sits on top of the helical core and makes only few contacts
to the rest of the protein, is not required for proper folding.
Comparing the sequence of the five ARS2 isoforms, only isoform 5 shows dif-
ferences within the crystallised constructs of isoform 4. Isoform 5 lacks residues
196-231, which belong exactly to the two helices connecting the N-terminal arm with
the helical core, while stabilising also the C-terminal arm in the solved structure.
This suggests that isoform 5 differs slightly in the structural organisation of this
domain and that contacts with other residues might be involved in stabilising the
protein. Within the solved structure residues 232-269 include an unstructured region
followed by two α-helices that are making contacts to the helical core. The expression
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of ARS2147-234+408-763 resulted in no soluble protein, suggesting that the truncation
of residues 147-270 to 147-234 led to improper folding. Thus, residues 235-270 seem
to be important for obtaining soluble ARS2147-270+408-763. In isoform 5 these residues
would be directly linked to the N-terminal arm and might take over the role of
residues 196-231 in connecting the N-terminal arm with the helical core, while also
making contacts to the C-terminal arm. Another possibility would be a complete
different structure of ARS2. However, so far there are no experimental data confirm-
ing the isoform 5 as protein. Also information about the abundance of the isoforms
within cell types and cell stages as well as about their functional differences are miss-
ing. As the other four isoforms differ only in one to six amino acids from each other,
which lie outside of the crystallised construct, their structure will not be affected.
4.1.3 ARS2 Contains Many Flexible, Unstructured Regions
The structure of human ARS2 revealed many flexible regions including the N- and
C-terminus, the mid domain residues 271-408 and two smaller loop regions 538-554
and 567-599. Interestingly, Thr543 within loop 538-554 is supposed to be phosphory-
lated according to the phosphorylation data bank [85]. Although this loop is present
in different lengths in all metazoan ARS2, its residues - including the threonine -
are only conserved within mammals. Until now the function of this loop and phos-
phorylation is still unknown. The replacement of the loop by GSA or AAA led to
an abnormal subnuclear localisation of ARS2 and a cell cycle arrest in G2/M phase.
However, none of the point mutations showed the same localisation as the deleted
loop construct and also the mutation of all residues of the loop to alanine showed
no effect within the affinity purification followed by mass spectrometric analysis and
cell cycle analysis. A possibility is that this loop is important for the intranuclear
transport of ARS2 or involved in the release of ARS2 from the RNA transported to
this distinct nuclear areas, which might be the nucleoli. To verify that the observation
indicates a function of this loop and is not due to a mislocalisation of the construct
further studies including protein-interaction and cell assays need to be performed.
Another conserved motif within metazoan ARS2 is the acidic helix ‘EEEE’ located
in loop 567-599. Within the crystal this acidic helix binds to the basic surface of the
RRM domain of a neighbouring molecule. In small angle X-ray scattering (SAXS) a
concentration dependent behaviour of the radius of gyration Rg was observed for
ARS2, whereas SEC-MALS experiments showed no oligomerisation of ARS2 (data
not shown). As the SEC-MALS experiments were carried out at lower final concen-
tration as the SAXS experiments and no information about the concentration of ARS2
within the cell is available, no conclusion about the oligomerisation of ARS2 in vivo
can be made at this stage. In case interaction of the ‘EEEE’ helix with the RRM do-
main of another ARS2 molecule is present within the cell, this occupation of the
RRM surface and/or the ‘EEEE’ motif could present an inhibition of ARS2 by an-
other ARS2 molecule. However, the crystal structure presumes that it is sterically
impossible for two ARS2 molecules to donate their loop 567-599 to each other and
thus to form a dimer, leaving only the possibility of an oligomerisation of ARS2.
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In general, flexible unstructured regions are thought to mediate protein-protein
or protein-RNA interactions. Within this study the binding of ARS2 to CBC was
mapped to the C-terminal residues (ARS2845-871), while the N-terminus contains the
NLS [114, 160]. Whether these two regions mediate additional interactions as well
as the function of the mid domain (residues 271-408) remain elusive. RNA binding
studies showed a possible involvement of the latter region in binding to pds RNA.
Thus, the region could enable RNA unwinding or specific binding of ARS2 to RNAs
with a distinct secondary structure.
4.1.4 The RRM Domain of ARS2 Binds RNA
The RRM domain of ARS2 is highly conserved in all metazoan and is also with a
divergent sequence present in S. pombe, whereas it is absent in plants.
The RNA binding studies illustrated that the RRM domain and not the C-terminal
arm as previously proposed by O’Sullivan et al. binds RNA with a micromolar affin-
ity. No sequence specificity of ARS2 apart from a difference of ARS2147-270+408-763
binding affinity to different pdsRNAs could be observed so far. This could imply an
involvement of the glutamate and lysine rich predicted unstructured region compris-
ing residues 271-407 in pdsRNA binding. Overall, ARS2 seems to associate in vivo
preferentially with RNAs containing a stem loop like replication dependent histone
pre-mRNAs, pre-miRNAs and 7SK RNA [71, 73, 129, 160]. However, recent studies
questioned the specific association of ARS2 and other proteins to RNAs by showing
no strong preference for distinct classes of capped RNAs [66]. Thus, the role of the
RRM domain and ARS2 in transcript class recognition remains unknown.
The highest structural similarity to ARS2 RRM domain shows the to the RRM
domain of RBM7. Remarkably, RBM7 binds via its RRM domain to a peptide of
ZCCHC8 within the NEXT complex [53] and the hydrophobic patch important for
RBM7-ZCC5C8 interaction is also present in ARS2. This supposes that the RRM do-
main of ARS2 could bind both RNA and protein. To clarify, whether ARS2 can distin-
guish RNAs by specific sequence and/or structural elements and if the RRM serves
as protein-protein interacting surface, further studies need to be performed.
4.1.5 The C-terminal Arm of ARS2 Mediates Several Protein-Protein Interactions
Although the RRM domain together with the C-terminal arm was previously pro-
posed to be involved in FLASH binding [160], the binding region of the FARB peptide
on ARS2 was mapped to the C-terminal arm and involves Lys719, Lys721 and Lys734.
This basic region was additionally identified as binding region of NCBP3, suggest-
ing that FLASH and NCBP3 binding to ARS2 is incompatible, which could be proven
within this study in vitro. Until now the N-terminal region of NCBP3 (residues 1-282)
was shown to interact with ARS2, whereas the C-terminal residues seem to mediate
the binding to CBP80.
This gives rise to the hypothesis that also mutually exclusive ARS2 and thus CBC-
ARS2 complexes are formed within RNA processing. The formation of individual
CBC-ARS2-FLASH and CBC-ARS2-NCBP3 complexes is supported by the fact that
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FLASH is involved in the processing of replication dependent histone mRNAs [13],
whereas NCBP3 associates with mRNAs [64]. Extending this hypothesis to other
processing machineries would lead to the recruitment of for example DROSHA to
CBC-ARS2 complexes containing pre-miRNAs, while RNAs target for degradation
would favour the recruitment of nuclear RNA decay complexes to CBC-ARS2. For
snRNAs it was already shown that a distinct CBC-ARS2-PHAX complex exists [73].
Interestingly, the deletion and mutation of the basic C-terminal patch of ARS2 led to
the loss of PHAX association (see Sec. 3.4.3.2). Until now a direct interaction between
ARS2 and PHAX was only observed for SERRATE and not for metazoan ARS2 [66].
However, it was demonstrated that in vivo ARS2 stimulates the binding of PHAX to
CBC [73]. Thus, the C-terminal arm might either enhance the recruitment of PHAX
and/or stabilise the CBC-PHAX interaction. The observed loss of PHAX association
to ARS2 (CBC-ARS2) for the two C-terminal domain mutants could be explained as
following. In the case of an interaction of PHAX and ARS2, possibly via its C-terminal
domain, within the CBC-ARS2-PHAX complex, the binding of other proteins to this
ARS2 interaction surface would be occupied and a stable CBC-ARS2-PHAX complex
be formed, whereas in the absence of the C-terminal arm or the mutation of the
interacting residues the CBC-PHAX interaction is weaker and other proteins might
be able to replace PHAX from the CBC-ARS2 complex.
Mutations of the C-terminally located basic patch as well as the deletion of the C-
terminal arm also altered the association of ARS2 with MTR4 and ZFC3H1, proteins
involved in the nuclear RNA decay. Recent studies showed that binding of ZFC3H1,
which is part of the PAXT complex, and ZCCHC8/RBM7, which belong to the NEXT
complex, to MTR4 is incompatible and that CBC-ARS2 is involved in both pathways
[144]. Thus, the C-terminal arm of ARS2 is likely to link the RNA-CBC complex to
either degradation via the NEXT or PAXT complex.
The result that also other proteins like ZC3H4 (zinc finger protein of unknown
function), WDR822 (protein involved in H3-Lys4 methylation), RALY (potential hn-
RNP) and THRAP3 (protein involved in splicing), associate to full length ARS2 but
not to the mutated and truncated ARS2 proteins, indicates that this basic patch prob-
ably links CBC-ARS2 to different processing machineries maintaining the exclusive
recruitment for each step. Additionally, the affinity purification followed by mass
spectrometry analysis showed an interaction between ARS2 and the export adapter
ALY, which links pre-mRNA splicing to nuclear export. Whether this interaction is
direct or mediated via CBC, which directly binds ALY, needs to be clarified.
Altogether these data confirm that ARS2 serves as additional interacting surface
besides CBC and supports the correct sorting and processing of the nascent transcript.
This might be achieved by the formation of mutually exclusive CBC-ARS2 complexes.
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4.2 mutually exclusive cbc complexes
More than 20 years ago CBC was identified as cap binding protein [94] and since then
several CBC complexes have been reported to be important for the correct process-
ing of different RNA classes. However, its role in the maturation of Pol II transcripts
as well as its interactions with the different processing machineries are not well un-
derstood. This study focused on the CBC-ARS2 complex, which is involved in the
maturation of different Pol II transcripts and interacts with several RNA processing
machineries. Recently, a trimeric complex containing CBC-ARS2 and additionally
PHAX has been shown to associate with snRNAs [73]. In the case of replication de-
pendent histone mRNAs NELF, which binds CBC via its subunit NELF-E, as well
as ARS2 seem to associate with CBC during the maturation [156]. This led to the
question, if ARS2 and NELF-E are binding together to the CBC-histone mRNA com-
plex. To better understand the individual CBC complexes and thus the individual
RNA processing steps biochemical, biophysical and structural methods were used to
analyse the individual interactions between CBC and ARS2, PHAX and NELF-E.
4.2.1 Identification of Mutually Exclusive CBC Complexes
Interestingly, the C-terminus of ARS2 (ARS2845-871) and NELF-E (NELF-E360-380) are
mediating the binding to CBC and their affinity is increased for cap bound CBC 12- or
8-fold, respectively. For ARS2, its C-terminus seems to be the only interaction with
CBC, whereas for NELF-E additional regions including the RRM domain (NELF-
E244-380) are involved and thus contribute to an increased binding affinity towards
CBC. However, NELF-E244-360, which lacks the C-terminus, was not able to bind CBC
in vitro. For PHAX the interaction site with CBC could be narrowed down to the
residues PHAX103-294, which include most of its RBD (residues 227-308). The CBC-
PHAX interaction, which in the absence of m7GTP, had a similar affinity as NELF-E,
showed no significant m7GTP dependence.
The results obtained showed that PHAX and ARS2 binding to CBC is not compat-
ible with NELF-E binding, suggesting a separation of different processing steps due
to mutually exclusive CBC complexes. Solving the crystal structure of CBC-ARS2
and CBC-NELF-E revealed the molecular mechanism of their incompatibility. ARS2
and NELF-E are not only binding with their highly conserved C-terminus to CBC,
they are also sharing the same binding site on CBC and their interactions show high
similarities (see Figure 3.13). The three key interacting residues Arg362, Tyr367 and
Phe380 for NELF-E and Arg854, Thy859 and Phe871 for ARS2 are identical and
highly conserved. For ARS2 it was shown that Arg854 and Tyr859 are the main
interacting sites and that Phe871 only contributes slightly to the interaction. Indeed,
both the arginine and tyrosine residues are absolutely conserved in ARS2 and NELF-
E, whereas the phenylalanine shows less conservation. For example in plants the
C-terminus of ARS2, which contains a six residue extension, lacks the phenylalanine
and only non-rodent mammals have an eight residue C-terminal extension of NELF-
E ending in Phe380. However, not only the key interacting residues are identical, but
also both peptides bound to CBC contain flexible residues (ARS2862-867 DAPADD
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and NELF-E375-377 NLV), for which no electron density could be detected. For ARS2
these residues show high conservation, suggesting that this motif may have another
functional role in case ARS2 is not bound to CBC.
Moreover, the phosphoSite database [85] contains strong evidence that ARS2 Y859
(Y864 in human isoform 1) can be phosphorylated. There is also evidence that
the equivalent tyrosine in NELF-E Y367 and possible Y372 can be phosphorylated.
The structures solved in this study show that these post-translational modifications
would likely impede ARS2 or NELF-E binding to CBC, since the tyrosines are buried.
Thus, the complex formation could be regulated by phosphorylation in vivo.
The incompatibility of NELF-E and PHAX binding to CBC, observed for NELF-E
constructs containing additionally the RRM domain, suggests an overlapping bind-
ing site and/or steric hindrance between NELF-E and PHAX when interacting with
CBC. As binding of PHAX and ARS2 to CBC are compatible, additional residues
apart from the C-terminus of NELF-E must lead to the mutual exclusive binding.
Interestingly, the residues of PHAX involved in CBC binding (PHAX103-294) include
most of its RRM domain (residues 227-308). Thus the RRM domain of PHAX and
NELF-E seem to be in close proximity to the 5’ end of the transcripts, which cap is
bound by CBC. Interaction of the transcript with PHAX or NELF-E via their RRM
domain could lead to the stabilisation and/or preference for one of the proteins for
the RNA-CBC complex. For PHAX the binding region on CBC could only be mapped
using cross-linking mass spectrometry and further investigation is needed to under-
stand it and its incompatibility with NELF-E on molecular level.
Additionally, a novel CBC complex containing CBC-NCBP3 was identified within
this study. Interestingly, NCBP3 was recently characterised to be a m7 cap binding
protein, although its affinity to the cap analogue is low. CBP80 was highlighted to
interact with NCBP3, despite the fact that the data showed also an association of
CBP20 with NCBP3 [64]. Earlier studies however suggested an association of NCBP3
with CBC during splicing [145]. The fact that NCBP3 binds m7GTP only in the micro-
molar range, whereas CBC shows a 50 times higher affinity and that NCBP3 binds
more stable to CBC than to CBP80 alone, raised questions about NCBP3’s role as a
cap binding protein in vivo. The result that CBC-NCBP3 was able to bind additionally
ARS2 but not PHAX indicates that CBC, ARS2 and NCBP3 form an alternative CBC
complex that might target the processing of specific RNA classes. This hypothesis is
supported by the affinity purification mass spectrometry carried out by Gebhardt et
al., showing that NCBP3 is associated to CBP80, CBP20 and ARS2, whereas CBP20
shows enrichment for CBP80, ARS2 and PHAX [64]. Additionally, NCBP3 could also
be identified in the CBP20 pull down, but showed no significant enrichment [64].
This could be explained by a weaker affinity of NCBP3 to CBC compared to the
other proteins, a lower abundance of NCBP3 in the cell and/or the limitations of the
technique. The formation of two individual CBC-ARS2 complexes containing either
NCBP3 or PHAX is in line with previous observations that PHAX associates with
snRNAs [158] whereas NCBP3 binds preferentially mRNAs [64] and was shown to
be involved in splicing [145]. Moreover, it suggests that CBC-ARS2 bound to snRNA
recruits PHAX, whereas CBC-ARS2 bound to mRNA would favor the association of
NCBP3.
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Furthermore, it was shown that NCBP3 and FLASH are binding both to the basic
patch in the C-terminal arm of ARS2 and that their binding is incompatible. Conse-
quently, it is likely that either a CBC-ARS2-FLASH complex or a CBC-ARS2-NCBP3
complex is formed. Thus, FLASH would associate with CBC-ARS2 complexes bound
to replication dependent histone mRNAs, whereas NCBP3 interacts with CBC-ARS2
when bound to mRNA. How the different RNAs are assigned to the appropriate
complex remains still to discover.
4.2.2 Mutually Exclusive CBC Complexes Mediate RNA Processing
In collaboration with Edouard Bertrand and Torben Heick Jensen the model of mu-
tually exclusive CBC complexes to coordinate the fate of the RNA has recently been
introduced [66]. In this study the existence of two individual CBC complexes, namely
CBC-ARS2-PHAX for snRNA export and CBC-ARS2-ZC3H18 for the degradation of
transcripts via the nuclear exosome was shown [66]. Additionally, another study re-
cently showed that the exclusive binding of ZFC3H1/PABPN1 and ZCCHC8/RBM7
to MTR4 targets transcripts for exosomal degradation via the PAXT or NEXT path-
way, respectively [144]. Thus, mutually exclusive binding seems to be a common
mechanism within RNA processing.
Taken together all the mentioned results, the following CBC complexes seem to be
mutual exclusive: CBC-NELF-E and CBC-ARS2 with CBC-ARS2-PHAX, CBC-ARS2-
NCBP3 and CBC-ARS2-FLASH and CBC-ARS2-ZC3H18 with CBC-ARS2-ZC3H18-
PAXT and CBC-ARS2-ZC3H18-NEXT (Figure 4.1).
But what is the biological significance and role of all these mutually exclusive
CBC complexes? They could be either components of parallel but different pathways
(i.e. acting on distinct RNAs) or be remodeled complexes at different time points
in the biogenesis pathway of the same RNA. Considering the distinct roles of the
proteins both possibilities seem plausible. In case of CBC-NELF-E, CBC-ARS2 and
other CBC-ARS2 complexes a sequential rearrangement within the processing of the
transcripts seems probable. NELF-E is generally thought to be associated only with
Pol II pausing early after transcription initiation, whereas ARS2 is linked to later
events such as 3’ end processing [6, 71, 73], nuclear exosome-mediated degradation
[6, 66, 144] or nuclear export [73]. Consequently, the CBC-NELF-E complexes would
form first and later during transcription ARS2 would replace NELF-E from CBC
(Figure 4.1).
Regarding the early co-transcriptional events, capping is thought to occur when
Pol II is paused as a result of the action of the negative elongation factors DSIF and
NELF. In the absence of the cap, CBC still showed in vitro weak affinity to NELF-E,
which could be one factor helping to recruit CBC to the transcript. Once capping has
occurred, CBC will bind the cap, which strengthens the CBC-NELF-E interaction. Fur-
thermore, the ternary CBC-NELF-E-capped RNA complex can be further reinforced
by NELF-E interactions, via its RRM, with the transcript, which has been proposed to
be one mechanism for regulating pausing in a transcript specific manner [163]. Tran-
scription pause release is promoted by multiple different phosphorylation events me-
diated by P-TEFb [127] including phosphorylation of DSIF (whereupon it becomes a
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positive elongation factor), NELF (leading to its dissociation) and Pol II CTD. What
exactly leads to the recruitment of P-TEFb is not well understood, but there is evi-
dence that CBC bound to the cap structure promotes the recruitment of P-TEFb and
links capping with transcription elongation [120]. Recent work demonstrated that the
Integrator complex is recruited by NELF and DSIF to the paused Pol II complex and
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Figure 4.1 – Model of RNA processing via mutually exclusive RNA complexes
Shortly after the initiation of Pol II transcription the 5’ cap of the nascent RNA acquires a
m7 cap structure, that is immediately bound by CBC, consisting of CBP20 and CBP80. Addi-
tionally, a stable complex of the transcript, CBC and NELF, which binds CBC via its subunit
NELF-E, is formed. This complex could be stabilised though the binding of NELF’s RRM
domains to the RNA. Then at an unknown stage during transcription, NELF-E dissociated
from the RNA-CBC complex and ARS2 is recruited, followed by the association of additional
RNA processing factors that are specific for a distinct RNA class.
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that Integrator subunits also regulate pausing [178, 196, 228]. As the precise function
of the Integrator complex remains elusive, the discussion will be restricted to how the
obtained results might fit into the current model of co-transcriptional processing of
snRNAs [66, 228]. It was reported that NELF accumulates at the downstream regions
of snRNA (and replication dependent histone mRNA) genes and is required for cor-
rect 3’ end processing. This suggests that NELF has a role in preventing aberrant
polyadenylation by inhibiting recruitment of the cleavage stimulation factor. Assum-
ing NELF is still bound to CBC at this stage, the CBC-NELF-E interaction will also
prevent premature recruitment of ARS2 and PHAX. However, at some currently un-
known 3’ end processing step, there must be a switch of CBC partner from NELF-E
to ARS2 (Figure 4.1). This may be concomitant with NELF dissociation and/or ad-
ditional phosphorylation events (e.g. as mentioned above on Y367/Y372 of NELF-E).
Once the switch has happened, PHAX can be recruited to the CBC-ARS2-snRNA
complex to promote its nuclear export. Alternatively, if there is some defect in 3’ end
processing such as read-through, leading to extended forms of snRNA, these aber-
rant RNAs can be bound by the RBM7 subunit of the NEXT complex and targeted
for degradation [6, 87]. Interestingly, it has recently been shown that the NEXT com-
plex, via the bridging protein ZC3H18, interacts with CBC-ARS2, which excludes
PHAX binding [66]. Thus, competition between mutually exclusive CBC complexes
contributes to either the productive export of mature or degradation of incorrectly
processed snRNA transcripts (Figure 4.1).
For other transcripts like mRNAs and replication dependent histone mRNAs, after
the switch from NELF-E to ARS2, NCBP3 and FLASH could be recruited to the CBC-
ARS2 complex, respectively. With FLASH other replication dependent histone mRNA
3’ end cleavage factors would be recruited, whereas NCBP3 seems to be part of
mRNPs during splicing [145]. After correct processing or in cases of misprocessing
another switch between the CBC-ARS2 bound proteins is likely to occur to either
export adaptors for the nuclear export of the mature mRNA or ZC3H18 for the
degradation of aberrant RNAs (Figure 4.1).
Until now no direct role of ARS2 in nuclear RNA export has been reported.
For snRNAs the CBC-ARS2-PHAX complex, comprising the snRNA export adaptor
PHAX, was described [158] and ARS2 seems to enhance the recruitment of PHAX to
CBC [73]. Within this study an association of the mRNA export adapter ALY with
ARS2 was identified via affinity purification followed by mass spectrometric analy-
sis. Whether this interaction is direct or mediated via CBC, which is binding ALY,
needs to be clarified. However, before mRNA export through the NPC the mRNP is
rearranged and ALY dissociates from the complex. Already testing the compatibil-
ity of ARS2 binding to the snRNA export complex snRNA-CBC-PHAX-CRM1-Ran
and the mRNA export complex mRNA-CBC-Nxf1-NXT1 will indicate, if ARS2 is co-
exported with the RNA. A rearrangement of the export complexes leading to the
replacement or dissociation of ARS2 from CBC, thus forming other mutual exclusive
CBC complexes for RNA export, could regulate RNA export.
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4.2.3 Regulation of Mutually Exclusive CBC Complexes
Although the existence of mutually exclusive RNA-CBC complexes has been shown
and these distinct complexes are likely to regulate RNA processing, it remains un-
clear what coordinates the recruitment of the correct processing machinery. Taking
into account that RNA processing takes part co-transcriptionally and that the Pol II
transcribes a couple of kbp per minute [130], the different processes must be efficient
and well-coordinated. This could be achieved by short-lived, mutually exclusive com-
plexes that have one common factor: CBC. Depending on the RNA maturation stage
additional factors such as NELF-E or ARS2 might bind to CBC and the RNA, label-
ing the complex for this specific maturation and/or transcription stage. As there are
several different RNA classes further labels need to be added to the complex. These
could be PHAX in the case of snRNA, FLASH for histone mRNA, NCBP3 for mRNA
and ZC3H18 for RNA targeted for degradation. Many of the proteins involved in
RNA processing contain RRM domains, which could be recruited specifically regard-
ing the bound transcript. However, recent results showed that ARS2, PHAX and
ZC3H18 bind capped transcripts without strong preferences regarding their class or
maturation [66]. Furthermore, the formed complexes seemed to be very transient,
presuming that exclusive transcript-CBC complexes are formed temporarily, which
only results in effective processing, if all requirements are fulfilled. These require-
ments would include the recruitment of all factors of the distinct processing step to
the RNA and specific features of the RNA that support its processing like secondary
structure or sequence elements.
The assembly and disassembly of exclusive CBC complexes could further be coor-
dinated by specific modification of proteins like phosphorylation. Phosphorylation
plays an important role within transcriptional regulation of Pol II and thus also the
processing could be coupled accordingly.
4.3 future perspectives
Within this doctoral thesis, the CBC complexes CBC-ARS2, CBC-PHAX and CBC-
NELF-E were studied from a molecular point of view leading to a better insight of
their arrangements and the discrimination between RNA processing steps. The stud-
ies on ARS2 support its role as interacting surface within the processing of capped
RNAs. However, it remains elusive how the different complexes are recruited. As
distinct RNAs are processed in different ways, the nature of the RNA (e.g. length,
presence of secondary structure) must determine to some extent its fate. Some of
these features have already been identified. For the distinction between snRNA and
mRNA it was shown that hnRNPC binds and replaces PHAX selectively from RNAs
longer than 200 nts [140]. For 3’ end processing different sequence and structural
elements have been identified that recruit distinct processing machineries. However,
the exact mechanism underlying the sorting of the individual RNA classes into the
appropriate pathways is not well understood. Structural insight into protein-RNA
interaction and the arrangement of the processing machineries at individual steps
will help disclosing the molecular mechanism of RNA processing.
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Within this study the structural characterisation was mainly based on crystallo-
graphy. However, alternative methods including NMR and cryo electron microscopy
can help to better understand individual domains of proteins and big complexes,
respectively. Using NMR the individual interactions for example between the RRM
domain of ARS2 and RNA or the C-terminal arm and FLASH and NCBP3 can be
analysed. Until now although using different solubility tags no folded construct of
both RRM and C-terminal arm could be purified. However, the C-terminal constructs
ARS2634-871, ARS2634-763 and ARS2677-758 showed weak affinity for the FARB peptide
and might be a starting point for further construct optimisations for NMR studies.
For the bigger complexes such as CBC-ARS2-NCBP3 or CBC-ARS2-PHAX electron
microscopy can be used to obtain insights about the arrangement of the complexes.
Although overall less protein might be needed for electron microscopy than for crys-
tallography, a stable complex must be formed or the complex needs to be stabilised
otherwise, for example by using chemicals to cross-link the proteins. Also the RNA it-
self could already lead to a stabilisation of the complex by interacting with the RRM
domains of the individual proteins. Furthermore, studying the complex in context
with the distinct RNAs is essential for a better understanding of RNA processing.
To help finding an RNA that could stabilise ARS2 or other components within the
CBC complexes additional RNA binding studies need to be performed to identify
a possible sequence or secondary structure preference. One possibility to identify a
motif or specific RNAs that show high affinity for ARS2 is the affinity RNA pull
down. The result would might give information about the recruitment of ARS2 to
specific RNAs and will be useful for further structural studies.
Besides studies of the already described complexes, it is still unclear if ARS2 stays
attached to the RNA-CBC complex during nuclear export. Testing the compatibility
of ARS2 binding to the snRNA export complex CBC-PHAX-CRM1-Ran could give
information about a possible export of ARS2 within this complex.
Moreover, the identification of NCBP3 as part of a CBC-ARS2 complex needs fur-
ther investigations including the mapping of the ARS2 and CBP80 binding site on
NCBP3, studies of its RRM domain regarding RNA and cap binding as well as its
interactions with other proteins, to better define its role within RNA processing.
All these studies of the individual proteins as well as the whole complexes will
help to shed light on how the different Pol II transcripts are processed and how the
processing and sorting is coordinated.

A
S U P P L E M E N TA RY M AT E R I A L A N D M E T H O D S
a.1 composition of solutions
The composition of buffers and media used in this study are listed Table A.1 and
Table A.2 respectively.
Table A.1 – Buffer
buffer components
Buffer A pH 7.8 120 mM NaCl
2 mM TCEP
20 mM HEPES
Buffer B pH 7.8 800 mM NaCl
2 mM TCEP
20 mM HEPES
CC1 pH 5.8 100 mM RbCl
50 mM MgCl2
10 mM potassium acetate
10 mM CaCl2
15% (v/v) glycerol
CC2 pH 6.5 10 mM RbCl
75 mM CaCl2
10 mM MOPS
15% (v/v) glycerol
HEK 293 Lysis Buffer 20 mM HEPES pH 7.4
120 mM NaCl
0.1% (v/v) Triton X-100
Labeling Buffer PBS pH 7.4
0.5% (w/v) BSA
0.5% (v/v) Tween-20
Lysis Buffer pH 7.8 120 mM NaCl
10% (v/v) glycerol
5 mM ß-mercaptoethanol
50 mM HEPES
Table A.1 – Continued on next page
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Table A.1 – Buffer (continued)
buffer components
PBS pH 7.4 137 mM NaCl
2.7 mM KCl
10 mM Na2 HPO4
1.8 mM KH2PO4
RNA Binding Buffer pH 7.8 115 mM NaCl
1 mM MgCl2
2 mM TCEP
7.5% (v/v) glycerol
20 mM HEPES
SDS Running Buffer pH 8.3 25 mM Tris
192 mM glycine
0.1% (w/v) SDS
4x SDS Sample Buffer 0.1% (w/v) bromophenol blue
25% (v/v) glycerol
5% (w/v) SDS
10% (v/v) β-mercaptoethanol
250 mM Tris pH 6.8
TAE Buffer pH 8.0 40 mM Tris
1 mM EDTA
20 mM acetic acid
Tris-EDTA Buffer pH 8.0 1 M Tris
0.1 M EDTA
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Table A.2 – Media
medium components
LB agar 1.5% (w/v) agar in LB
High Five insect cells medium Express Five SFM (Gibco)
50 μg/ml penicillin-streptomycin
(Gibco)
18 mM L-Glutamine (Gibco)
HEK293T medium high glucose Dulbecco’s Modified
Eagle Medium (DMEM) (Gibco)
10% (v/v) FBS (Sigma)
M9 medium pH 7.2 33.7 mM Na2 HPO4
22 mM KH2PO4
8.55 mM NaCl
9.35 mM NH4Cl
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a.2 instruments
Instruments used in this study are listed in Table A.3.
Table A.3 – Instruments
instrument type manufacturer
Agarose gel chamber Horizontal Apparatus Bio-Rad
Centrifuges Avanti J-26-XP Beckman Coulter
Centrifuge 5424 Eppendorf
Centrifuge 5804 Eppendorf
Centrifuge 5427 R Eppendorf
SpeedVac Concentrator Savant
Chromatography
columns
Superdex 200 10/300
GL
GE Healthcare
Superdex 200 PC 3.2/30 GE Healthcare
Superdex 75 10/300 GL GE Healthcare
Superose 6 GE Healthcare
Superose 6 increase
10/300
GE Healthcare
Superdex peptide
PC3.2/30
GE Healthcare
HiTrap Heparin HP
5 ml
GE Healthcare
HiTrap Q FF 5 ml GE Healthcare
HiTrap Q HP 5 ml GE Healthcare
HiTrap SP HP 5 ml GE Healthcare
Chromatography
systems
Äktra Prime GE Healthcare
Äktra Purifier GE Healthcare
Äktra GE Healthcare
Concentrator Amicon Ultra Merck Millipore
Flow cytometer BD LSRFortessa BD Bioscience
Formulator Formulator Formulatrix
Electrophoresis
Chamber
Vertical electrophoresis
cell
Bio-Rad
Gel documentation
system
Gel Doc XR+ Bio-Rad
Table A.3 – Continued on next page
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Table A.3 – Instruments (continued)
instrument type manufacturer
Isothermal titration
calorimeter
MicroCal iTC200
System
Malvern
Microplate reader CLARIOstar BMG LABTECH
Microscope TCS SP5 Leica
NanoDrop
spectrophotometer
ND-1000, ND-2000 Thermo Scientific
Spectrophotometer Ultrospec 1100 pro
UV/Visible
Amersham Pharmacia
pH meter Microprocessor pH WTW
Rotors JA25.50 Beckmann Coulter
JA8.100 Beckmann Coulter
Sonicator Ultrasonic Liquid
Processors
Misonix
Thermal block ThermoMixer Eppendorf
Thermocycler T3000 Biometra
T3 Biometra
Vortex mixer MS2 Minishaker IKA
Water bath TW8 Water Bath JULABO
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a.3 kits
Kits used in this study are listed in Table A.4.
Table A.4 – Kits
kit manufacturer
Additive Screen HT Hampton Research
Bradford Protein Assay Bio-Rad
Gel filtration LMW calibration kit GE Healthcare
In-Fusion HD Cloning Kit Clontech
QIAprep Spin Miniprep Kit Qiagen
QIAquick Gel Extraction Kit Qiagen
QIAquick PCR Purification Kit Qiagen
NucleoSpin Plasmid Kit Macherey-Nagel
PCR clean-up Gel extraction Macherey-Nagel
Page Ruler Prestained Protein Ladder, 10-180 kDa Thermo Fisher Scientific
Color Prestained Protein Standard, Broad Range New England Biolabs
MassRuler Express Forward DNA Ladder Mix,
ready-to-use
Thermo Fisher Scientific
PACT premier Molecular Dimensions
JCSG+ Screen Molecular Dimensions
The Classics Suite Qiagen/NeXtal
Salt Grid Hampton Research
Wizard I&II Rigaku Reagents
The PEGs-I Qiagen/NeXtal
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a.4 plasmids
An overview of all plasmids encoding protein constructs is given in Table
A.5. Within this study the following sequences were used for the individ-
ual proteins: ARS2 (isoform-e, NP_001122326/isoform-4, Q9BXP5-4, 871 residues);
NELF-E (NP_002895.3); PHAX (NP_115553.2); NCBP3 (NP_001107590.1); CBP20
(NP_031388.2); CBP80 (NP_002477.1); FLASH (NP_036247.1).
Table A.5 – Plasmids
plasmid protein construct comment
CBP20 constructs
pRSET A CBP20 1-471 full length, wild type
pETM30 CBP20 1-471 full length, wild type
pETM30 CBP20 1-471 Y50A CBP20 ARS2 binding
mutant
pETM30 CBP20 1-471 Y50A Y89A CBP20 ARS2 binding
mutant
pETM30 CBP20 1-471 Y50A Y89A
D107R
CBP20 ARS2 binding
mutant, lower m7GTP
affinity in complex with
CBP80
CBP80 constructs
pFASTBac CBP80 20-791 ∆NLS [138, 139]
pFASTBac CBP80 20-791 ∆653-701 G ∆NLS ∆CC [138, 139]
pFASTBac CBP80 20-791 Y461A R610E
H651A
CBP80 ARS2 binding
mutant
pFASTBac
DUAL
CBP80 +
NCBP3
20-791 + 1-620 co-expression
CBP80/NCBP3
ARS2 constructs
pETM11 ARS2 1-871 full length, wild type, no
expression
pFASTBac ARS2 1-871 full length, wild type, no
soluble expression
pETM11 ARS2 147-871 deletion of the predicted
unstructured N-terminus,
slight C-terminal
degradation
Table A.5 – Continued on next page
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Table A.5 – Plasmids (continued)
plasmid protein construct comment
pFASTBac ARS2 147-871 deletion of the predicted
unstructured N-terminus,
slight C-terminal
degradation
pETM30 ARS2 147-871 deletion of the predicted
unstructured N-terminus
pETM11 ARS2 147-845 C-terminal truncation, no
CBC binding
pETM11 ARS2 147-871 N496E
pETM11 ARS2 147-871 ∆539-554 GSA deletion of loop 539-554
pETM11 ARS2 147-871 ∆567-599
GSGSGS
deletion of loop 567-599
pETM11 ARS2 147-871 K719A K722A
K734A
mutations in the
C-terminal basic patch
pETM11 ARS2 147-871 ∆692-743 GSG deletion of the C-terminal
arm
pETM11 ARS2 147-871 ∆271-408
GSGSGSGS
deletion of the predicted
unstructured region
271-408
pETM11 ARS2 147-871 R426G R470G
R498A R502A
mutations of the basic
patch within the RRM
domain
pETM11 ARS2 147-871 R424A R426G
R463A R465A
mutation within the RRM
domain
pETM11 ARS2 147-270 predicted structured
region, N-terminal
fragment for co-expression
pFASTBac ARS2 147-270 predicted structured
region, high aggregation
pETM11 ARS2 163-270 N-terminal fragment for
co-expression
pETM11 ARS2 171-270 N-terminal fragment for
co-expression
pETM11 ARS2 193-270 N-terminal fragment for
co-expression
pETM11 ARS2 147-234 N-terminal fragment for
co-expression, no soluble
expression
Table A.5 – Continued on next page
A.4 plasmids 99
Table A.5 – Plasmids (continued)
plasmid protein construct comment
pETM11 ARS2 673-871
pETM30 ARS2 673-871
pETM30 ARS2 673-871 K719A K722A
K734A
mutations in the
C-terminal basic patch
pETM11 ARS2 673-845 C-terminal truncation, no
CBC binding
pETM11 ARS2 673-763
pETM30 ARS2 673-763
pETM30 ARS2 673-763 K719A K722A
K734A
mutations in the
C-terminal basic patch
pETM11 ARS2 763-871
pETM11 ARS2 763-845 C-terminal truncation, no
CBC binding
pETM11 ARS2 811-871
pETM11 ARS2 827-871
pETM11 ARS2 827-871 R854A Y859A ARS2 CBC binding
mutant
pETM11 ARS2 827-871 F871A ARS2 CBC binding
mutant
pETM11 ARS2 827-871 R854A Y859A
F871A
ARS2 CBC binding
mutant
pETM11 ARS2 408-763 predicted structured
region, no soluble
expression
pFASTBac ARS2 408-763 predicted structured
region, no soluble
expression
pETM11 ARS2 408-494 RRM domain, no protein
expression
pETM41 ARS2 408-494 RRM domain, only
expression of MBP
pETM11 ARS2 408-508 RRM domain, no protein
expression
pETM41 ARS2 408-508 RRM domain, only
expression of MBP
pETM11 ARS2 690-750 C-terminal arm
pETM30 ARS2 690-750 C-terminal arm
Table A.5 – Continued on next page
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Table A.5 – Plasmids (continued)
plasmid protein construct comment
pETM11
SUMO
ARS2 690-750 C-terminal arm
pETM11 ARS2 691-746 C-terminal arm
pETM30 ARS2 691-746 C-terminal arm
pETM11
SUMO
ARS2 691-746 C-terminal arm
pETM11 ARS2 677-758 C-terminal arm
pETM30 ARS2 677-758 C-terminal arm
pETM11
SUMO
ARS2 677-758 C-terminal arm
Plasmids used for co-expression with pETM11
pDUET ARS2 408-763 predicted structured
region
pDUET ARS2 408-763 ∆539-554 GSA deletion of loop 539-554
pET15b ARS2 408-871 ∆567-599
GSGSGS
deletion of loop 567-599
pET15b ARS2 408-763 ∆539-554 GSA
∆567-599 GSGSGS
deletion of loop 539-554
and loop 567-599
pET15b ARS2 408-871 ∆764-827 fusion of structured
region to C-terminus
pET15b ARS2 494-763 RRM domain
PHAX constructs
pETM11 PHAX 1-394 full length, wild type
pETM11 PHAX 103-308
pETM11 PHAX 120-308
pETM11 PHAX 103-327
pETM11 PHAX 103-294 minimal CBC binding
construct
NELF-E constructs
pETM11 NELF-E 1-380 full length, wild type, no
soluble expression
pFASTBac
HTb
NELF-E 1-380 full length, wild type
pETM11 NELF-E 244-380 deletion of the N-terminal
predicted unstructured
region
Table A.5 – Continued on next page
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Table A.5 – Plasmids (continued)
plasmid protein construct comment
pETM11 NELF-E 244-360 C-terminal truncation
pETM11 NELF-E 335-380 no expression
FLASH construct
pETM30 FLASH 903-943 includes FARB sequence
FLASH931-943
NCBP3 constructs
pETM11 NCBP3 1-620 full length, wild type, no
soluble expression
pFASTBac
HTb
NCBP3 1-620 slight degradation
pETM11 NCBP3 1-282 high C-terminal
degradation
pETM11 NCBP3 1-282 41-49A 41-49: VEEGELEI mutated
to polyA
pETM11 NCBP3 1-282 213-225A 213-225:
DEAEEGEVEDENS
mutated to polyA
pFASTBac
DUAL
NCBP3 +
CBP80
1-620 + 20-791 co-expression
NCBP3/CBP80
Plasmids for cell assays
pcDNA3.1 EGFP EGFP + GSGGGS GSGGGS linker used for
all pcDNA3.1 EGFP
constructs
pcDNA3.1 EGFP-
ARS2
1-871 full length, wild type
pcDNA3.1 EGFP-
ARS2
147-871 N-terminal truncation
pcDNA3.1 EGFP-
ARS2
1-871 K719A K722A
K734A
mutations in the
C-terminal basic patch
pcDNA3.1 EGFP-
ARS2
1-871 ∆692-743 GSG deletion C-terminal arm
DNA3.1 EGFP-
ARS2
1-871 ∆271-408
GSGSGSGS
deletion of the predicted
unstructured region
271-408
pcDNA3.1 EGFP-
ARS2
1-871 R426G R470G
R498A R502A
mutations of the basic
patch within the RRM
domain
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Table A.5 – Plasmids (continued)
plasmid protein construct comment
pcDNA3.1 EGFP-
ARS2
1-871 R424A R426G
R463A R465A
mutation within the RRM
domain
pcDNA3.1 EGFP-
ARS2
147-871 ∆539-554 GSA deletion of loop 539-554
pcDNA3.1 EGFP-
ARS2
147-871 ∆539-554
AAA
deletion of loop 539-554
pcDNA3.1 EGFP-
ARS2
147-871 Δ539-554 15A mutation of loop 539-554
pcDNA3.1 EGFP-
ARS2
147-871 ∆567-599
GSGSGS
deletion of loop 567-599
pcDNA3.1 EGFP-
ARS2
147-871 T543A mutation of reported
phosphorylated T543 [85]
pcDNA3.1 EGFP-
ARS2
147-871 S549A L550A
P551A S552A
549-552 AAAA
pcDNA5 mCherry (Bertrand lab)
pcDNA5 mCherry-
Nop58
Nop58 nucleoli marker (Bertrand
lab)
pcDNA5 mCherry-
coilin
coilin nucleoli marker (Bertrand
lab)
Plasmids for yeast two-hybrid assay
p422 CBP20 1-471 (Bertrand lab)
p422 CBP20 1-471 Y50A CBP20 ARS2 binding
mutant
pAS CBP80 1-791 (Bertrand lab)
pAS CBP80 1-791 Y461E R610E
H651A
CBP280 ARS2 binding
mutant
pACT II ARS2 1-871 (Bertrand lab)
pACT II ARS2 1-871 R854A Y859A
R871A
ARS2 CBC binding
mutant
pACT II Alix Alix negative control (Bertrand
lab)
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Figure B.1 – Analysis of the CBC-ARS2827-871 complex
A: SEC-MALS of CBC and CBC together with ARS2 in the presence of m7GTP were per-
formed and revealed an 1:1 binding ratio.
B: Reconstitution of the m7GTP-CBC-ARS2827-871 complex. CBC was mixed with molar ex-
cess of ARS2827-871and m7GTP and subjected to SEC. The protein containing elution fractions
were analysed by Coomassie-stained SDS-PAGE.
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Table B.1 – CBC-ARS2 interactions
Different ARS2 constructs were tested for CBC binding using SEC and ITC.
interaction partners observation
CBC + ARS2 147-871 SEC: no co-elution
m7GTP-CBC + ARS2 147-871 SEC: co-elution
m7GTP-CBC + ARS2 147-845 SEC: no co-elution
m7GTP-CBC + ARS2 147-763 SEC: no co-elution
CBC + ARS2 827-871 SEC: no co-elution
ITC: KD~12.2 ± 3.5 µM
m7GTP-CBC + ARS2 827-871 ITC KD~1.0 ±0.2 µM
m7GTP-CBC + ARS2 634-871 SEC: co-elution
m7GTP-CBC + ARS2 763-871 SEC: co-elution
ITC: KD~1.0 ± 0.3 µM
m7GTP-CBC + ARS2 763-845 SEC: no co-elution
ITC: KD~n.d.
m7GTP-CBC + ARS2 787-871 SEC: co-elution
m7GTP-CBC + ARS2 811-871 SEC: co-elution
m7GTP-CBC + ARS2 845-871 ITC: KD~1.1 ± 0.16 µM
m7GTP-CBC + ARS2 827-871 F871D ITC: KD~1.8 ± 0.26 µM
m7GTP-CBC + ARS2 827-871 R854A
Y859A
ITC: KD~n.d.
m7GTP-CBC + ARS2 827-871 F871D
R854A Y859A
ITC: KD~n.d.
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Figure B.2 – Overview of interactions within the ARS2-CBC binding site
LIGPLOT [210] was used to visualise the CBC-ARS2 peptide interactions. ARS2 bonds and
residues are shown in blue and CBC bonds in orange.
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97.8% (6876/7030)  of  a l l  res idues  were  in  favored  (98%) regions .
100 .0% (7028/7030)  of  a l l  res idues  were  in  a l lowed (>99 .8%) reg ions .
There  were  2  out l ie rs  (phi ,  ps i ) : D  489 ASP (-65.5, -81.2)
     M  489 ASP (-65.5,  -81.3)
Figure B.3 – Ramachandran plot for m7GTP-CBCΔNLS-ARS2827-871 structure
Validation of the structure of m7GTP-CBCΔNLS-ARS2827-871 was performed with MolProbity
[31].
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b.2 identification of cbc-phax cross-links
Table B.2 – Identified intra-protein CBC-PHAX cross-links
The CBC-PHAX complex was reconstituted in vitro and cross-linked with DSS. After proteo-
lysis the purified cross-linked peptides were analysed by mass spectrometry. Cross-linked
lysines are in italic and underlined.
ld (linear discriminant) confidence scores were calculated by xQuest/xProphet. The cross-
links were deemed highly confident if their ld score was above 30. Cross-linked peptides
marked with * were identified at least twice.
Cross-linked peptide
sequence
protein1 protein2 AA 1 AA 2 ld-score
NHPQMIAVLVDKMIR-
TDWDAGFKEGR
CBP8-0 CBP20 607 120 36.51
LGNRPEMNYKGR-
TDWDAGFKEGR
PHAX CBP20 216 120 35.25
KESQEHTK-SHWKER* PHAX CBP80 162 327 34.91
HVLKIQK-SGDIKK CBP80 CBP20 654 67 34.57
KESQEHTK-SHWKER* PHAX CBP80 162 327 34.1
NHPQMIAVLVDKMIR-
KIIMGLDK
CBP80 CBP20 607 68 33.35
KESQEHTK-SHWKER* PHAX CBP80 162 327 32.24
KESQEHTK-SHWKER* PHAX CBP80 162 327 31.6
TDWDAGFKEGR-
SHWKER*
CBP20 CBP80 120 327 31.03
TDWDAGFKEGR-
SHWKER*
CBP20 CBP80 120 327 30.84
TDWDAGFKEGR-IIGNKK CBP20 PHAX 120 256 30.03
DLDKELDEYMHGGKK-
GDNEEQEKLLK
PHAX CBP20 173 34 28.13
DLDKELDEYMHGGK-
GDNEEQEKLLKK
PHAX CBP20 173 34 15.41
SGDIKKIIMGLDK-
KDAEMDR
CBP20 CBP80 68 188 15.21
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b.3 cbc-nelf-e interactions
Table B.3 – CBC-NELF-E interactions
Different NELF-E constructs were tested for CBC binding using SEC and ITC.
interaction partners observation
CBC + NELF-E SEC: no co-elution
m7GTP-CBC + NELF-E SEC: co-elution
ITC: KD~0.07 ± 0.02 µM
CBC + NELF-E 244-380 SEC: no co-elution
ITC: KD~0.4 ± 0.2 µM
m7GTP-CBC + NELF-E 244-380 SEC: co-elution
ITC: KD~0.05 ± 0.01 µM
m7GTP-CBC + NELF-E 244-360 SEC: no co-elution
ITC: KD~n.d.
m7GTP-CBC + NELF-E 354-380 ITC: KD~3.8 ± 1.4 µM
m7GTP-CBC + NELF-E 360-380 ITC: KD~3.3 ± 1.1 µM
C-ter
Phe380
Tyr372
Tyr367
Arg362
DKRTQIVYSDDVYKENLVDGF - 380A B CBP20 m7GTP
1H2T
1H2U
1H2V
NELF-E
CBP80
Figure B.4 – NELF-E peptide within the CBC-NELF-E crystal structure
A: Omit difference density map for NELF-E peptide contoured at 2σv. The main interacting
residues are labeled and the highly conserved residues within the C-terminus of NELF-E are
highlighted in red within the sequence.
B: Superposition of CBC structures (1H2V apo (gray), 1H2T (rose) and 1H2U (light blue)
bound to m7GpppG (cyan)) with m7GTP-CBC-NELF-E360-380 via CBP80 shows successive
relative displacements of the CBP20 subunit.
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Figure B.5 – Overview of interactions within the NELF-E-CBC binding site
LIGPLOT [210] was used to visualise the CBC-NELF-E peptide interactions. NELF-E bonds
and residues are shown in blue and CBC bonds in orange.
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96.7% (3407/3523)  of  a l l  res idues  were  in  favored  (98%) regions .
99 .8% (3516/3523)  of  a l l  res idues  were  in  a l lowed (>99.8%) reg ions .
There  were  7  out l ie rs  (phi ,  ps i ) :A  667 ARG (-64.0, 82.6);  E  375 ASN (64.7,  -76.4);
E  379 GLY (-176.6, -45.1); K  379 GLY (-176.3, -43.9); Z  375 ASN (48.3,  -85.3); 
Z  376 LEU (53.6,  88.4); Z  379 GLY (-175.1, -44.7)
Figure B.6 – Ramachandran plot for m7GTP-CBCΔNLS-NELF-E360-380 structure
Validation of the structure of m7GTP-CBCΔNLS-NELF-E360-380 was performed with MolPro-
bity [31].
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b.4 cbc-ars2/phax/nelf-e interaction assays
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Figure B.7 – Competition of NELF-E and ARS2/PHAX for CBC-binding
The in vitro reconstituted m7GTP-CBC-NELF–E244-380complex was mixed with molar excess
of PHAX or ARS2827-871 and subjected to SEC. The individual elution profiles were overlaid
and the protein containing fractions analysed by Coomassie-stained SDS-PAGE. The fraction
marked with * showed an additional bands, which seems to be due to a contamination of the
collection tube as the elution profile shows no high absorbance for this fraction.
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Figure B.8 – Fluorescence polarisation experiments including controls
To exclude interactions between ARS2827-871(FAM) and PHAX or NELF-E and NELF-
E354-380(FAM) and ARS2 or PHAX control experiments without CBC were performed. To
validate the competition between PHAX and NELF-E, PHAX was titrated to a preformed
m7GTP-CBC-ARS2845-871(FAM) complex.
A: ARS2827-871 titrated to m7GTP/NELF-E354-380(FAM) and
to m7GTP-CBC-m7GTP-NELF-E354-380(FAM).
B: PHAX103-327 titrated to m7GTP/NELF-E354-380(FAM) and
to m7GTP-CBC-m7GTP-NELF-E354-380(FAM).
C: PHAX103-327 titrated to m7GTP/ARS2845-871(FAM),
to m7GTP-CBC-m7GTP-ARS2845-871(FAM) and
to m7GTP-CBC-ARS2845-871(FAM)/NELF-E244-380.
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b.5 structural analysis of ars2
Table B.4 – Diffraction data statistics for human ARS2
crystal 147-763 trypsinised
native
Diffraction Data
Beamline ID29
Wavelength (Å) 0.984
Space group P64
Cell dimensions (Å) a=b=117.7 c=147.9
Cell angles (°) α=β= 90 γ=120
Resolution range of data (last shell) (Å) 50.0-6.98 (7.17-6.98)
Completeness (last shell) (%) 99.3 (99.4)
R-sym (last shell) (%) 5.8 (102.6)
I/σvI (last shell) 22.85 (2.00)
CC(1/2) (last shell) (%) 100.0 (85.3)
Redundancy (last shell) 11.1 (10.3)
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Table B.5 – Diffraction data and refinement statistics for human ARS2 I
crystal 147-270
+408-763
native
171-270
+408-763
+ 0.1 M FARB
native
171-270
+408-763
+ 0.1 M FARB
native
Diffraction Data
Beamline ID30A1 ID29 ID29
Wavelength (Å) 0.966 0.984 0.984
Space group P3121 P6522 P65
Cell dimensions (Å) a=b=136.64
c=158.79
a=b=90.92
c=267.02
a=b=105.21
c=267.04
Cell angles (°) α=β=90
γ=120
α=β=90
γ=120
α=β=90
γ=120
Resolution range of data
(last shell) (Å)
50.0-3.7
(3.8-3.7)
50.0-3.22
(3.3-3.22)
50.0-3.48
(3.57-3.48)
Completeness (last shell) (%) 99.7 (98.2) 97.0 (99.9) 97.9 (86.6)
R-sym (last shell) (%) 8.1 (115.8) 25.9 (167.5) 11.4 (161.6)
I/σvI (last shell) 12.11 (1.44) 10.15 (1.42) 8.71 (0.80)
CC(1/2) (last shell) (%) 100 (76.3) 99.6 (54.4) 99.7 (2.3)
Redundancy (last shell) 6.33 (6.16) 10.13 (9.13) 3.12 (2.98)
Refinement
Reflections used in
refinement work (free)
17679 (979) 10435 (516) 20048 (922)
R-work (last shell) 0.282 (0.429) 0.285 (0.398) 0.276 (0.452)
R-free (last shell) 0.311 (0.437) 0.323 (0.424) 0.301 (0.517)
Number of non-hydrogen
atoms
7194 3433 6530
Geometry and B-factors
RMSD (bonds) (Å) 0.007 0.007 0.007
RMSD (angles) (°) 1.03 0.990 0.963
Ramachandran favoured (%) 91.2 95.1 91.4
Ramachandran outliers (%) 1.4 0.5 0.52
Clash score 0.97 0.44 2.52
MolProbity score 1.55 1.35 1.73
Average B-factor 203.3 81.7 161.2
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Table B.6 – Diffraction data and refinement statistics for human ARS2 II
crystal 171-270
+408-763
seleno-Met
147-270
+408-763
Δ569-599
native
147-270
+408-763
Δ539-555
native
Diffraction Data
Beamline ID30A1 ID30A1 ID30A1
Wavelength (Å) 0.966 0.966 0.966
Space group P6522 C2221 P3121
Cell dimensions (Å) a=b=90.29
c=265.72
a=85.51
b=148.27
c=235.66
a=b=139.58
c=156.16
Cell angles (°) α=β=90
γ=120
α=β=γ=90 α=β=90
γ=120
Resolution range of data
(last shell) (Å)
50.0-3.30
(3.40-3.30)
50.0-3.37
(3.46-3.37)
45.04-3.50
(3.60-3.50)
Completeness (last shell) (%) 98.6 (99.9) 94.3 (67.1) 99.9 (99.8)
R-sym (last shell) (%) 32.4 (245) 9.8 (67.4) 9.4 (258.4)
I/σvI (last shell) 10.75 (1.45) 12.62 (1.97) 13.75 (0.77)
CC(1/2) (last shell) (%) 99.7 (67.6) 99.8 (53.7) 99.9 (61.8)
Redundancy (last shell) 19.82 (17.78) 4.12 (3.82) 9.93 (9.60)
Refinement
Reflections used in
refinement work (free)
9723 (478) 19276 (1017) 21538 (1112)
R-work (last shell) 0.274 (0.307) 0.257 (0.383) 0.312 (0.466)
R-free (last shell) 0.309 (0.373) 0.300 (0.448) 0.355 (0.412)
Number of non-hydrogen
atoms
3447 7146 7194
Geometry and B-factors
RMSD (bonds) (Å) 0.007 0.007 0.008
RMSD (angles) (°) 0.968 0.949 1.016
Ramachandran favoured (%) 92.7 93.9 91.4
Ramachandran outliers (%) 0.74 0.24 2.11
Clash score 0.58 0.91 2.07
MolProbity score 1.35 1.40 1.65
Average B-factor 102.9 124.9 215.5
116 supplementary results
93.9% (798/850)  of  a l l  res idues  were  in  favored (98%) regions .
99 .8% (848/850)  of  a l l  res idues  were  in  a l lowed (>99.8%) regions .
There  were  2  out l ie rs  (phi ,  ps i ) : A  161 ASP (-163.0, -66.5)
     B  161 ASP (-162.6,  -66.5)
Figure B.9 – Ramachandran plot for ARS2147-270+408-763Δ567-599 structure
Validation of the structure of ARS2147-270+408-763Δ567-599 was performed with MolProbity [31].
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b.6 identification of ars2 interaction partners
Identified interaction partners of EGFP-ARS2 and difference detected for the enrich-
ment of proteins for the wildtype and ARS2K712A K722A K734A and ARS2Δ692-743 GSG as
well as the enrichment of proteins for EGFP compared to the sample transfected with
the empty plasmid are listed in Table B.7.
The interaction partners were captured by affinity chromatography (Figure B.10)
followed by mass spectrometric analysis. For Limma analysis the replicates were
combined and a protein was considered as significantly enriched (Table B.7), if
its adjusted p-value is below 0.05 and the fold change above two. The volcano
plots comparing the enrichment of EGFP-ARS2 wild type associated protein against
the enrichment of the proteins for EGFP, EGFP-ARS2K719A K722A K734A and EGFP-
ARS2Δ692-743 GSG as well as the control EGFP-empty plasmid are shown in Sec.
3.4.3.2 Figure 3.25.
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Figure B.10 – Affinity purification of EGFP-ARS2 constructs
48 h post transfection cells were harvested, lysed and the EGFP tagged ARS2 constructs
purified using GFP-Trap. The elutions were analysed by SDS-PAGE followed by Coomassie
staining.
Table B.7 – Identified ARS2 interaction partners
protein log2
(fold change)
p-value adjusted p-value
EGFP- ARS2 wt - EGFP
NCBP3 3.707205166 2.3965E-06 0.00101931
ZC3H4 3.48016806 4.74707E-06 0.00101931
KPNA4 3.51978504 6.28858E-06 0.00101931
RBMX 2.482868451 6.82934E-06 0.00101931
KPNA2 2.406548938 7.34809E-06 0.00101931
Table B.7 – Continued on next page
118 supplementary results
Table B.7 – Identified ARS2 interaction partners (continued)
protein log2
(fold change)
p-value adjusted p-value
PYCR2 2.555103913 8.40889E-06 0.00101931
KPNA3 2.53445435 1.16707E-05 0.00101931
TRA2B 1.768313987 1.17915E-05 0.00101931
WDR82 2.110603166 1.24206E-05 0.00101931
THRAP3 2.08454206 1.2874E-05 0.00101931
PDCD6 2.309762297 1.35089E-05 0.00101931
PLOD3 2.774852473 1.92175E-05 0.001227944
PHAX 4.049685359 1.92329E-05 0.001227944
INPP5K 1.556435136 2.27941E-05 0.001351365
DDX5 2.227303277 2.66309E-05 0.001473578
PLOD1 2.240920311 3.98423E-05 0.002013094
TUBB4B 1.760164722 4.1232E-05 0.002013094
DDX17 2.566519356 5.07625E-05 0.002260791
LUC7L 2.67796549 5.1753E-05 0.002260791
ALY/REF 2.334103834 5.51108E-05 0.002287097
ZFC3H1 2.289790107 6.01963E-05 0.002368146
RBM14 1.522553166 6.37365E-05 0.002368146
BCKDK 2.572257584 6.56233E-05 0.002368146
PYCR1 1.901144505 7.55868E-05 0.002614044
COLGALT1 2.160954992 8.41819E-05 0.002687347
HSPA1B|HSPA1A 2.181931341 0.000102396 0.003147731
PPP2R5C 3.35292468 0.000135439 0.004014788
CBP80 3.429717745 0.000166668 0.004644559
DDX3X 1.766630902 0.000193711 0.005024384
ZCCHC8 2.263541664 0.000217439 0.005468921
SRSF10 1.600775352 0.000229266 0.005591209
FAM120A 2.219510248 0.000235774 0.005591209
MTR4 1.830769374 0.000260394 0.006003533
RALY 1.518538806 0.000287034 0.006438865
SRSF9 1.477396193 0.000355608 0.007767232
KPNA6 1.303844472 0.000489255 0.010152045
STUB1 1.27173672 0.00052102 0.010547482
THOC2 2.035342902 0.000538233 0.010636515
Table B.7 – Continued on next page
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Table B.7 – Identified ARS2 interaction partners (continued)
protein log2
(fold change)
p-value adjusted p-value
CASC3 1.513791359 0.000581895 0.010976658
HNRNPK 1.208927669 0.000619656 0.011180744
HNRNPUL1 1.084229926 0.000766377 0.012886399
SAFB2 1.25120203 0.000792252 0.012886399
CPSF2 2.015977269 0.000793305 0.012886399
LUC7L3 1.350123837 0.000822866 0.012886399
SRSF7 1.346829717 0.000891312 0.013699794
GBAS 2.403728479 0.000945514 0.014268668
THOC1 1.660122866 0.001044681 0.015483668
SAFB 1.238422047 0.001063591 0.015487377
USP7 1.345917852 0.001146098 0.016401061
PPP2R1A 1.515670069 0.0012342 0.016811671
PPP2CA 1.110134966 0.001313657 0.017036494
HNRNPH3 1.424191363 0.001535749 0.018745166
TRA2A 1.139792449 0.001568274 0.018864742
CBP20 2.496608623 0.001614136 0.019139037
MRPS27 1.568009154 0.001790276 0.020018442
DHX30 1.012875561 0.001808895 0.020018442
RPS27 1.30546679 0.001950129 0.021297458
HNRNPA0 1.006488389 0.002106293 0.02212941
KPNA1 1.091074899 0.002148586 0.022204769
PRMT5 1.066808247 0.002462182 0.024621823
SRSF5 1.331080617 0.002527885 0.024977907
AGGF1 2.181359242 0.002633092 0.025254025
HSPA8 1.265098503 0.002647109 0.025254025
RIOK1 1.19838374 0.003215876 0.029331616
DAP3 1.421862281 0.003316398 0.029919682
WDR77 1.071060009 0.003475335 0.031016428
HNRNPF 1.230006549 0.003718166 0.03189783
AKAP8L 1.500890324 0.004372698 0.034813738
DNAJA2 1.108010879 0.004710324 0.036199715
HNRNPH2 1.243924289 0.004870933 0.037090594
PRPF38B 1.900155997 0.005435607 0.039230906
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Table B.7 – Identified ARS2 interaction partners (continued)
protein log2
(fold change)
p-value adjusted p-value
FUS 1.588197445 0.005929165 0.041354681
SSBP1 1.056819114 0.006429627 0.042476399
IPO11 1.41079766 0.006448224 0.042476399
CPSF3 1.40694141 0.006825053 0.044604677
HNRNPC 1.452460114 0.007155421 0.04568461
CTNND1 1.043731251 0.007449023 0.046381391
MRPS18B 1.397996745 0.007656738 0.046493091
EIF4B 1.447075063 0.007759779 0.046671133
HSPA4 1.206122999 0.007949629 0.047469007
PPP2R2A 1.167941198 0.008254726 0.048938732
empty plasmid - EGFP
PARK7 2.239308991 0.000356612 0.295988223
EGFP- ARS2 wt - EGFP-ARS2 K719A K722A K734A
WDR82 2.553492114 1.64412E-06 0.001364617
NCBP3 3.286340045 8.61842E-06 0.002645791
ZC3H4 3.255334604 9.5631E-06 0.002645791
THRAP3 2.024485379 1.73384E-05 0.003597721
ZFC3H1 2.237285952 7.50363E-05 0.012456027
LUC7L 2.491726864 0.000102324 0.012980354
RALY 1.690937799 0.000109473 0.012980354
PDCD6 1.666612036 0.000297788 0.030895542
PHAX 2.908296098 0.0004174 0.038493585
MTR4 1.630218721 0.00069137 0.057383678
SNRNP70 2.031091413 0.000800001 0.060363699
HNRNPC 1.919537412 0.00102845 0.065662601
PRPF40A 1.366741504 0.00145551 0.086290926
SNRPD2 1.107723569 0.001628387 0.090104106
AGGF1 2.220149266 0.002323802 0.120547246
CASC3 1.082997907 0.006520053 0.284823385
PTCD3 1.515297002 0.007328348 0.304126433
SNRPA 2.332481199 0.009122535 0.336326781
RBM8A 1.353795952 0.009725112 0.336326781
SNRPB|SNRPN 1.424693232 0.012669024 0.413851423
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Table B.7 – Identified ARS2 interaction partners (continued)
protein log2
(fold change)
p-value adjusted p-value
PRPF3 1.224829507 0.0131079 0.413851423
MRPS27 1.066498069 0.019503793 0.578148159
PPP1CC 1.210117189 0.022473688 0.621772048
CPSF2 1.146448126 0.027790083 0.63869136
SF3A1 1.285215854 0.028188845 0.63869136
EGFP- ARS2 wt - EGFP-ARS2 Δ692-743 GSG
WDR82 2.534294659 1.78553E-06 0.001481986
NCBP3 3.448059261 5.20697E-06 0.001675443
ZC3H4 3.400909638 6.05582E-06 0.001675443
THRAP3 2.100454417 1.19078E-05 0.002470869
RALY 1.897515804 3.65205E-05 0.006062395
ZFC3H1 2.332197415 5.04741E-05 0.006982249
PHAX 3.274670495 0.000147628 0.017504487
SNRPD2 1.408418553 0.000230693 0.023934433
MTR4 1.67211756 0.000562048 0.051833353
LUC7L 2.009275546 0.000666829 0.055346829
HNRNPC 1.878201922 0.001216962 0.087132796
AGGF1 2.411878801 0.001259751 0.087132796
BCLAF1 1.122560696 0.001647468 0.105184486
PRPF6 1.009331831 0.002773502 0.164429022
SNRNP70 1.671781855 0.00338105 0.187084769
RBM8A 1.371631009 0.009009209 0.383771456
CASC3 1.02544145 0.009067173 0.383771456
SNRPE 1.579258951 0.009247505 0.383771456
CPSF3 1.311876871 0.010347505 0.408972807
PRPF40A 1.001083027 0.011308433 0.426636353
SNRPB|SNRPN 1.356688842 0.016485882 0.547331274
ALY/REF 1.015431383 0.023600326 0.653489881
SNRPA 1.932595581 0.024803708 0.653489881
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